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Semi-invariant natural killer T (iNKT) cells are critical components of the host 
immune response in peripheral tissues such as the lung, liver, and gut, and they play 
important roles in cancer, bacterial infections, autoimmunity, wound repair, and 
atherosclerosis. Tissue-resident iNKT cells exert their effects early in the developing 
immune response by rapidly producing a wide variety of cytokines and chemokines, and 
it was recently discovered that different tissues possess iNKT cell subsets that 
preferentially produce IFN- (NKT1), IL-4 (NKT2), or IL-17 (NKT17). Despite their 
critical role in the immune response, the mechanisms that regulate iNKT cell function in 
the periphery remain unclear. Signaling lymphocyte activation marker (SLAM) proteins 
are cell surface-expressed molecular switches that are expressed on all hematopoietic 
cells. The nine SLAM family receptors serve a variety of functions including promotion 
of cell-cell adhesion, regulation of cytokine production, co-stimulation, and inhibition. 
Importantly, SLAM family receptors are critical for the development of iNKT cells. Yet, 
numerous efforts to ascribe discrete roles of SLAM family receptors in iNKT cell 
function has proven difficult.  
We conducted a comprehensive analysis of SLAM family receptor co-
expression on iNKT cell subsets in the lung, spleen, liver, and thymus and identified co-
expression profiles that varied in a tissue and strain-dependent manner. Interestingly, we 
found that SLAM family receptor expression profiles varied among different iNKT cell 
subsets. In particular, we noted a close association of SLAMf6 expression with the NKT2 
and NKT17 subsets in both the periphery and in the thymus. Further investigation using 
SLAMf6-deficient mice revealed a critical role for SLAMf6 in NKT2 and NKT17 subset 
development, and in iNKT IL-4 and IL-17 cytokine production in the periphery. This 
investigation also revealed that the SLAMf6high NKT2 and NKT17 subsets exhibited 
significantly higher proliferative capacity than the NKT1 subset and the NKT2 and 
NKT17 proliferation was dependent, in part, on SLAMf6 expression.  
Since Slam family genes are highly polymorphic, we next investigated whether 
these polymorphisms regulated iNKT function. We employed a B6.129 congenic mouse 
exhibiting impaired NKT cell function, in which a 6.6 Mbp 129/SvJ locus encompassing 
Slam genes was introgressed onto the C57BL/6 background. To test the hypothesis that 
Slam gene polymorphisms regulate iNKT cell function, we refined this genetic interval 
by generating B6.129 subcongenic lines and assessing iNKT cell function. Unexpectedly, 
we found that while Slam gene polymorphisms in this model do regulate iNKT cell 
function, the dominant regulator was in a 0.14 Mbp interval centromeric to the Slam 
genes. Further experimentation revealed that impaired iNKT cell development and 
function was associated with changes in the expression of Fcgr3 (Fc gamma receptor III) 
on iNKT cells, suggesting it as a novel candidate gene regulating iNKT cell function.  
Taken together, these data reveal for the first time a specific role for SLAMf6 on 
NKT2 and NKT17 subset development and function. In addition, these data identify 
Fcgr3 as a novel candidate gene that regulates iNKT cell subset development and 
cytokine production. Cumulatively, these data reveal the presence of discrete regulatory 
mechanisms at work in different iNKT subsets, a finding that has broad implications for 
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To Grandpa Arnold M. Bartz 




“A ship in the harbor is safe, but that is not what ships are built for.” 
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 CHAPTER 1: COMPREHENSIVE LITERATURE REVIEW 
 
1.1 Introduction to Innate-Like Cells 
 
In introductory Immunology classes, we are taught that there are two arms of the 
immune system: the quick responding innate immune system that is triggered within 
minutes to hours after infection followed by the more specific adaptive immune system 
(Murphy et al., 2012). There are common cells that fit into each of these arms with 
dendritic cells, macrophages, neutrophils, and natural killer cells on the innate side, and T 
and B cells comprising adaptive immunity (Murphy et al., 2012) (Figure 1-1). Recently, 
the definitions of innate and adaptive have become less static, with the discovery of new 
subsets of cells comprised of innate lymphoid cells (ILCs) and innate like T cells that 
bridge the gap between these two classic arms (Gao and Williams, 2015; Mjosberg and 
Spits, 2012). ILCs and innate like T cells are unique in that they can orchestrate a 
symphony of immune cell activation allowing the host to combat many different types of 










Innate-lymphoid cells are comprised of three different types: ILC1, ILC2, and 
ILC3 (Cella et al., 2009; Kiessling et al., 1976; Luci et al., 2009).  These subsets are 
similar to those described for T helper subsets, where ILC1 cells make type 1 cytokines 
including the pro-inflammatory IFNγ (Fuchs et al., 2013). ILC2 have a type 2 phenotype 
producing IL-4 and IL-13 (Monticelli et al., 2011; Neill et al., 2010), and ILC3 cells 
produce IL-17 (Luci et al., 2009). While these cytokines in T helper subsets have been 
The quick acting innate immune system is comprised of cells such as neutrophils, 
dendritic cells, and macrophages, which aid in antigen presentation or engulfment of 
bacteria. The adaptive side is comprised of conventional CD4 and CD8 T cells 
which respond to specific pathogen peptides, as well as B cells which are important 
for antibody production. Innate like T cells, of which NKT cells are a part of, bridge 
the gap between the innate an adaptive immune system, rapidly becoming effectors 




associated with fighting intracellular bacteria, helminth, and extracellular and fungal 
infections respectively (Murphy et al., 2012), ILCs are different in that these early waves 
of cytokine production activate antigen presenting cells, leading to activation of the 
adaptive immune system (Eberl et al., 2015). ILC’s however, are fully innate cells, and 
do not have adaptive qualities in that they fail to recognize specific antigens (Colonna, 
2018). Innate-like T cells, however, function to bridge that gap.  
 Innate lymphoid cells and innate-like T cells reside in peripheral tissues where 
they participate in site specific immune responses (Dusseaux et al., 2011; Gasteiger et al., 
2015; Hayday and Tigelaar, 2003; Lee et al., 2015). Innate-like T cells are comprised of 
natural killer T cells (NKT), gamma-delta T cells (γδT), and the newly described mucosal 
associated invariant T (MAIT) cells. These cells patrol mucosal barriers such as the gut 
and lung, providing surveillance and direction for other cell types. In most cases, these 
innate-like T cells are the first cells to recognize an infection at mucosal sites (Chien et 
al., 2014; Kurioka et al., 2016; Van Kaer and Joyce, 2005). Gamma-delta T cells were 
first described in 1986 (Bank et al., 1986; Brenner et al., 1987; Saito et al., 1984), 
followed by NKT cells in 1987 (Budd et al., 1987; Fowlkes et al., 1987), and MAIT cells 
in 2003 (Treiner et al., 2003).  While the first innate-like T cells have been recognized for 
over 30yrs, little is known about their precise roles in different types of infection and host 
immunity. Even less is known about what regulates these cells, and how these 
determinants modify the cellular responses of these cells. For example, the ligands for 
gamma-delta T cells are yet to be discovered and we still do not understand how NKT 




disorders (Brutkiewicz, 2006). The field has only just discovered that MAIT cells are 
highly abundant in the human as compared to the mouse model organism (Garner et al., 
2018).   
 One of the most unique innate-like T cells are invariant natural killer T (NKT) 
cells. First described as having low levels of CD3 and a unique conservation of Vβ7 and 
Vβ8 chains in the T cell receptor (TCR) (Budd et al., 1987), researchers could not agree 
on what these unique cells were for 8 years until the NK1.1 T cell, and later termed 
natural killer T cell, in 1995 was defined (Makino et al., 1995). It was shown that these 
cells were indeed a separate cell from the previously known innate natural killer cells and 
adaptive CD4+/CD8+ conventional T cells. Indeed, NKT cells have markers and killing 
capabilities like that of natural killer cells (Yankelevich et al., 1989), but also have the 
adaptive quality of MHC-class 1 like restriction (Adachi et al., 1995). Understanding 
some of the factors that regulate iNKT cell biology was a major goal of this dissertation.   
 
1.2   Introduction to Natural Killer T cells 
Natural killer T cells are restricted to the non-classical MHC molecule CD1d 
and exhibit distinct properties of adaptive T cells and fast acting innate natural killer cells 
(Adachi et al., 1995; Makino et al., 1995). There are two types of NKT cells, type 1 
which use a semi-invariant TCR α chain, and type 2 NKT cells which are less abundant 
in number in the mouse and use a more varied TCR α chain (Budd et al., 1987; Rhost et 
al., 2012). Type 1 NKT cells, also known as invariant natural killer T cells (iNKT), use 




1990; Porcelli et al., 1993). Throughout this thesis, I will only discuss properties of iNKT 
cells.  
iNKT cells are considered the first line of defense upon responding to infection 
in the peripheral organs such as the spleen, liver, lung, and gut (Crosby and Kronenberg, 
2018; Van Kaer and Joyce, 2005). The percentages of iNKT cells circulating in the blood 
in a mouse is 0.1%, while the spleen, liver, lung, and gut can yield between 0.5-2%, 10-
30%, 3-5%, and 10-15% respectively as a percentage of CD45+ cells (Lee et al., 2015; 
Rymarchyk et al., 2008). In the human, iNKT cells in circulation are variable, in some 
reports measuring 0.1% to 1% of the leukocytes (Bienemann et al., 2011).  iNKT cells 
become effectors within minutes to hours after activation as evidenced by identification 
of cytokines such as IFNγ, IL-4, and TNFα, in the serum 60min after in vivo challenge 
(Bendelac and Schwartz, 1991; Christmas et al., 1987; Nishimura et al., 1997). Due to 
this rapid response, NKT cells may play the role of  “generals of the immune system” 
directing and recruiting other immune cells to carry out their respective roles in 
combating infection (Carnaud et al., 1999; Hermans et al., 2003; Kitamura et al., 1999). 
The rapid production of cytokines is in part due to the fact that iNKT cells have pre-
formed mRNA transcripts for IFNγ, IL-4, and IL-23R and RORγt, the latter two of which 
mediate IL-17 production (Rachitskaya et al., 2008; Stetson et al., 2003). The IFNγ 
produced by iNKT cells indirectly activates NK cells (Smyth et al., 2002), which aid in 
killing cells that the body recognizes as foreign (non-self). NKT cells also activate 
dendritic cells through CD40L binding to CD40 on the APC (Fujii et al., 2004). 




adaptive CD4 and CD8 T cells (Kitamura et al., 1999). NKT cells also help B cells to 
produce antibodies via the production of IL-4 and increased contact time for the 
formation of germinal centers (Kitamura et al., 2000) (Chang et al., 2011). Additionally, 
NKT cell production of IL-17 is important for the activation and recruitment of 
neutrophils (Li et al., 2007). Thus, cytokine production by NKT cells are important for 
the activation of many other cells of the immune system.  
In addition to cytokine production, NKT cells are prolific cytotoxic cells (Nicol 
et al., 2000). NKT cells make copious amounts of granzyme b and perforin (Nguyen et 
al., 2008), and can kill any cells that present a glycolipid on CD1d to the iNKT cell. This 
is especially important in cancer models where iNKT cells have been shown to be 
important for preventing tumor growth. In a cytotoxicity killing assay, ligation of 
NKG2D resulted in increased killing from iNKT cells by degranulation of perforin 
(Kuylenstierna et al., 2011). Activation of iNKT cells within the tumor microenvironment 
can also trigger NK cells to produce IFNγ, leading to increased NK cell cytotoxicity and 
reduced tumor burden (Hayakawa et al., 2002). Thus, iNKT cells serve many roles in the 
immune system, be it cytokine production to recruit other cells, or direct or indirect 
cytotoxicity.  
Importantly, NKT cells develop by fundamentally different mechanisms than 
CD4 and CD8 conventional T cells (Bendelac, 1995; Capone et al., 2001). Like 
conventional T cells, iNKT cells develop and undergo both positive and negative 
selection in the thymus. Selection of iNKT cells occurs via other double positive 




(Egawa et al., 2005). Early iNKT cell precursors mature into double positive 
(CD4posCD8pos) cells, and move through several developmental stages, finally becoming 
either CD4pos or CD4neg (Coles and Raulet, 2000). The stages of iNKT cell development 
can be identified using the iNKT cell markers CD44 and NK1.1 (Benlagha et al., 2002; 
Benlagha et al., 2005). Stage 0 iNKT cells are CD24hiCD44negNK1.1neg. Subsequently, 
iNKT cells progress through Stage 1 CD24lowCD44negNK1.1neg, Stage 2 
CD24lowCD44highNK1.1low, and mature into Stage 3 CD24loCD44highNK1.1high iNKT cells 
(Coquet et al., 2008; Gadue and Stein, 2002; Pellicci et al., 2002). Some iNKT cells stay 
in the thymus as long-term residents (Berzins et al., 2006), while others emigrate from 
the thymus into the periphery, where they gain expression of NK1.1 (McNab et al., 
2005). Recent work has shown diversity and heterogeneity in the subsets of iNKT cells 
that remain in the thymus and those that migrate to peripheral tissue, but the signals that 
regulate these movements are incompletely understood.  
 
1.3  Activation of NKT cells 
Activation of iNKT cells can be achieved by direct CD1d/TCR interactions. 
Using the semi-invariant TCR, iNKT cells recognize lipids and glycolipids that are bound 
to CD1d (Kawano et al., 1997). There are numerous glycolipids that can bind to CD1d, 
each having different length side chains or different head groups (Birkholz et al., 2015; 
Tsuji, 2006; Tupin and Kronenberg, 2006). The change in composition or position of the 
head groups of said glycolipids alters the avidity of the iNKT cell TCR for the CD1d 




galactosylceramide, an activator of NKT cells, can bind to the iNKT TCR with a strong 
affinity, while β-galactosylceramide has a reduced affinity for the TCR leading to 
reduced activation and cytokine production of iNKT cells (Morshed et al., 2009). 
Changes in glycolipid configuration and binding to CD1d can therefore have dramatic 
effects on iNKT cell responses.  
Glycolipids that preferentially activate iNKT cells are derived from self, 
commensal bacteria such as Bacteroides fragilis (Wieland Brown et al., 2013), or 
pathogenic bacteria such as Streptococcus pneumonia and Borrelia burgdorferi (Godfrey 
and Rossjohn, 2011).  One of the most potent glycolipid agonists for iNKT cells is alpha-
galactosylceramide (αGalCer). Originally derived from a sea sponge, and now shown to 
be expressed on Bacteroides species, the alpha-galactose head group sits above the CD1d 
molecule directly interacting with the iNKT TCR (Morita et al., 1995). The hydrophobic 
side chains are buried deep in the CD1d pockets (Koch et al., 2005). The length of the 
side chain on the glycolipid can affect how the sugar moiety interacts with the TCR 
(Girardi and Zajonc, 2012), changing the avidity of the CD1d/TCR interaction. This 
change in the avidity has direct consequences on the magnitude of the iNKT cell cytokine 
response, wherein some αGalCer-like molecules induce more IL-4 production while 
others attenuate cytokine production (Parekh et al., 2004). Interestingly, the CD1d/TCR 
interaction is highly conserved in that αGalCer loaded mouse CD1d can activate human 
iNKT cells and vice versa (Brossay et al., 1998). This observation suggests the presence 
of strong evolutionary pressure to maintain the recognition of αGalCer or αGalCer-like 




The second way that iNKT cells can be activated is indirectly from dendritic 
cells (DCs) stimulated with TLR ligands such as LPS, self-antigens presented on CD1d, 
or by IL-12 and IL-18 produced by activated DCs (Brigl et al., 2003).  This activation is 
especially important for the iNKT cell response to bacteria that do not have glycolipids 
that are directly presented via CD1d. The endogenous pathway allows for iNKT cells to 
respond to bacterial invasion from pathogens such as Staphylococcus aureus and 
Salmonella typhimurium (Kinjo et al., 2011). IL-12 mediated activation of iNKT cells  
has also been shown in response to mouse cyteomegalovirus (MCMV), indicating a role 
for iNKT cells in viral infection as well (Wesley et al., 2008) (Tyznik et al., 2014). 
Therefore, iNKT cells can be activated in numerous ways to aid in the control of 
infection. 
 
1.4  NKT cell TCR Agonists  
iNKT cells can be activated by numerous glycolipid antigens. The most well-
known and characterized is αGalCer (Morita et al., 1995). αGalCer, also called 
KRN7000, was first derived from an Okinawan sea sponge called Agelas mauritianus, 
and was selected initially for use against solid tumors in a B16 melanoma model (Morita 
et al., 1995). Initial reports stated that KRN7000 activated dendritic cells (Natori et al., 
1997). It was not until several years later that Kawano et al. reported that KRN7000 
specifically activated mouse splenic iNKT cells in a CD1d dependent manner (Kawano et 




stimulated with KRN7000 (Spada et al., 1998). These observations show that αGalCer is 
a potent CD1d ligand.  
Since the initial description of αGalCer as a CD1d ligand, there have been 
numerous reports describing CD1d ligands that activate iNKT cells. Several groups 
reported simultaneously the discovery of CD1d ligands from Sphingomonas paucimobilis 
(Mattner et al., 2005; Sriram et al., 2005; Wu et al., 2005). These cell wall ligands were 
structurally similar to αGalCer in that these glycosphingolipids (GSL) contain alpha-
oriented sugars attached to the lipid backbone (Sriram et al., 2005).  Other agonists 
include the galactosyl diacylglycerol BbGL-II from Borellia burgdorferi (Tupin et al., 
2008). Stimulation of iNKT cells with this antigen improved joint inflammation and 
reduced spirochete load in BALB/c mice (Tupin et al., 2008). The initial endogenous 
CD1d glycolipid discovered was isoglobotrihexosylceramide (iGb3), which has been 
shown to activate both mouse and human iNKT cells (Mattner et al., 2005; Sanderson et 
al., 2013; Zhou et al., 2004). Other iNKT cell agonists include glycosylceramides and 
lysophospholipids (lysophosphatidylcholine), both of which have been reported as 
endogenous human iNKT self-ligands (Fox et al., 2009; Kain et al., 2015).  
While treatment with αGalCer induces iNKT cells to produce both IFNγ and IL-
4, the synthesized iNKT cell agonist OCH has been shown to elicit a Th2 bias, priming 
iNKT cells to make IL-4 (Oki et al., 2004). OCH is a molecule like αGalCer except with 
a shorter sphingosine moiety (Velmourougane et al., 2009). In an EAE model, OCH was 
shown to protect C57BL/6 mice stimulated with OCH and sensitized with MOG peptide 




modification of a sphinganine backbone instead of sphingosine, and the addition of a 
hydrocinnamoyl ester to the galactose sugar (Chennamadhavuni et al., 2018) resulted in a 
compound (AH10-7) capable of inducing higher amounts of IFNγ from both mouse and 
human iNKT cells. This agonist aided in protection from B16 melanoma metastasis in 
both mouse and humanized CD1d mouse models (Chennamadhavuni et al., 2018).  
 Although iNKT cells are resistant to polarization in the traditional sense 
(Matsuda et al., 2003), modification of CD1d agonists can elicit differential cytokine 
responses from both mouse and human iNKT cells. This is an active area of investigation 
as new compounds are being synthesized to specifically activate iNKT cell responses to 
combat solid tumors (Hung et al., 2017).    
 
1.5  NKT cell Cytokines and Immunity  
Cytokine production is one of the major mechanisms through which iNKT cells 
mediate their action (Figure 1-2).  Like T helper cell subsets, NKT cell IFNγ is important 
for preventing B16 melanoma tumor burden (Smyth et al., 2002), and is being 
investigated for treatments for other solid tumors (Ma et al., 2018; Tagawa et al., 2013). 
Interferon-gamma from iNKT cells is also critical for mediating protection in several 
disparate models of infectious disease (Behar et al., 1999; Gonzalez-Aseguinolaza et al., 
2002; Li et al., 2007; Nakamatsu et al., 2007). For example, IFNγ from iNKT cells was 
shown to protect BALB/c mice from Pseudomonas by increasing the engulfment of 




Interleukin-4 from iNKT cells is also critical in many different disease models, 
especially in the regulation of airway diseases such as allergy, asthma, and 
transplantation (Akbari O, 2003; Chuang et al., 2018; Meyer EH, 2006). In a model of 
organ transplantation tolerance, iNKT cell IL-4 induced T-reg production of IL-10, 
(Hongo et al., 2012) aiding in organ tolerance. Additionally, the iNKT IL-4 production 
was associated with activation of myeloid derived suppressor cells (MDSCs) which was 
important for host acceptance of heart and bone marrow transplants (Hongo et al., 2014).  
Third, IL-17 producing iNKT cells are important for inhibiting growth of ocular 
Staphylococcus aureus in C57BL/6 mice (St Leger et al., 2018). Another study showed 
that lung iNKT cells produced IL-17 and IFNγ after activation by respiratory DC’s. This 
cytokine production subsequently lead to the recruitment of dendritic cells and 
neutrophils to the lung after Streptococcus pneumonia infection, aiding in increased 







FIGURE 1-2: Cytokine Production from NKT cells 
    
 
iNKT cells in the germinal center, also termed NKT follicular helper (NKTfh), 
produce IL-21. IL-21 is known to have many effects on immune cells including 
activation of macrophages, NK cells, conventional T cells and iNKT cells (Skak et al., 
2008). The IL-21 produced by human iNKT cells is crucial for B cell production of IgG 
 
Upon activation with a glycolipid agonist, NKT cells produce a myriad of cytokines 
including type 1, type 2, IL-17, and IL-10. These cytokines are important for mediating a 
cascade of immune cell activation, priming and recruiting other cells of the innate and 




and IgA (Wu et al., 2015). IL-21 from iNKT cells also provides a feedback loop inducing 
further activation of iNKT cells, NK cells, T cells, and B cells (Coquet et al., 2007). 
These regulatory mechanisms were especially important for controlling Mycobacterium 
tuberculosis infection (Paidipally et al., 2018). Patients undergoing recombinant IL-21 
therapy for the treatment of malignant melanoma showed increases in the frequency of 
iNKT cells during therapy (Coquet et al., 2013). Taken together, IL-21 from iNKT cells 
results in activation of other immune cells while further activating iNKT cells.  
The regulatory cytokine IL-10 is produced by iNKT cells in disease specific 
contexts as well. In a model of cardiac ischaemia-reperfusion, αGalCer treated  C57BL/6 
mice showed reduced blood pressure and increased prevalence of heart remodeling due to 
an infiltration of IL-10 producing iNKT cells to the heart (Wang et al., 2018). IL-10 
producing iNKT cells are also important in regulation of adipose tissue (Sag et al., 2014). 
iNKT cells are abundant in fat tissue, and over 25% of the iNKT cells in the adipose 
tissue produce IL-10 (Exley et al., 2014). Interestingly, Jα18-/- and CD1d-/- mice, which 
lack iNKT cells, gained more weight and had increased serum glucose as compared to 
wild-type controls. These data implicate IL-10 producing adipose tissue iNKT cells as 
being critically important for the regulation of metabolic disease (Lynch et al., 2012).  
Therefore, the cytokines produced by iNKT cells are important in regulating the 





1.6  Compartmentalizing NKT cells: iNKT cell subsets 
Recently, new subsets of iNKT cells have been described that possess preformed 
transcripts of IFNγ (NKT1), IL-4 (NKT2), IL-17 (NKT17), IL-10 (NKTreg), and IL-21 
(NKTfh) (Chang et al., 2011; Lee et al., 2013; Lee et al., 2016; Sag et al., 2014). These 
are functionally similar to their conventional T helper cousins in that they express 
primarily IFNγ, IL-4, IL-17, IL-10, and IL-4 and IL-21 respectively. Each of these 
subsets express specific transcription factors that enable their identification. All iNKT 
cells express the master transcription factor promyelocytic leukaemia zinc finger (PLZF) 
to various degrees as well as specific transcription factors that regulate cytokine 
production (Savage et al., 2008). NKT1 cells are PLZFlowTbethigh, NKT2 cells 
PLZFhighGATA3high, and NKT17 cells are PLZFintRORγthigh (Lee et al., 2013). NKTfh 
cells express Bcl-6 and markers on their surface similar to conventional Tfh cells 
including the chemokine CXCR5 and the inhibitory markers PD-1 and ICOS (Chang et 
al., 2011). NKT10 cells are still an enigma in the field (Sag et al., 2014). These cells do 
not express PLZF, but E4 promoter-binding protein 4 (E4BP4) which has been 
implicated in IL-10 and IL-13 production in CD4 T cells (Motomura et al., 2011). 
Some reports suggest that iNKT10 cells are indeed a distinct subset, while others suggest 
that earlier subsets may differentiate into iNKT10 cells after stimulation and proliferation 
(Cameron and Godfrey, 2018). Recently, an additional subset of iNKT2 cells that do not 
produce IL-4 but express Tbet in addition to GATA3 has been identified (Engel et al., 
2016). It has been suggested that this is a precursor population to the IL-4 producing 






FIGURE 1-3: NKT cell Subset Characteristics 
 
   
 
iNKT cell subsets are contributors to iNKT cell mediated tissue immunity. Each 
organ appears to have a specific iNKT cell milieu with great diversity in the percentages 
of subsets (Lee et al., 2015). For example, NKT1 cells are highly represented in the liver 
and gut, which receive microbial products from portal circulation. NKT2 cells are 
enriched in the lung and mesenteric lymph node, and NKT17 cells are highly enriched in 
the lung and peripheral lymph nodes.  Not only do iNKT cell subset frequencies vary 
among different tissues, but the anatomical location of NKT cell subsets vary within 
NKT cell subsets are comprised of NKT1, NKT2, and NKT17 cells, each expressing a 
different transcription factor repertoire as well as surface marker expression patterns. 
Distinct subsets are localized to specific tissues and primarily make cytokines such as IFNγ, 




tissues (Lee et al., 2015). This location specificity is presumably to position iNKT cells at 
strategic locations for cross-talk with other immune cells and for specific activation 
requirements. In the spleen, NKT1 cells are thought to reside in the red pulp, while NKT2 
cells are located within the T cell zone (Lee et al., 2015). In the lung, NKT17 cells are 
located within the interstitial tissue, whereas NKT1 and NKT2 cells are primarily in the 
vasculature (Scanlon et al., 2011; Thanabalasuriar et al., 2016). NKT10 cells are 
primarily found in the gut while (Sag et al., 2014) liver NKT1 cells patrol the liver 
sinusoids (Lee et al., 2010).  The anatomical locations of iNKT cells appear to have 
consequences for differences in iNKT cell activation. For example, NKT1 cells in the 
spleen and liver were activated after intravenous administration of αGalCer whereas only 
NKT2 and NKT17 cells in the mediastinal lymph node were activated after oral gavage 
(Lee et al., 2015). These data suggest that location within the tissue and route of 
activation are all important for the cytokine milieu produced by iNKT cells.  
The mechanisms underlying NKT cell subset development in the thymus remain 
unclear. There are two models to explain how iNKT cell subset development fits into 
classical models of iNKT cell development. Classic NKT cell staging, discussed in 
section 1.2, postulates that iNKT cells follow a linear stage model progressing from Stage 
0 (CD44negNK1.1neg), to Stage 3 (CD44posNK1.1pos) passing through each stage 
sequentially (Benlagha et al., 2005). Upon the identification of iNKT subsets however, it 
was found that these developmental stages were characterized by specific NKT cell 
subsets (Lee et al., 2013). NKT1 cells are the most mature Stage 3 cells, Stage 2 are 




iNKT cells do not follow a sequential model of development and instead suggests that 
each iNKT cell subset may have a separate precursor cell (Chen et al., 2017; Lee et al., 
2013). Evidence for a precursor population comes from thymic transcriptome analyses 
that show non-traditional iNKT2 cells can express Tbet, indicating a distinct cell type 
other than those able to express IL-4 (Engel et al., 2016; Georgiev et al., 2016). To date, 
the mechanisms that regulate each of the iNKT cell subsets and how they are 
developmentally controlled in both the thymus and periphery remain undetermined.   
While definitive iNKT cell subsets based on transcription factors in the human 
have not been identified, there are subsets of human iNKT cells that have propensities for 
different cytokines. The human subsets consist of CD4+CD8neg, CD4negCD8+, DN and DP 
(O'Reilly et al., 2011). After in vitro stimulation, human iNKT cell subsets produce 
similar levels of IFNγ and TNFα, but CD4+ iNKT cells specifically make higher levels of 
IL-4 (Montoya et al., 2007). The CD8+ and DN human iNKT cells are also thought to be 
more cytotoxic (Baker et al., 2001). The CD4+ human iNKT cells have been shown to 
provide an important role in antibody production by inducing B cell proliferation (Zeng 
et al., 2013). Therefore, iNKT cell subsets in both mouse and human contribute to tissue 
specific immune responses. 





1.7  Genetic regulation of NKT cells 
Invariant natural killer T cells exhibit immense strain specific diversity in 
number and function in mice (Chen et al., 2012; Rymarchyk et al., 2008). A comparison 
of iNKT cell numbers in common inbred strains of mice revealed a 50% difference in the 
percentage of iNKT cells in the liver (Rymarchyk et al., 2008). C57BL/6 mice, the most 
commonly used inbred mouse strain, has an above average number of iNKT cells, 
whereas BALB/c and C3H/HeJ mice harbor half as many (Hammond et al., 2001). 
Additionally, wild-derived inbred strains of mice such as Cast/EiJ and PWD/PhJ have 
barely detectable numbers of iNKT cells (Chen et al., 2012). Invariant NKT cell subsets 
also show variation in number and localization among different inbred strains of mice 
(Lee et al., 2015). C57BL/6 mice have the most NKT1 cells in all organs while BALB/c 
mice are enriched in NKT2, and NOD in NKT17. These analyses indicate that the host 
genetic background is important for the development of iNKT cells. 
Strain dependent differences in NKT cell number are associated with strain 
dependent variation in pathogen clearance. For example, infection with Borrelia 
burgdorferi manifests as joint inflammation in CD1d-/- animals on a BALB/c background 
(Tupin et al., 2008) but myocarditis on a C57BL/6 background (Olson et al., 2009). Data 
from the Boyson lab show that the magnitude of lung iNKT cell cytokine responses in 
BALB/c mice was higher than the responses of C57BL/6 after stimulation with both 
αGalCer and anti-CD3 (Benoit et al., 2015). These data indicate that strain dependent 




 Numerous groups have been working to identify genetic elements that regulate 
iNKT cell number and function. Early work showed that iNKT cell number was 
drastically diminished in the autoimmune prone non-obese diabetic (NOD) mouse model. 
It was also shown that the number of iNKT cells in type 1 diabetic and SLE patients were 
also diminished (Beristain-Covarrubias et al., 2015; Cho et al., 2011). Upon further 
investigation to the cause of reduced iNKT cell number in the NOD mouse, the Nkt1 
locus located on chromosome 1 was identified (Rocha-Campos et al., 2006). Numerous 
congenic mice on the NOD and C57BL/6 background were generated, identifying smaller 
regions of NOD alleles that could control NKT cell number and function (Esteban et al., 
2003; Jordan et al., 2004; Jordan et al., 2011; Jordan et al., 2007a). Importantly, a 
congenic line in which the NOD Nkt1 locus was replaced with C57BL/6 alleles showed 
no role in the disease susceptibility of type-1 diabetes, indicating that the susceptibility to 
autoimmune disease in the NOD mouse may be due to several different genetic loci 
(Rocha-Campos et al., 2006).  
 Numerous other studies have shown other genetic loci that control iNKT cell 
number (Wesley et al., 2007; Zhang et al., 2003). One of the most interesting and studied 
genetic regions, Sle1b on chromosome 1, was identified as a susceptibility locus for SLE 
in New Zealand White (NZW) mice (Morel et al., 2001).  This locus was associated with 
increased auto-antibody production as well as germinal center formation. When the Sle1b 
locus was introgressed onto the B6 background, only the mice harboring the NZW alleles 
at the Sle1b locus (B6.Sle1b) exhibited signs of increased autoimmunity indicating that a 




2002). This locus contained several hundred immunologically relevant genes, including 
the signaling lymphocyte activation markers (Slam genes) which had been associated 
with lupus susceptibility in GWAS studies (Cunninghame Graham et al., 2008; 
Wandstrat et al., 2004). Similar decreases in iNKT cell numbers were shown when 
129X1/SvJ alleles were introgressed onto the C57BL/6 background from chr1: 171.24-
176.09Mbp (Ensemble build m38.p6). B6.129 congenic mice exhibited reduced numbers 
of iNKT cells in the liver as well as reduced iNKT cell cytokine production upon 
activation (Aktan et al., 2010), indicating that a gene or genes controlling iNKT cell 
number was within this region on chromosome 1.  
 The same region was subsequently investigated for control of iNKT cell subset 
numbers. A 6.0Mbp locus on chr1:171-177Mbp derived from NZB mice was 
introgressed onto the C57BL/6 background. Importantly, this locus overlapped 
extensively with the previous Nkt1, Sle1b, and B6.129 congenic loci and contained the 
Slam genes. This locus also appeared to control iNKT cell subset development. B6.NZB 
congenic mice exhibited increased numbers of NKT1 and NKT2 cells as compared to 
C57BL/6 controls (Baglaenko et al., 2017). While each of the genetic loci reported used 
different strains of mice, the data clearly demonstrated that a gene or multiple genes on 
chromosome 1 from 171-177Mbp affected iNKT cell development.   
These large genetic loci however, contained over 80 immunologically relevant 
genes, including the Slam genes, which were suspected candidates in controlling iNKT 
cell number and function (Aktan et al., 2010; Wandstrat et al., 2004). The Boyson lab 




varied 129X1/SvJ congenic intervals and assessed iNKT cell responses. Identification of 
the candidate gene or genes regulating iNKT cell number and function was a major goal 
of this dissertation in Chapter 4.  
  
1.8  SLAM receptors: fine-tuning the immune system 
Signaling lymphocyte activation markers (SLAMs) are cell surface receptors 
expressed on all hematopoietic cells (Wu and Veillette, 2016) (Figure 1-4). These 
receptors are part of the CD2 family of cell surface receptors sharing similar Ig domain 
folds on their cell surface. The SLAM family receptors, except for SLAMf2 which binds 
SLAMf4, bind homotypically to self-receptors on opposite cells. Crosslinking of SLAM 
family receptors results in signaling leading to numerous functions on immune cells such 
as cell-cell adhesion, activation, cytokine production, cell proliferation, cell death, and 
cytotoxicity (Cannons et al., 2011). Interestingly, the SLAM family receptors are 
heterogeneously expressed on different cell types. These patterns of expression could 
possibly aid in lending specificity of signaling to cell interactions, be it co-stimulation 
leading to cytokine production from T cells (Howie et al., 2002), adhesion of T cells to B 
cells or antigen presenting cells (Zhao et al., 2012), antibody production from B cells 
(Cannons et al., 2006), or cytotoxicity from NK cells (Dong et al., 2012; Meinke and 
Watzl, 2013). SLAMf1 has been shown to function as a costimulatory receptor on T 
cells, SLAMf6 signaling aids in B cell help for proliferation and antibody production, 
while SLAMf4 mediates both inhibitory and activating signals for NK cell cytotoxicity 





FIGURE 1-4: SLAM Family Receptors 
 
 
Deletion of SLAM family receptor signaling by mutating the SLAM adaptor 
protein (SAP) gene has detrimental effects on multiple immune cell functions (Cannons 
et al., 2006; Nichols et al., 2005a; Nichols et al., 2005b; Rivat et al., 2013). SAP is 
located on the X-chromosome, and is the mutated gene in X-linked lymphoproliferative 
disorder (XLP) (Coffey et al., 1998; Nichols et al., 1998; Sayos et al., 1998). Young boys 
SLAM family receptors are a family of nine cell surface expressed molecular switches that 
signal via immuno-tyrosine switch motifs within the cytoplasmic domain. These receptors, 
with the exception of SLAMf2-SLAMf4, primarily bind homotypically to each other on 
neighboring cells. This crosslinking allows for the phosphorylation of traditional tyrosine 
motifs or ITSMs via the adaptor molecule SLAM adaptor protein (SAP), or other adaptor 
moleculars such as the phosphatase SHP-1.  Each SLAM family receptor has a different 




who acquire this deletion are unable to control Epstein Bar Virus and succumb to the 
virus at a young age. These patients have increased white blood cells due to defects in 
activation induced cell death. Conventional CD8 T cells and NK cells fail to kill virally 
infected cells. These patients also have defects in antibody production and formation of B 
cell blasts (Purtilo et al., 1975). XLP patients fail to develop iNKT cells, indicating that 
SLAM/SAP signaling is required for the development of this subset of αβ T cells 
(Pasquier et al., 2005). Therefore, SLAM family receptor signaling is necessary for the 
proper functioning and development of immune cells.    
SLAM family receptors 1-7, except for SLAMf2, contain immuno-tyrosine 
switch motifs (ITSM) on their cytoplasmic tails (Shlapatska et al., 2001) (Figure 1-4). 
ITSMs are different from other immune regulatory motifs such as the immune-tyrosine 
activation motif (ITAM) and immune-tyrosine inhibitory motif (ITIM). Whereas the 
activation and inhibitory motifs can only bind adaptor molecules that result in activation 
or inhibition respectively, the ITSM regulatory tails allow for activating or inhibitory 
signaling based on the repertoire of adaptor molecules expressed in the cell. The SLAM 
adaptor molecule, slam adaptor protein (SAP), can bind to the immuno-tyrosine switch 
motifs, which leads primarily to activation phenotypes (Shlapatska et al., 2001). If SAP is 






 FIGURE 1-5: Signaling Through SLAM Receptors 
  
   
 
phosphatase 1 (SHP-1), can also bind (Kageyama et al., 2012) (Figure 1-5). Which 
adaptors are bound to the SLAM family receptors in different cells remains controversial. 
Initial reports observed that SAP was constitutively bound to SLAM family receptors on 
T cells, while SHP-1 could displace SAP (Dong et al., 2009; Sayos et al., 1998; Tangye 
et al., 2000), resulting in a decreased activation signal or possibly even an inhibitory 
signal. An alternative model states that SHP-1 may be constitutively bound and SAP 
outcompetes SHP-1 for binding to the same ITSM, thereby decreasing the inhibitory 
Schematic of SLAM family receptor signaling via the adaptor molecules SAP or SHP-1. 
SAP is thought to provide activation signals via the recruitment of Fyn kinase. Binding of 
SAP to an ITSM blocks SHP-1 from binding. Alternatively, in the absence of SAP binding, 





signal (Wilson et al., 2014).  Other reports speculate, but have not unequivocally shown, 
that SAP can be bound to one ITSM and SHP-1 to a second on the same SLAM family 
receptor (Kageyama et al., 2012). Therefore, SLAM family receptor signaling on 
different immune cells can have both activating and inhibitory phenotypes.  
One of the most striking examples of activation and inhibitory signaling 
phenotypes is shown by analysis of SLAMf4 expression on NK cell lines (Chlewicki et 
al., 2008). In vitro, high expression of SLAMf4 resulted in inhibition of cytokine 
production while a lower level of SLAMf4 correlated with an activation phenotype and 
increased cytokine production of NK cells. The inhibitory and activation levels were 
dependent not only on SLAMf4 expression, but on ligand crosslinking (i.e. with 
SLAMf2), as well as the expression level of SAP. Interestingly, lower levels of SAP were 
associated with inhibition while higher levels showed activation, indicating that the ratio 
of adaptor molecule binding to ITSMs on the SLAM family receptor contribute to how 
the receptor mediates function (Chlewicki et al., 2008).  
Furthermore, analysis of SLAMf4 and SLAMf6 in SAP-/- mice show that these 
receptors can have both inhibitory and activating functions in vivo. In the presence of 
SAP, SLAMf4 and SLAMf6 were required for activation signals to mediate adhesion of 
T cells to target cells at the immunological synapse (Zhao et al., 2012). In SAP deficient 
mice, SHP-1 was recruited to the ITSM, and cell-cell contact time was diminished 
resulting in decreased cell killing and activation of B cells. Thus, SLAMf4 and SLAMf6 
can have an activating function in the presence of SAP, but inhibitory functions without 




SLAM family receptor signaling is critical for the development of certain 
lineages of innate-like T cells. There are SLAM/SAP dependent γδ T cells, innate-like 
CD8+ T cells, and iNKT cells (De Calisto et al., 2014; Griewank et al., 2007; Kreslavsky 
et al., 2009). SAP deficient mice lack a specific subset of “NKT-like” gamma-delta T 
cells that express a characteristic Vγ1.1Vδ6.3 TCR (Kreslavsky et al., 2009). The field 
still has yet to determine which SLAM family receptors in particular are required for 
development of this cell type. SLAMf5 deficient mice have an increase in CD8+ innate T 
cells as compared to wild-type mice, implicating SLAMf5 as a regulator of innate CD8+ 
T cell development (De Calisto et al., 2014). SLAMf1, SLAMf6, and recently SLAMf3 
have all been implicated in the development of iNKT cells, which will be discussed more 
in the next section (Griewank et al., 2007; Sintes et al., 2013). MAIT cells do not appear 
to be dependent on SLAM/SAP for development (Garner et al., 2018). To date, SLAM 
family receptors have not been shown as crucial for the development of conventional T 
cells, indicating that innate like T cells are more dependent on SLAM family receptor 
signaling than conventional T cells.  
 
1.8.1. SLAM family receptor 6 (SLAMf6, Ly108, NTB-A) 
SLAM family member receptor 6 (SLAMf6) is thought to have diverse effector 
functions on multiple immune cells. This receptor has been shown to have costimulatory 
functions on naive CD4 T cells and NK cells, and inhibitory functions on re-stimulated 
conventional T cells as well as iNKT cells. Initial investigations into the role of SLAMf6 




after Leishmania mexicana challenge (Howie et al., 2005),  as well as reduced 
phagocytosis of Salmonella typhimurium by neutrophils, showing that SLAMf6 could 
control functions of both innate and adaptive immune responses.  
Next, SLAMf6, also termed Ly108, and “NK, T and B cell antigen (NTB-A)” in 
the human, was identified as a potential susceptibility gene for autoimmunity, especially 
in systemic lupus erythematosus (SLE) (Wandstrat et al., 2004). The first identification of 
SLAMf6 as having a role in autoimmunity was due to an increase in the expression of 
SLAMf6 on autoimmune prone (B6.Sle1b) mouse T cells as compared to C57BL/6 mice 
(Wandstrat et al., 2004). Numerous reports showed that SLAMf6 enhanced signaling in 
CD4 T cells (Chatterjee et al., 2011), regulated autoantibody production (Keszei et al., 
2011), and was important with SAP for B cell help and germinal center formation (Wong 
et al., 2015). SLAMf6 and SLAMf3 expression were increased on CD4 T cells of SLE 
patients, indicating that SLAMf6 functioned, in part, to aid in promoting SLE aberrant T 
cell signaling (Chatterjee et al., 2012).  
Recently, SLAMf6 has been shown to have roles as a negative regulator in 
humoral immunity. Deletion of SLAMf6, SLAMf5, and SLAMf1 resulted in higher 
antibody responses, T follicular helper cell formation, and germinal center formation. 
Additionally crosslinking SLAMf6 with an anti-SLAMf6 antibody reduced Tfh 
formation, and antibody responses, indicating that SLAMf6 also acts as a negative 
regulator in modulating antibody responses (Wang et al., 2015). 
SLAMf6 is also thought to play an active role in binding bacteria such as 




SLAMf6 with the OmpF and OmpC proteins on E. coli allowed SLAMf6 to transmit 
signaling to activate neutrophils and phagocytic cells. SLAMf6-/-Rag-/- mice were 
protected from C. rodentium mediated colitis due to decreased inflammatory cell 
localization to the gut decreasing the pathology from inflammation in this organ (van 
Driel et al., 2015).  
How is it that SLAMf6 could have a myriad of roles in both innate and adaptive 
immune responses? The answer, in part, is due to the biology of SLAM family 
receptors themselves. Since SLAM family receptors have ITSM motifs and can bind 
multiple signaling molecules, as discussed earlier, SLAM receptors can change 
signaling dependent on expression level and the strength of the signal received. Indeed, 
SLAMf6 has been shown to act as “immune modulatory switch” providing activation 
of T cells in the presence of SAP and inhibition of NKT cell development in SAP 
deficient mice (Kageyama et al., 2012). Chapters 2 and 3 explore how SLAMf6 can 
have multiple functions on the same immune cell type.  
 
1.9 Slam gene polymorphisms  
There are 9 SLAM family receptors within the Slam gene family, each of which 
are termed SLAMf1-SLAMf9 (Cannons et al., 2011). Slams 1-7 are located within a 
0.410Mbp region on chromosome 1. Slams 8 and 9 are located another 0.6Mbp telomeric 
to the main Slam locus located at Chr1:171.55-171.96 (Ensembl Gene Browser, Build 93 




human (Engel et al., 2003), indicating an evolutionary need to constrain these genes 
(Limaye et al., 2008).  
The Slam genes are found in 3 distinct haplotypes in inbred mouse strains, with 
C57BL/6 harboring one haplotype, while NZW/B, BALB/c, and 129X1/SvJ harbor a 
second. The third haplotype is only found in wild-derived inbred strains of mice such as 
CAST/EiJ and PWD. Each of these haplotypes show variability in SLAM family receptor 
gene expression, copy number, or isoform expression. For example, Slamf4 has 4 
pseudogenes duplicated in mice that carry haplotype 2 alleles while C57BL/6 mice, 
which harbor haplotype 1 alleles, express an inhibitory isoform of the SLAMf6 protein. 
Slam polymorphisms have been shown to affect iNKT number and function 
(Aktan et al., 2010; Esteban et al., 2003; Jordan et al., 2004; Jordan et al., 2007b). 
Previous reports had indicated immense strain dependent variability in the number of 
iNKT cells in different inbred strains of mice, raising questions about which genes 
controlled the development of iNKT cells in these strains. The regions first identified as 
iNKT cell control genes, Nkt1 and Sle1b, both contained Slam gene polymorphisms in 
addition to many other immunologically relevant genes (Jordan et al., 2007a; Morel et al., 
2001). A major goal of the Boyson lab has been to refine these regions to identify the 
gene or genes that control iNKT cell number and function.  
Slam polymorphisms are also important for infection models. Boyson and Huber 
showed that mice harboring the autoimmune prone Slam haplotype 2 promoted NKT cell 
activation after coxsackie-B3 infection resulting in liver pathology. Slam haplotype 1 




of myocarditis (Huber et al., 2013). In addition, BALB/c mice, which harbor Slam 
haplotype 2 alleles were more dependent on iNKT cells for the clearance of 
Pseudomonas from the lung than C57BL/6 mice (Benoit et al., 2015). These infection 
models describe how Slam polymorphisms may control iNKT cell responses to infection. 
 
1.10 SLAM receptor regulation of NKT cells 
iNKT cells are dependent on SLAM and SAP signaling in the thymus for 
development. Using elegant chimeric models, Griewank et al. showed that SLAMf1 and 
SLAMf6 with the adaptor molecule SAP are required on double positive thymocytes for 
iNKT cell selection (Griewank et al., 2007). Subsequent reports have now shown that 
SLAMf3 is a negative regulator of iNKT cell development (Sintes et al., 2013). Analysis 
of numerous SLAM family receptor single knockouts, as well as multiple SLAM family 
receptor knockouts have shown skewed ratios of NKT1, NKT2, and NKT17 subsets as 
compared to wild-type parental controls, indicating that multiple SLAM family receptor 
signals play a role in iNKT cell subset development (Baglaenko et al., 2017; Graham et 
al., 2006; Huang et al., 2016).  
The role of SLAM family receptor signaling on iNKT cell subset development is 
exemplified by the fact that SAP appears to contribute to IL-4 and NKT2 development 
(Michel et al., 2016). SAP deficient mice crossed with transgenic Vα14 mice, which 
allow for iNKT cell production even though these mice lack SAP, showed an increase in 
the level of iNKT17 cells along with a decrease in NKT2 cells (Michel et al., 2016). 




development, the transgenic mouse model used may have confounded results. Initial 
reports show that this mouse has an increase in NK1.1 NKT cells compared to parental 
controls, indicating that the Vα14 transgenic has developmental differences in iNKT cell 
subsets (Bendelac et al., 1996). Additional investigation into the role of SLAM/SAP 
signaling on the development of iNKT cell subsets is ongoing by us and others.  
 Several studies have shown that SLAMf6 specifically is a regulator of iNKT cell 
development. SLAMf6 is required for the induction of the iNKT cell master transcription 
factor promyelocytic leukaemia zinc finger (PLZF). Treatment of pre-selected 
thymocytes with anti-SLAMf6 and anti-CD3 induced higher expression of PLZF than 
treatment with anti-CD3 alone (Dutta et al., 2013). Another report showed that SLAMf6 
was a negative regulator of NKT cell development. SLAMf6 deficient mice show a 50% 
reduction in NKT cells, and SAP deficient mice lack all NKT cells completely 
(Kageyama et al., 2012; Nichols et al., 2005a). Interestingly, a partial restoration of NKT 
cells was observed in SLAMf6-/-SAP-/- mice, suggesting that SLAMf6 acts as negative 
regulator in SAP-/- animals (Kageyama et al., 2012). Additionally, crosslinking of 
SLAMf6 on APCs and iNKT cells are critical for the cytokine production of iNKT cells 
in the mouse and human, indicating that SLAMf6 can also act as an activation receptor 
upon homotypic binding (Baglaenko et al., 2017). SLAMf6 has been shown to be 
involved in the induction of PLZF, yet the deletion of SLAMf6 by itself is not sufficient 
to completely block iNKT cell development, indicating that other SLAM family receptors 




iNKT cell subsets. These observations raise questions about the mechanisms of SLAMf6 
function on peripheral iNKT cell subsets, which are discussed in Chapters 2 and 3.  
Multiple SLAM family receptors can provide both positive and negative signaling 
in iNKT cell development. As noted above, deletion of SLAMf6 decreases the number of 
iNKT cells in the thymus by 50% (Dutta and Schwartzberg, 2012). A SLAMf1, SLAMf5, 
SLAMf6 triple knockout, however, decreases NKT development by over 80% (Huang et 
al., 2016). This report indicates that SLAMf1 and SLAMf5 may provide positive 
signaling for NKT cell development while SLAMf6 provides an inhibitory signal. 
Additional reports observed that total SLAM family receptor knockouts had a less severe 
decrease in iNKT cells as compared to SAP-/- mice, indicating that all SLAM family 
receptors can negatively regulate iNKT cell development when SAP is absent (Chen et 
al., 2017). Interestingly, SAP deficiency induced after iNKT cell development resulted in 
a decrease in peripheral iNKT cell mediated cytotoxicity, but not cytokine production, 
indicating that the major role for SAP on iNKT cells could possibly be only in 
development (Das et al., 2013). These phenotypes highlight the importance of 
SLAM/SAP signaling in iNKT cell development. 
 
1.11 The role of SLAM family receptors on iNKT cell proliferation 
 
 iNKT cells are thought to have an activated phenotype immediately upon 
emigration from the thymus (Kumar et al., 2017). This primed state not only leads to 
quick secretion of cytokines, but also rapid proliferation, and as a result, rapid cell death. 




since iNKT cells were discovered, but these studies have been controversial (Eberl and 
MacDonald, 1998) (Crowe et al., 2003; Subleski et al., 2011). One of the first reports on 
this topic suggested that liver iNKT cells rapidly undergo apoptosis after activation with 
in vivo anti-CD3ɛ (Eberl and MacDonald, 1998). Numerous reports further showed that 
this cell death was due to Fas/FasL interactions since FasL is highly expressed on iNKT 
cells (Leite-de-Moraes et al., 2000). Subsequently, it was shown that splenic NKT cells 
down regulate their TCR in response to a strong stimulus, making these cells impossible 
to detect using CD1d/αGalCer loaded tetramer (Crowe et al., 2003). Recently, both 
models were found to occur in that NKT cells in the liver undergo activation induced cell 
death but iNKT cells in the spleen do not. Surprisingly, iNKT cells from both the spleen 
and liver downregulated their TCR, but cells in the lymph node did not downregulate 
their TCR or undergo cell death (Subleski et al., 2011). These data point to specific 
subsets of iNKT cells being more susceptible to cell death than others. Indeed, recent data 
has shown than NKT2 cells are much more proliferative than NKT1 cells (Cameron and 
Godfrey, 2018). Further transcriptomic reports indicate that iNKT cell subsets have 
different propensities and thresholds for activation and cell death (Engel et al., 2016; 
Georgiev et al., 2016), the implications of which are only now being addressed.  
 Little is currently known about the role of SLAM family receptors in 
homeostatic mechanisms of peripheral iNKT cells. Although SLAMf1 and SLAMf6 are 
required for iNKT cell development (Griewank et al., 2007), it remains to be determined 
whether SLAMf6-SLAMf6 interactions mediate proliferation or cell death in the 




involved in regulating iNKT cell homeostasis. Signaling of SLAMf6 via the adaptor 
molecule SHP-1 in XLP patients, who lack SAP, caused CD8 T cells to over proliferate 
and prevented them from undergoing cell death (Snow et al., 2009). When SLAMf6 was 
knocked-down, however, the resistance to cell death was reversed, and the majority of 
CD8 T cells underwent apoptosis (Snow et al., 2009). Additionally, SLAMf6 and 
SLAMf4 were shown to regulate CD8 T cell mediated cytotoxicity against B cells, which 
is an important function for fighting EBV infection (Zhao et al., 2012).  
 In the past several years, the unique property of SLAMf6 to change the signaling 
thresholds for cell death has been exploited in new immuno-therapeutics for leukemia 
and metastatic melanoma (Eisenberg et al., 2018; Korver et al., 2007). SLAMf6 has been 
shown to be highly expressed on B cells, with even greater expression on leukemic B 
cells. Monoclonal antibodies that target SLAMf6 result in enhanced cell death against the 
leukemic B cells, preventing the cancer from progressing (Korver et al., 2007). In 
addition, soluble SLAMf6 has been shown to improve CD8 T cell cytotoxicity and 
activation against melanoma tumors in a mouse model (Eisenberg et al., 2018). These 
data suggest that SLAMf6 can modulate the cytotoxic and cell death thresholds of 






1.12 Gaps in knowledge of NKT cell regulation 
 
 SLAM family receptors have been regulated as modulators of lymphocyte 
function since 1993 (Garni-Wagner et al., 1993). Although there have been many studies 
of SLAM family receptors on T cells and NK cells leading to identification of SLAM 
family receptors mediating cell-cell contact at the immunological synapse, co-stimulation 
of T and B cells, and inhibition of cytokine production, little is known about how SLAM 
family receptors function on iNKT cells in the peripheral tissues. Most studies of SLAM 
family receptors on iNKT cells are centered upon how these receptors mediate signals 
during development, leading to broad knowledge of how iNKT cell development is 
fundamentally different from that of conventional T cells. Other reports have investigated 
cytokine production after thymic iNKT cell stimulation in vitro, but not on iNKT cells 
from the spleen, lung and liver. Therefore, there is a gap in knowledge of how SLAM 
family receptors are expressed and if these patterns mediate functionality of peripheral 
iNKT cell subsets.  
 The recent discovery of iNKT cell subsets raises new questions about how the 
SLAM family receptors are involved in development and function of these subsets. We 
know that SLAMf1 and SLAMf6 with SAP are required for the development of all iNKT 
cells (Griewank et al., 2007), but how these two proteins affect subset development has 
not been addressed. Since C57BL/6 mice have mostly NKT1 cells (70% or higher in the 
spleen) (Lee et al., 2015) (Boyson lab observations), differences in iNKT cell phenotypes 
have not been discovered until NKT1 cells were separated from NKT2 and NKT17. 




performed. Therefore, a major goal of this dissertation was to assess SLAM family 
receptor patterns of expression and how these patterns controlled NKT cell subset 
development and peripheral function. A second goal was to analyze specific co-
expression of SLAM family receptors on subsets of iNKT cells in both the C57BL/6 and 
SLAMf6-/- mice, identifying specific roles for SLAMf6 on iNKT cell subsets.   
 Finally, there have been numerous studies implicating Slam gene 
polymorphisms in the control of total iNKT cell number and function (Aktan et al., 2010; 
Baglaenko et al., 2017). Whether these loci control all iNKT cell numbers or just certain 
subsets still needs to be determined. Most of the susceptibility studies were performed on 
mice with large congenic loci, containing numerous immunologically relevant genes. 
There has not been a definitive study showing that the Slam genes were the regulators of 
iNKT cell number and function. How to refine one of these loci and whether Slam genes 
may be involved in the regulation of iNKT cell number and function is discussed in 
Chapter 4.  
 Therefore, the major goals of this dissertation were first, to broadly analyze 
SLAM family receptor expression on peripheral iNKT cells in the lung, liver, and spleen 
and assess the functional implications of these patterns of expression. Second, to assess 
the role of SLAMf6 signaling on the newly described iNKT cell subsets, and whether this 
receptor can lead to multiple phenotypes across the iNKT cell lineage. Third, to address 
whether Slam genes control iNKT cell number and function. These data, overall, provide 
novel understanding of the mechanisms by which iNKT cells are modulated in secondary 
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 Invariant natural killer T cells (iNKT) are crucial for mediating host immunity in 
a tissue specific manner. When activated, these cells produce a myriad of cytokines 
including IFNγ, IL-4, IL-10, and IL-17. Each of these cytokines is primarily produced by 
specific iNKT cell subsets termed NKT1, NKT2, NKTreg, and NKT17, respectively. The 
cell surface-expressed family of signaling lymphocyte activation markers (SLAM) have 
been shown to play a role both in the development and function of iNKT cells, but a role 
on specific iNKT cell subsets has not been shown. Here, we analyze SLAM family 
receptor co-expression on iNKT cell subsets revealing tissue and strain dependent 
differences in SLAM family receptor expression. These observations led us to 
hypothesize that SLAM family receptors could fine-tune development and function of 
iNKT cell subsets. Indeed, SLAMf6 was highly expressed on NKT2 and NKT17 subsets. 
Deficiency of SLAMf6 resulted in decreased NKT2 and NKT17 cell numbers as well as 
IL-4 and IL-17 production from sorted NKT2/NKT17 cells. Taken together, these data 
show that SLAM receptor expression patterns define iNKT cell subsets, and that 
SLAMf6 has a functional role in NKT2 and NKT17 subset specific development. 
Additionally, this is the first report that SLAMf6 deficiency has a specific effect on 
NKT17 IL-17 production and NKT2 IL-4 production, showing that SLAM family 





 Invariant natural killer T cells are innate-like T cells that play a crucial role in the 
host immune response (Behar and Porcelli, 2007; Godfrey and Rossjohn, 2011; 
Gumperz and Brenner, 2001). These invariant cells recognize glycolipids bound by the 
MHC class-1 like molecule CD1d (Kawano et al., 1997; Spada et al., 1998). When 
activated by the prototypical agonist alpha-galactosylceramide (αGalCer), iNKT cells 
make a host of inflammatory mediators such as IFN-γ, IL-4, TNFα, IL-17, and the anti-
inflammatory cytokine IL-10 (Coquet et al., 2008; Hameg et al., 2000; Yoshimoto and 
Paul, 1994).  
 iNKT cell cytokines play critical roles in immune function and underlie the 
critical role of iNKT cells in many disease models (Crosby and Kronenberg, 2018). For 
example, IFN- produced by iNKT cells is critical for secondary activation of NK cells 
and subsequent killing of metastatic tumors in a B16 melanoma model (Smyth et al., 
2002), and activation of macrophages by IFNγ-producing lung iNKT cells is crucial for 
decreasing Pseudomonas bacterial burden in the lung (Nieuwenhuis et al., 2002). 
Similarly, IL-17 from lung iNKT cells is associated with neutrophil recruitment 
clearance of Streptococcus pneumoniae from the lung (Ivanov et al., 2012). Finally, 
iNKT-derived IL-21 has been implicated in aiding clearance of Mycobacterium 
tuberculosi (Wu et al., 2015), and iNKT-derived IL-10 has been shown to protect mice 
from metabolic disease (Lynch et al., 2012).  
Recently, several subsets of iNKT cells have been identified that preferentially 




helper subsets of conventional T cells (Coquet et al., 2008; Hameg et al., 2000; Lee et al., 
2013). Invariant NKT cells that produce IL-21 (NKTfh) (Chang et al., 2011) and IL-10 
(NKTreg) (Sag et al., 2014) have also been described. The iNKT cell subsets reside 
preferentially in distinct peripheral tissues, with NKT1 cells homing to the liver, NKT2 in 
the spleen, NKT17 in the lung and mesenteric lymph node, and NKTreg cells 
preferentially homing to the gut and adipose tissue (Lee et al., 2015; Lynch et al., 2015). 
Invariant NKT cell subsets are also highly mouse strain dependent in that C57BL/6 mice 
possess more NKT1 cells than do BALB/c, while BALB/c possess increased numbers of 
NKT2 cells. NKT17 cells are most prevalent in NOD mice (Lee et al., 2015). These 
newly defined subsets could explain the heterogeneity in iNKT cell function and how 
these cells can regulate the immune response in a tissue-dependent manner. However, the 
mechanisms by which iNKT cell subsets develop and how they can regulate the immune 
response are largely unknown.  
The signaling lymphocyte activation markers (SLAMs) and the associated 
signaling adapter protein SAP play critical roles in NKT cell development (Chen et al., 
2017; Griewank et al., 2007; Nichols et al., 2005a; Sintes et al., 2013). The nine SLAM 
family receptors are widely expressed on all hematopoietic cells where they play critical 
roles in signaling and in cell adhesion (Cannons et al., 2011). Specifically, homophilic 
interactions among the SLAMf1 and SLAMf6 receptors expressed on thymocytes have 
been demonstrated to be critical in iNKT cell development (Griewank et al., 2007; 
Kageyama et al., 2012), while SLAMf3 has been demonstrated to be a negative regulator 




Importantly, SLAM family receptors have been implicated in the modulation of 
cytokine production in multiple leukocyte subsets. SLAMf6 was demonstrated to be 
critical in CD4+ T cell IL-4 production (Howie et al., 2005). SLAMf3 and SLAMf6 
engagement has been linked to IL-17A production in human lupus patients (Chatterjee et 
al., 2012) and SLAMf1 leads to increased TNFα and IL-1β after mycobacteria infection 
(Aversa et al., 1997; Jordan et al., 2007b; Song et al., 2015). However, the extent to 
which SLAM receptors modulate iNKT cell cytokine production is far less clear. While 
deletion of multiple SLAM receptors does have a significant impact on iNKT cell 
cytokine production (Chen et al., 2017; Huang et al., 2016), the pleiotropic nature of the 
Slam gene family has made it difficult to assign specific functional roles for individual 
SLAM family receptors to iNKT cells.  
Here, we explored the levels of SLAMf1, SLAMf4, and SLAMf6 co-expression 
on αβ T cells and report the presence of a distinct profile of SLAM family receptor 
expression on iNKT cells. These SLAM family receptor expression profiles were organ 
specific and strain-dependent. Importantly, when we extended our analysis to the subsets 
of iNKT cells, we found that the SLAM family receptor co-expression of SLAMf1, 
SLAMf4, and SLAMf6 allowed us to delineate specific iNKT cells subsets in the spleen, 
lung, and liver. We found that SLAMf6high NKT cells were enriched in NKT2 and 
NKT17 cells, and subsequently demonstrate that iNKT cells from SLAMf6-/- mice 
exhibit specific defects in IL-4 and IL-17 production that is associated with decreased 





2.3.1 Distinct SLAM family receptor expression profiles on conventional αβ T and 
iNKT cells 
SLAM family receptors, together with the intracellular signaling adaptor molecule 
SAP, are required for the development of iNKT cells (Chen et al., 2017; Chung et al., 
2005; Griewank et al., 2007; Kageyama et al., 2012; Nichols et al., 2005a; Sintes et al., 
2013). The function of SLAM family receptors on iNKT cells in the periphery, however, 
is still mostly unclear. Since previous reports suggest that distinct SLAM family 
receptors exhibit variable expression among NKT cells (Aktan et al., 2010), we assessed 
the co-expression of three SLAM family receptors, SLAMf1, SLAMf4, and SLAMf6 on 
iNKT cells and conventional  T cells among different organs in two different strains of 
mice (Figure 1). This analysis revealed the presence of a unique pattern of SLAM family 
receptor co-expression that distinguished iNKT cells from conventional  T cells, and 
this pattern varied among different tissues (Figure 1). For example, we found that B6 
spleen iNKT cells were primarily SLAMf1negSLAMf4negSLAMf6pos or 
SLAMf1intSLAMf4negSLAMf6pos. In contrast, B6 lung iNKT cells were 
SLAMf1negSLAMf4negSLAMf6neg, SLAMf1negSLAMf4negSLAMf6pos, or 
SLAMf1posSLAMf4negSLAMf6pos. Conventional  T cells in the B6 spleen and lung, in 
contrast, were primarily SLAMf1negSLAMf4negSLAMf6pos (Figure 1). We also noted that 
while both iNKT cells and conventional  T cells expressed SLAMf6, a distinct 
population of SLAMf6high iNKT cells could be observed in both the spleen and lung. 




also analyzed the patterns of SLAM co-expression on conventional T cells and iNKT 
cells in the spleen, liver and lung in BALB/c mice (Figure 1). This analysis revealed 
significant differences in SLAM family receptor co-expression in both iNKT cells and 
 T cells (Fig. 1). Notably, while B6 lung iNKT cells were 
SLAMf1negSLAMf4negSLAMf6neg, SLAMf1negSLAMf4negSLAMf6pos, or 
SLAMf1posSLAMf4negSLAMf6pos, we found that the majority of BALB/c lung iNKT 
cells were SLAMf1negSLAMf4negSLAMf6pos (Figure 1). Similarly, we noted an increased 
frequency of SLAMf1negSLAMf4negSLAMf6neg conventional  T cells in all organs 
(Figure 1). Taken together, these data indicated the presence of a unique pattern of 
SLAM family receptor co-expression that distinguished iNKT cells from their 
conventional T cell counterparts and that these SLAM receptor expression profiles varied 
significantly among different peripheral tissues and among different genetic backgrounds.  
 
2.3.2 SLAM family receptor co-expression profiles define NKT cell subsets 
The iNKT cell population is comprised of functionally distinct NKT1, NKT2, and 
NKT17 subsets (Lee et al., 2013). Therefore, we asked whether the SLAM family 
receptor co-expression profiles varied among the different iNKT cell subsets. iNKT cell 
subsets are defined according to their expression of the transcription factors PLZF and 
RORγt (Lee et al., 2013). NKT1 cells express low levels of PLZF and no RORγt. NKT2 
cells express high levels of PLZF and no RORγt, and NKT17 express intermediate levels 
of PLZF and RORγt (Figure 2A). Interestingly, analysis of splenic iNKT subsets revealed 




(Figure 2A). NKT1 cells were primarily SLAMf1intSLAMf4lowSLAMf6int. All iNKT2 
cells were SLAMf1lowSLAMf4lowSLAMf6high (Figure 2A). NKT17 cells were comprised 
of two distinct populations, one that is SLAMf1highSLAMf4lowSLAMf6low, and a second 
that is SLAMf1lowSLAMf4lowSLAMf6high (Figure 2A). These data demonstrated that 
iNKT cell subsets were each characterized by a distinct SLAM family receptor 
expression profile. 
The frequency of NKT cell subsets varies among different organs (Lee et al., 
2015), and it has been reported that NKT1 cells are enriched in the liver, NKT2 cells in 
the lung, and NKT17 cells in the lung and lymph node (Lee et al., 2015). Therefore, we 
asked whether SLAM family receptor expression profiles on NKT cells also varied in an 
organ-specific manner. We analyzed SLAM family receptor expression on the different 
iNKT cell subsets in the spleen, lung, and liver of C57BL/6 and BALB/c mice (Figure 
2B). Interestingly, we found that the lung was enriched in 
SLAMf1highSLAMf4lowSLAMf6low and SLAMf1lowSLAMf4lowSLAMf6high cells 
consistent with NKT17 cells (Figure 2B). Consistent with a previous report of tissue-and 
strain-dependent variation in NKT cell subset frequencies (Lee et al., 2015), we observed 
a greater frequency of NKT17 cells in the lungs of BALB/c mice and a concomitant 
increase of SLAMf1highSLAMf4lowSLAMf6low iNKT cells (Figure 2B). Similarly, 
BALB/c spleen and lung had an increased abundance of SLAMf6high NKT2 cells, and 
livers of both strains were dominated by SLAMf1intSLAMf4lowSLAMf6int NKT1 cells 
(Figure 2B).  Taken together, these data suggest that SLAM family receptor expression 





2.3.3 SLAM family receptor co-expression profiles on iNKT cell subsets are 
established during thymic development 
 NKT1, NKT2, and NKT17 subsets are established during thymic development 
(Lee et al., 2013; Lee et al., 2015). Therefore, we asked whether the SLAM family 
receptor expression profiles observed in the periphery were established coincident with 
NKT cell subset development in the thymus. Analysis of CD4+CD8+ double positive 
(DP) thymocytes, CD4 and CD8 single positive (SP) thymocytes, and NKT cells in the 
thymus revealed that DP thymocytes were uniformly SLAMf1highSLAMf4lowSLAMf6high, 
consistent with previous reports (Chen et al., 2017; Griewank et al., 2007; Jordan et al., 
2007a). Expression of SLAMf6 decreased significantly in CD4 and CD8 SP populations, 
while SLAMf1 decreased only slightly (Figure 3A). In contrast to the homogeneous 
SLAM family receptor expression on conventional T cells, thymic iNKT cells exhibited 
distinct SLAM family receptor expression profiles. We observed a distinct 
SLAMf1lowSLAMf4lowSLAMf6high population, as well as a 
SLAMf1lowSLAMf4highSLAMf6low population (Fig. 3A).  
We next investigated whether the thymic SLAM family receptor profiles varied in 
a strain-dependent manner as was observed in the peripheral tissues. Interestingly, we 
noted an increased percentage of iNKT cells from C57BL/6 mice that were 
SLAMf1negSLAMf4negSLAMf6neg (Figure 3B). Conversely, we observed an enrichment 
of SLAMf6pos iNKT cells in BALB/c mice, consistent with increased NKT2 and NKT17 




SLAM family receptor expression profiles were not only confined to iNKT cells, as we 
noted significant differences between C57BL/6 and BALB/c conventional αβ T cells 
(Figure 3B). Taken together, these data suggested that the SLAM family receptor 
expression profiles on iNKT cells and conventional T cells observed in the peripheral 
tissues are established during thymic development and that the distinct expression 
profiles are established upon divergence of the NKT and conventional  T cell lineages. 
 The classic developmental stages for thymic iNKT cells are defined by the 
expression of CD44 and NK1.1 (Benlagha et al., 2002; Pellicci et al., 2002): Stage 1 is 
CD44negNK1.1neg, Stage 2 is CD44highNK1.1neg, and Stage 3 is CD44highNK1.1high (Figure 
3C/D). We confirmed recent reports that developmental stages defined by CD44 and 
NK1.1 are roughly correlated with the NKT1, NKT2, and NKT17 subsets (Fig. 3C). We 
next analyzed the SLAM family receptor co-expression on each of the iNKT cell stages. 
We found that the SLAM family receptor expression patterns mirrored the expression 
patterns we observed on the iNKT cells after gating with PLZF and RORγt in the 
periphery (Figure 3D). Stage 1 iNKT cells expressed both SLAMf1 and SLAMf6 which 
was indicative of both an NKT2 and NKT17 phenotype (Figure 3D). Stage 2 iNKT cells 
express high SLAMf6, reminiscent of NKT2 cells (Figure 3D). Finally, the majority of 
Stage 3 iNKT cells are low in both SLAMf1 and SLAMf6, with a subpopulation of cells 
expressing SLAMf4 (Figure 3D), which is indicative of an NKT1 phenotype. 
Finally, we assessed whether the distinct marking of iNKT cell subsets by SLAM 
family receptor expression profiles was strain-dependent in the thymus as was observed 




populations, one that was SLAMf1intSLAMf4lowSLAMf6low  and a second that was 
SLAMf1lowSLAMf4highSLAMf6low (Fig. 3E). In contrast, NKT2 cells were characterized 
by a SLAMf1lowSLAMf4lowSLAMf6high phenotype (Figure 3E). NKT17 cells in both 
strains also showed two populations of cells, SLAMf1highSLAMf4lowSLAMf6high and 
SLAMf1highSLAMf4lowSLAMf6low.  Intriguingly, the SLAM family receptor expression 
profiles in either C57BL/6 or BALB/c marked the same thymic iNKT cell subsets. 
Together, these data suggest that the SLAM family receptor expression profiles that mark 
functionally distinct NKT cell subsets in the periphery are established during thymic 
development.  
 
2.3.4 SLAMf6 deficiency results in a defect in NKT17 cells and IL-17 production  
 Given our findings that SLAMf6 was preferentially expressed on NKT2 and 
NKT17 cells, we investigated whether SLAMf6 played a significant role in the 
development of these specific NKT cell subsets. We first compared the number of iNKT 
cell subsets between C57BL/6 and SLAMf6-/- mice. We observed a significantly lower 
number of thymic NKT2 and NKT17, but not NKT1, subsets in SLAMf6-/- mice 
compared to their C57BL/6 counterparts (Figure 4A). Analysis of the splenic NKT cell 
subsets revealed a significant decrease in the number of NKT17, but not NKT1 cells 
(Figure 4B). While there was a decrease in the number of iNKT2 cells in the spleen, this 
did not reach statistical significance (Figure 4B). Therefore, these data suggested that the 
NKT cell subsets on which SLAMf6 is preferentially expressed are present at 




 Next, we investigated whether SLAMf6-deficient mice exhibited an impaired 
ability to produce NKT2 and/or NKT17 cytokines. We sorted spleen NKT cells from 
C57BL/6 and B6.Slamf6-/- mice and cultured them for 72 h on anti-CD3-coated plates. 
An analysis of NKT cell cytokine production revealed a significant decrease in the 
production of IL-2 and IL-17 in SLAMf6-/- NKT cells (Figure 4C). We observed no 
difference between the two mouse strains in IL-4, IL-5, or IL-13 production (Figure 4C). 
These data indicated that SLAMf6-deficient NKT cells exhibited an impaired ability to 
produce IL-17, consistent with the lower numbers of NKT17 cells in these mice. To 
investigate whether NKT17 cells were impaired in their ability to produce IL-17, we 
compared IL-17 production between B6 and B6.SLAMf6-/- NKT17 cells. To identify 
NKT17 cells in B6.SLAMf6-/- mice, we used the surrogate markers ICOS (Cameron and 
Godfrey, 2018; Engel et al., 2016) and NRP-1 (Milpied et al., 2011), which allowed us to 
identify the NKT2 and NKT17 populations that also express high levels of SLAMf6 
(Figure 4D).  In our hands, we found that ICOShighNRP-1high cells contain the NKT2 and 
NKT17 populations, while the ICOSlowNRP-1lowsubset contains the NKT1 cells (Figure 
4D).  
We sorted ICOSlowNRP-1low and ICOShighNRP-1high iNKT subsets from C57BL/6 
and B6.SLAMf6-/- mice and assessed IL-17 production after culturing equal numbers of 
cells for 72 h on anti-CD3-coated plates (Figure 4E). As expected, there was a low level 
of detectable IL-17 produced in the ICOSlowNRP-1low population in both the wild-type 
and B6.SLAMf6-/- mice, consistent with the prevalence of NKT1 cells in this population 




fold lower in the NKT17 cells from B6.SLAMf6-/- mice. More surprising was that the IL-
4 production from the ICOShighNRP-1high NKT2 and NKT17 B6.SLAMf6-/- population 
was also significantly decreased (Figure 4E). Taken together, these data suggested that 






SLAM family receptors are widely expressed on all hematopoietic cells and 
individual leukocyte populations are known to express a distinct, characteristic 
complement of SLAM family receptors (Cannons et al., 2011). Here, we find that 
examination of just 3 SLAM family receptors reveals distinct patterns of SLAM family 
receptor co-expression that not only distinguish iNKT cells from their conventional αβ T 
cell counterparts, but distinguish functionally distinct subsets of iNKT cells. Furthermore, 
we find that these SLAM receptor expression profiles stably mark iNKT cell subsets in 
naïve mice in different tissues and in different strains of mice. Our finding that the 
development and function of SLAMf6high NKT2 and NKT17 subsets are dependent on 
SLAMf6 indicates a segregation of SLAM receptor roles in regulating iNKT cell function 
not previously appreciated. Indeed, these findings are reminiscent of a recent report 
demonstrating that SLAM receptor expression profiles defined functionally distinct 
populations of hematopoietic stem cells (Oguro et al., 2013). In addition, recent findings 
from our laboratory indicate the presence of SLAM receptor expression profiles that 
distinguish functional  subsets in mice (manuscript in preparation). These findings 
demonstrate that the heterogeneity in SLAM family receptor expression is much greater 
than previously thought, and suggest that discrete modulation of the array of SLAM 
family receptors expressed by a cell may be a mechanism used to fine-tune cell function. 
  Despite the critical role played by the SLAM/SAP signaling pathway in iNKT 
cell development, elucidation of the specific functions regulated by individual SLAM 




results in impaired iNKT cell function (Hu et al., 2016), it has been difficult to identify 
significant impairments in iNKT cell function in mice deficient in only a single SLAM 
family receptor. One study using an inducible conditional SAP knockout mouse to delete 
SAP after iNKT cells had developed, reported that deletion of SAP had no effect on IFN-
 or IL-4 production and found a defect only in iNKT cell cytotoxicity (Das et al., 2013). 
Our data demonstrating that SLAMf6 specifically regulates NKT2 and NKT17, but not 
NKT1, is consistent with this finding since most iNKT cell cytotoxicity is mediated by 
NKT1 cells. In addition, our data indicate that after in vivo αGalCer administration, the 
vast majority of IL-4 is produced by the predominant NKT1 population and not by the 
minor NKT2 population (data not shown), providing a possible explanation for why this 
defect was not previously observed. This would be consistent with a recent report 
demonstrating that all thymic iNKT subsets, including NKT1 cells, can produce IL-4 
after stimulation (Cameron and Godfrey, 2018; Georgiev et al., 2016; Tang et al., 2014).  
Using a Vα14 transgenic mouse to force iNKT cell development in the absence of 
SAP, Michel et al., demonstrated that iNKT cells developing in the absence of SAP 
exhibited a marked defect in NKT2 cells but an expansion of NKT17 cells (Michel et al., 
2016). These data are in partial agreement with our observation that mice deficient in 
SLAMf6, which signals using the SAP adapter, are also deficient in NKT2 cells. While 
our data differed in that we observed a reduction in NKT17 cells, this discrepancy could 
be due to either the different experimental approaches used, or it could point to the 




Studies using SLAMf1/5/6 triple knockouts demonstrated significantly reduced 
numbers of iNKT cells versus those observed in SLAMf6–deficient mice (Huang et al., 
2016), suggesting that SLAMf1, SLAMf5, and SLAMf6 can each contribute to the 
positive signaling required for iNKT cell development (Chen et al., 2017). Our data, 
combined with these previous reports, suggest that SLAMf6 may have the greatest effect 
on the development of NKT2 and NKT17 cells while SLAMf1 and SLAMf5 may affect 
NKT1 cells specifically, or provide compensatory signaling in the absence of SLAMf6 
on this subset.  
Our data suggest that SLAMf6 has a specific effect on iNKT cell IL-17 
production. Unlike the case with IL-4, which can be produced by NKT1 and NKT2 cells 
after stimulation by αGalCer, we found that only NKT17 cells produced IL-17 consistent 
with a recent report (Cameron and Godfrey, 2018). SLAMf6 has previously been 
implicated in the production of IL-17 (Tang et al., 2014). In a study comparing the 
cytokine production of splenic IL-17 producing iNKT cells, SLAMf6lowCD4negNK1.1neg 
NKT17 cells produced IL-17, whereas SLAMf6highCD4posNK1.1neg produced IL-21. 
While the reason for these discrepant findings is not clear, they may result from the use in 
that study of autoimmune-prone NZB/W mice. In addition, we note that a small 
percentage of CD4negSLAMf6high cells, which comprise up to 30-50% of the NKT17 cells 
in the spleen (Cameron and Godfrey, 2018), were not analyzed (Tang et al., 2014).  
 Slam family genes are highly polymorphic and these polymorphisms are known 
to have functional consequences. Recently, it was shown that mice that possess Slam 




ratio while the NKT17 subset was unaffected (Baglaenko et al., 2017). There are 
profound differences in the level of SLAM receptor expression as well as receptor 
signaling capabilities between the Slam haplotypes (Wandstrat et al., 2004). For example, 
Slam haplotype 1 contains an isoform for SLAMf6 that is more inhibitory than the 
isoform present in Slam haplotype 2 expressing animals (Keszei et al., 2011). SLAMf1 
and SLAMf6 receptor expression is decreased in Slam haplotype 2 animals, while 
SLAMf3 expression is increased (Baglaenko et al., 2017). Our data demonstrating that 
SLAMf6 plays a role in NKT2 development suggests the possibility that the strain-
dependent differences in NKT2 subsets result from the differing signaling capabilities of 
the SLAMf6 isoforms expressed in each of these strains. 
 Together, our data linking SLAM family receptor expression profiles with 
functional iNKT cell subsets provides a new conceptual framework that may help 
elucidate the specific roles of SLAM family receptors on iNKT cells as well as other 
leukocyte subsets. Specifically, the data demonstrating that SLAMf6 specifically 
regulates NKT2 and NKT17 development could represent an important link in our 
understanding the connection between iNKT cell development and iNKT cell functional 




2.5. Materials and Methods 
 
2.5.1 Mice and Reagents 
Female C57BL/6 and BALB/cJ mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME) and were bred at the University of Vermont. SLAMf6-/- 
mice were described previously (Dutta et al., 2013). Mice were bred and housed in the 
specific pathogen-free barrier facility at the University of Vermont. All procedures 
involving animals were approved by the University of Vermont Institutional Animal Care 
and Use Committee.  
 
2.5.2 Flow cytometry  
Splenocytes and thymocytes were obtained by gently pressing through a 70 m 
nylon mesh. Liver leukocytes were obtained by gently pressing through a 70 µm nylon 
mesh, followed by washing in PBS, and separation of hepatocytes via a 33.8% Percoll 
gradient (GE Healthcare, Chicago, IL)  as described (Rymarchyk et al., 2008). Lung 
leukocytes were isolated via mechanical dissociation followed by enzymatic degradation 
using 200µg/mL DNAse (Sigma Aldrich, St. Louis, MO)  and 1mg/mL Collagenase Type 
IV (Life Technologies, ThermoFisher, Waltham, MA) as described (Benoit et al., 2015). 
RBC’s were lysed using Gey’s solution. Cells were stained at 4°C in PBS + 2% FBS 
containing 0.2% sodium azide for 30 min., after which they were washed and 
resuspended in PBS + 1% PFA when appropriate. Surface antibodies used in these 




SLAMf1, SLAMf4, SLAMf3, SLAMf2, SLAMf5, SLAMf6, ICOS, and NRP-1 
(Biolegend, San Diego, CA). Additional antibodies CD11b, CD19, and CD44 were 
obtained from BD biosciences. UV Live Dead staining reagent was included in all 
experiments (Life Technologies, ThermoFisher, Waltham, MA). CD1d tetramer loaded 
with PBS-57 was provided by the National Institutes of Health (NIH) tetramer facility 
(Emory University Vaccine Center, Atlanta, GA).   
For nuclear transcription factor staining, cells were surface stained as above, after 
which they were fixed overnight using the Foxp3 transcription factor staining buffer set 
(EBiosciences, ThermoFisher, Waltham, MA). The next day cells were washed, blocked 
with rat IgG, and stained with anti-PLZF (9E12) and RORγt (Q31-378) (BD 
Biosciences). After staining, cells were washed, resuspended, and data were immediately 
collected on a LSRII flow cytometer (BD Biosciences, Franklin Lake, NJ) and analyzed 
with FlowJo software (FlowJo LLC). 
   
2.5.3 Analysis of SLAM receptor expression patterns 
 Three-way analysis of SLAM receptor expression was performed with 
combinatorial gating using FlowJo software (FlowJo LLC). In brief, iNKT cells were 
first identified using anti-TCRβ and CD1d tetramer. Positive SLAMf1, SLAMf4, and 
SLAMf6 gates were identified using specific SLAM fluorescence minus-one controls. 
Combination gates were then applied for the positive gates resulting in multiple 




When appropriate, percent expression for multiple mice were averaged and plotted in 
GraphPad Prism (GraphPad Software, San Diego, CA). 
 
2.5.4 Statistics 
All animal experiments were conducted in a non-randomized and non-blinded 
fashion.  Statistical analyses were performed using an unpaired T test or multiple T tests 
where appropriate. In all cases, tests were considered significant when p ≤ 0.05. All 
groups were shown to have similar variance in distribution.   Sample size estimates were 
based on previous experience. When data were combined from multiple different 
experiments, data were first normalized to the C57BL/6 reference strain in each 
experiment. Normalization was accomplished by dividing each data point in an 
experiment by the average of the C57BL/6 response in that experiment. All statistical 
analysis was performed using Graph Pad Prism (GraphPad Software, San Diego, CA). 
 
2.5.5 Cell isolation and culture for ex vivo cytokine analysis 
 Splenocytes were enriched for NKT cells using the STEMCELL EasySep CD4+ 
negative selection kit according to the manufacturer’s instructions. After which, cells 
were stained with Live/Dead efluor780 (EBiosiences), anti-TCRβ, CD11b, CD8, Nkp46, 
ICOS and NRP-1, and the addition of CD1d/PBS-57 loaded-tetramer. NKT cells were 
subsequently purified by fluorescent activated cells sorting (FACS Aria III). Cell purity 
for all sorts was between 80% and 95%. After sorting, cells were placed in modified 




20µg/mL gentamycin) and incubated on anti-CD3 (5 g/ml) and anti-CD28 (1 g/ml)-
coated plates at 37 oC and 5% CO2. 72 h later, supernatants were harvested and analyzed 
via Milliplex assay or ELISA, according to the manufacturer’s instructions (EMD 
Millipore, Darmstadt, Germany).  The milliplex kits used were the Mouse 
cytokine/chemokine magnetic bead panel followed by a custom kit containing GM-CSF, 




 Interleukin-4 and IL-17 ELISAs were performed on cultured supernatants from 
sorted NKT cell cultures as above. IL-4 capture was plated on a COSTAR high protein 
binding plate overnight at 4°C. After which, the plate was washed, blocked, and 
detection, strep-HRP, TMB substrate, and stop solution added after the appropriate 
incubations. All IL-4 reagents were obtained from Biolegend. TMB substrate was from 
BD Biosciences. IL-17 ELISA was performed via the R&D mouse IL-17 Duo kit 
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FIGURE 2-1: Strain-dependent and organ-specific heterogeneity in SLAM family 
receptor co-expression profiles on iNKT cells.  
 
Representative contour plots of SLAMf1, SLAMf4, and SLAMf6 receptor expression on 
spleen, liver, and lung conventional αβ T cells and iNKT cells from B6 (upper) and 
BALB/c mice (lower). iNKT cells and conventional αβ T cells were identified using 
CD1d-tetramer/PBS57 and TCRThree-way expression profiles of the different SLAM 
receptors were calculated using combination gating and are presented as a percentage of 
total iNKT or αβ T cells. Data is representative of 4 separate experiments using B6 mice 












FIGURE 2-2: SLAM family receptor co-expression marks iNKT cell subsets in 
peripheral tissues.  
iNKT cell subsets from the spleen, lung, and liver were identified using CD1d-
tetramer/PBS57 and TCRβ followed by staining for transcription factors. A). SLAM 
family receptor expression profiles on spleen iNKT cell subsets. Top: Gating scheme 
used for identification of iNKT cell subsets using PLZF and RORγt expression. Bottom: 
Co-expression of SLAMf1, SLAMf4, and SLAMf6 on iNKT1 (green), iNKT2 (red), and 
iNKT17 (blue) subsets. B). Strain-dependent and organ-specific heterogeneity in SLAM 




comparing SLAMf1, SLAMf4, and SLAMf6 receptor expression in C57BL/6 mice (top) 
and BALB/c mice (bottom). Overlays of NKT1 (grey), NKT2 (red), and NKT17 (blue) 
subsets reveal that SLAM family receptor expression profile marking of NKT cell subsets 
are relatively stable amidst strain-dependent and organ-specific variability in the 
frequency of NKT cell subsets. Data is representative of 4 separate experiments using B6 
mice (total of 18 mice), and 2 separate experiments using BALB/c mice (total of 10 









 FIGURE 2-3: SLAM family receptor expression profiles are established during 
thymic development.  
Thymic iNKT cells and conventional  T cells from C57BL/6 or BALB/c mice were 
identified using TCRβ and CD1d-tetramer/PBS-57 or CD4 and CD8, respectively. A). 
Representative flow cytometry plots of SLAM family receptor expression profiles on 
C57BL/6 thymic CD4+, CD8+, DP, and iNKT cells. Examination of SLAMf1, SLAMf4, 
and SLAMf6 co-expression revealed heterogeneous co-expression on iNKT cells but not 
conventional T cells. B). Cumulative SLAM family receptor co-expression profiles on 
thymic iNKT and conventional T cells from C57BL/6 and BALB/c mice. C). iNKT cell 
subset profiles correlate with C57BL/6 iNKT cell developmental stages. Representative 
flow cytometry of iNKT subsets identified using PLZF and RORγt, followed by analysis 
of CD44 versus NK1.1 expression. D). Distinct SLAM family receptor expression 
profiles associated with NKT cell developmental stages. Thymic NKT cells were 
identified using TCR and CD1dtetramer/PBS57, then stained with CD44 and NK1.1 to 
identify classical NKT cell developmental stages and SLAMf1, SLAMf4, and SLAMf6 
expression was evaluated. Representative flow cytometry of SLAMf1, SLAMf4, and 
SLAMf6 co-expression on Stage 1 (blue), Stage 2 (red), and Stage 3 (green) iNKT cells.  
E). Strain-dependent SLAM family receptor expression profiles are established during 
thymic development. Representative flow cytometry plot overlays of SLAMf1, SLAMf4, 
and SLAMf6 expression on NKT1 (grey), NKT2 (red), and NKT17 (blue) subsets. Data 
are representative of 2 separate experiments, n= 9 mice per strain per experiment. Mice 








FIGURE 2-4: SLAMf6-dependent NKT2 and NKT17 development and function.  
 
A). Decrease in thymus iNKT2 and iNKT17 subsets in SLAMf6-/- animals. Top: 
Representative flow cytometry plots of thymic iNKT cell subsets defined using PLZF and 
RORγt staining. Subsets are indicated by colored boxes: NKT1 (green), NKT2 (red), and 
NKT17 (blue). Bottom: Relative number of iNKT cell subsets in B6 and SLAMf6-/- 
animals. Data are the cumulative quantification of 4 separate experiments. Statistical 
analysis was performed using an unpaired T test. *p ≤ 0.05 **p ≤ 0.01 B). Decrease in 
spleen NKT17 cells in SLAMf6-/- animals. Upper: Representative flow cytometry of 
iNKT cells and iNKT cell subsets between C57BL/6 and SLAMf6-/- animals identified as 
above. Lower: Relative number of total splenic iNKT cells and iNKT cell subsets 
between B6 and SLAMf6-/- animals. Data are the cumulative quantification of 4 separate 
experiments. Statistical analysis was performed using an unpaired T test. **p ≤ 0.01 C). 
NKT-intrinsic reduction in IL-17 production from SLAMf6-/- iNKT cells. iNKT cells 
from C57BL/6 and SLAMf6-/- animals were sorted and incubated on anti-CD3-coated 
plates for 72 h, after which supernatant cytokine levels were assessed using Milliplex. 
Data represent the cumulative results of 2 separate experiments. Statistical analysis was 
performed using an unpaired T test. *** p ≤ 0.001, ****p ≤ 0.0001 D).  Confirmation of 
NKT2-specific surrogate markers ICOS and NRP-1 for use in sorting. Top: iNKT cell 
subsets (shown in colored boxes) were evaluated for ICOS, NRP-1, and SLAMf6 




strategy for isolating specific iNKT1 versus iNKT2 and iNKT17 subsets using ICOS and 
NRP-1. Representative flow cytometry of iNKT cells identified using CD1d-
tetramer/PBS57 and TCRβ. Middle: ICOShighNRP1high identify NKT2 and NKT17 cells 
while ICOSlowNRP1low identify NKT1 cells in both C57BL/6 and SLAMf6-/- mice. E). 
Significantly reduced IL-17 and IL-4 production from sorted ICOShighNRP-1high 
NKT2/NKT17 subsets in Slamf6-/- mice. Sorted NKT2/NKT17 and NKT1 subsets were 
stimulated on anti-CD3-coated plates for 72hrs. IL-4 and IL-17 production from 
supernatants were determined via ELISA. Data are representative of 2 separate 
experiments. Statistical analysis was performed using multiple T tests. **p ≤ 0.01 ****p 
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 Semi-invariant natural killer T cells (iNKT) are important mediators of host 
immunity. This innate-T cell subset is now thought to encompass specific subsets 
responsible for the production of IFNγ (NKT1), IL-4 (NKT2), and IL-17 (NKT17). 
While these cell subsets are distinct within the thymus, less is known about the regulation 
of iNKT cell subsets in the periphery. Regulation of iNKT cells in general is thought to 
occur via the signaling lymphocyte activation markers (SLAMs), which are required with 
the SLAM family receptor adaptor protein (SAP) for the development of iNKT cells. A 
complete analysis of SLAM family receptors on iNKT cell subsets has not been 
completed. Here, we show that SLAMf6, which can have both activating and inhibitory 
function on iNKT cells, is responsible for cytokine production and the proliferation of 
NKT2 and NKT17 subsets after activation. Additionally, we show preferential expansion 
of an NKT2 cell like population 3 days after activation with the iNKT cell agonist 
αGalCer.  These data reveal a role for SLAMf6 on the regulation of distinct NKT2 and 
NKT17 subsets in the periphery. Our data also challenge the definitions of iNKT cell 
subsets, revealing potential changes to the iNKT cell milieu after activation. Taken 
together, these data improve our understanding of the mechanisms regulating NKT1, 






Invariant natural killer T (iNKT) cells are innate-like T cells that play critical 
roles in the host immune response (Behar and Porcelli, 2007; Godfrey and Rossjohn, 
2011; Gumperz and Brenner, 2001). iNKT cells recognize glycolipids bound by the MHC 
class-1 like molecule CD1d (Kawano et al., 1997; Spada et al., 1998). When activated by 
the prototypical agonist alpha-galactosylceramide (αGalCer), iNKT cells produce a wide 
variety of cytokines such as IFNγ, IL-4, TNFα, IL-17, and IL-10 (Coquet et al., 2008; 
Hameg et al., 2000; Yoshimoto and Paul, 1994). During iNKT cell development, three 
distinct iNKT cell subsets have been described: NKT1, which produces IFN- and is 
characterized by low PLZF and high T-bet expression, NKT2, which produces IL-4, IL-5, 
and IL-13 and is characterized by high PLZF expression, and NKT17, which produces 
primarily IL-17 and is characterized by high RORt expression (Lee et al., 2013; Lee et 
al., 2015).  
NKT cell development is highly dependent on signaling by multiple SLAM 
family receptors and their associated signal adapter protein SAP (Griewank et al., 2007; 
Nichols et al., 2005a; Sintes et al., 2013). The best characterized interactions are 
SLAMf1-SLAMf1 and SLAMf6-SLAMf6 interactions that are thought to occur between 
developing iNKT cells and neighboring DP thymocytes that express high levels of both 
of these proteins as well as CD1d (Coles and Raulet, 2000; Gapin et al., 2001; Griewank 
et al., 2007). Multiple engagements of different SLAM family receptors appear to be 
necessary for iNKT cell development as mice deficient in either SLAMf1 or SLAMf6 




type counterparts (Griewank et al., 2007; Huang et al., 2016). Although SLAM family 
receptor signaling is critical for iNKT cell development, the exact mechanisms through 
which they act is still unclear. Accumulating data suggest that SLAMf6 induces the 
expression of PLZF and Egr2, transcription factors critical for iNKT cell development 
(Baglaenko et al., 2017; Dutta et al., 2013; Tuttle et al., 2018). However, it has also been 
reported that SLAMf6 possesses inhibitory functions that are modulated by the SAP 
signaling adapter (Kageyama et al., 2012). Finally, very little is known about the role of 
SLAMf6 in regulation of the development of different iNKT cell subsets and how this 
affects iNKT cell function in peripheral tissues. 
We have previously shown that SLAMf1, SLAMf4, and SLAMf6 are co-
expressed in a heterogeneous manner among different iNKT cell subsets (Chapter 2). We 
found that SLAMf6 was highly expressed on all NKT2 cells and a significant fraction of 
NKT17 cells, and that SLAMf6 regulated IL-17 and IL-4 cytokine production from 
NKT17 and NKT2 subsets, respectively (Chapter 2). We next examined whether 
SLAMf6 could also affect the proliferation of iNKT cells in a subset specific manner. 
Here, we report that the SLAMf6-expressing NKT2 and NKT17 subsets in the 
peripheral tissues encompass the majority of the proliferating NKT cells both in vivo and 
in vitro.  Ki67 and BrdU+ NKT cells are highly enriched in SLAMf6high NKT2 and 
NKT17 cells. Using surrogate markers ICOS and NRP-1 for NKT2 and NKT17 (without 
the use of SLAMf6), we showed that NKT2 and NKT17 cells are also more proliferative 
than NKT1 cells in the B6.SLAMf6-/- mouse. Interestingly, SLAMf6 deficient NKT2 and 




show that NKT2 cells may preferentially expand after activation with the prototypical 
glycolipid alpha-galactosylceramide (αGalCer). This manuscript supports a model in 
which SLAMf6 has multiple roles on iNKT cells subsets, not only in activation of 








3.3.1 SLAMF6 marks highly proliferative NKT2 and NKT17 cells  
To investigate the proliferative capacity of thymic iNKT cells, we assessed the 
expression of Ki67, a marker of cells in either the S or G2/M phase of the cell cycle, on 
thymic iNKT cell subsets. A comparison of naïve thymic iNKT cell subsets in the 
C57BL/6 mouse (Figure 1A) revealed significant differences in Ki67 expression among 
NKT1, NKT2, and NKT17 subsets. Whereas high levels of Ki67 expression were 
observed in the NKT2 and NKT17 subsets, little Ki67 expression was observed in the 
NKT1 subset which comprises the majority of thymic iNKT cells (Figure 1A). 
Calculation of the frequency of Ki67+ iNKT cells revealed that a significantly higher 
percentage of NKT2 and NKT17 cells were Ki67+ (Figure 1A), indicating that the thymic 
NKT2 and NKT17 subsets constitute the highly proliferative iNKT cells in the thymus.   
Since we previously observed that the population of SLAMf6high NKT cells in the 
thymus was composed primarily of NKT2 and NKT17 subsets (Chapter 2), we 
investigated the association of SLAMf6 expression with Ki67. An analysis of total 
thymic iNKT cells revealed a clear correlation between high SLAMf6 expression and 
Ki67 expression (Figure 1B). These data indicated that the vast majority of proliferating 







3.3.2 SLAMf6 marks highly proliferative peripheral NKT2 and NKT17 cells after 
activation 
We next investigated whether SLAMf6 expression on iNKT cells in peripheral 
tissues was associated with proliferative capacity. First, we confirmed that SLAM6high 
iNKT cells marked the NKT2 (PLZFhighRORtlow) and NKT17 (PLZFintRORthigh) 
subsets while SLAMf6low iNKT cells marked the NKT1 (PLZFlowRORtlow) and NKT17 
spleen iNKT cells (Figure 2A). To determine whether there was a difference in the 
proliferative capacity of the SLAMf6high (NKT2/NKT17) cells and SLAMf6low 
(NKT1/NKT17) iNKT cells, we sorted spleen iNKT cells based on their SLAMf6 
expression (Supplementary Figure 1) and assessed their proliferation after anti-CD3 
stimulation. FACS-sorted iNKT cell subsets were labelled with VioTracker fluorescent 
dye and cultured for three days on anti-CD3-coated plates after which we assessed 
proliferation (Figure 2B). Interestingly, we observed a significantly higher number of live 
SLAMf6high iNKT cells versus their SLAMf6low counterparts, and we found that 
SLAM6high iNKT cells had proliferated significantly more than the SLAMf6low iNKT 
cells (Figure 2B). The association of SLAMf6 with increased proliferative capacity was 
not specific to C57BL/6 NKT cells, as we also observed increased proliferation in 
SLAMf6high iNKT cells from BALB/c mice (Supplementary Figure 2). Taken together, 
these data indicate that SLAMf6 expression marks NKT2 and NKT17 cells that are 
homeostatically proliferating in vivo, and that SLAMf6 expressing NKT2/NKT17 cells 
exhibit a significantly higher proliferative capacity than their SLAM6low NKT1 




3.3.3 Expansion of SLAMf6high NKT2-like cells after in vivo activation  
Next, we evaluated the relationship of SLAMf6 expression on iNKT cells and 
proliferation in vivo after activation with the more physiological CD1d ligand, αGalCer, 
which induces rapid proliferation of NKT cells (Kawano et al., 1997) (Supplementary 
Figure 3).  First, we assessed SLAM family receptor expression on iNKT cells 3 and 5 
days afterαGalCer administration. This analysis revealed a 12.5-fold increase in the 
expression of SLAMf6 on NKT cells 3 days after activation (Figure 3A). In contrast, we 
observed a 3.5 and 3.2 fold increase in SLAMf1 and SLAMf3 expression respectively at 
this time (Figure 3A). Interestingly, while iNKT cell SLAMf6 expression in naïve mice 
was quite heterogeneous, SLAMf6 expression was uniformly high 3 days after activation 
and cells retained this level of expression 5 days after activation (Figure 3A), at which 
time iNKT cell numbers were returning to baseline levels (Supplementary Figure 4). In 
contrast, the expression of SLAMf1 and SLAMf3 had returned to baseline levels 5 days 
after activation. These data reveal that after activation and expansion of iNKT cells, the 
iNKT cell population is dominated by SLAMf6high iNKT cells.  
 Since we have shown that SLAMf6 is preferentially expressed on naïve NKT2 
and NKT17 cells, we next determined whether the SLAMf6high iNKT cells present on day 
3 exhibited an NKT2 phenotype. A comparison of splenic iNKT cell subsets between 
vehicle-treated and αGalCer-treated mice revealed a dramatic increase in a population of 
PLZFhighRORγtlowSLAMf6high iNKT cells (Figure 3B), which was reminiscent of the 
phenotype of NKT2 cells. To determine the proliferative capacity of the iNKT cell 




were challenged with αGalCer i.p., BrdU was administered 48 h later, and iNKT BrdU 
incorporation was assessed 72 h after αGalCer administration. After 72hrs, iNKT cells 
showed increased proliferation, with 20% of all iNKT cells actively incorporating BrdU 
at this time point (Figure 3C). Interestingly, the only cells that were actively 
incorporating BrdU were the PLZFhigh iNKT cells (Figure 3C). Together, these data 
suggested that a PLZFhigh SLAMf6high NKT2-like population of iNKT cells preferentially 
expanded after activation in vivo. Whether these cells are, in fact, NKT2 cells remains 
unclear since an analysis of the NKT1-specific transcriptional regulator T-bet revealed 
that it was also highly expressed in the PLZFhigh SLAMf6high “NKT2-like” population of 
iNKT cells 3 days after activation (data not shown), raising the possibility that altered 
expression of the diagnostic PLZF, RORt, and T-bet transcription factors after activation 
may preclude their use for identification of iNKT cell subsets.  
 
 
3.3.4 Slamf6-dependent proliferation of NKT2/NKT17 subsets 
 Since our data indicated that SLAMf6 expression was closely associated with 
iNKT cell proliferation in vivo and in vitro, we next investigated whether SLAMf6 
regulated iNKT cell proliferation by assessing the proliferative capacity of SLAMf6-
deficient iNKT cell subsets. Since our previous results suggested that identification of 
iNKT cell subsets in vivo after activation was difficult, we compared proliferation in vitro 
using anti-CD3 stimulation. To identify iNKT cell subsets in both C57BL/6 and 
B6.SLAMf6-/- mice, we employed the previously identified surrogate markers ICOS 




demonstrated reproducibly distinguished the NKT1 subset from the NKT2/NKT17 
subsets in both B6 and B6.SLAMf6-/- mice (Chapter 2).  
 We sorted ICOShighNRP-1high (NKT2/NKT17) and ICOSlowNRP-1low (NKT1) 
splenic iNKT cells, stimulated equal numbers of cells with anti-CD3 and anti-CD28, and 
assessed the number of viable cells after 72 hours. As expected, we observed a 
significantly higher number of live ICOShighNRP-1high NKT2/NKT17 cells compared to 
their ICOSlowNRP-1low NKT1 counterparts (Figure 4). Interestingly, we observed a 
striking decrease in the number of the ICOShighNRP-1high NKT2 cells in B6.SLAMf6-/- 
mice compared to their C57BL/6 counterparts (Figure 4). Taken together, these data 
reveal a specific role for SLAMf6 in the regulation of SLAMf6high NKT2/NKT17 iNKT 




3.4. Discussion   
SLAM family receptors and the signaling adapter protein SAP play critical roles 
in iNKT cell development (Griewank et al., 2007; Kageyama et al., 2012; Nichols et al., 
2005a). However, elucidation of the specific roles that individual SLAM family receptors 
play in iNKT cells has been difficult. Here, we show that SLAMf6 is highly expressed on 
homeostatically proliferating iNKT cells that we identify as NKT2 and NKT17 subsets. 
In addition, we demonstrate that SLAMf6 controls activation-induced proliferation of 
NKT2 and NKT17, but not NKT1, subsets. These data not only reveal a specific role for 
SLAMf6 in iNKT cell function, but also indicate that functions of individual SLAM 
family receptors are not evenly distributed among each of the iNKT cell subsets.   
Our finding that SLAMf6 controls the proliferation of NKT2 and NKT17 subsets 
is consistent with recent transcriptomic studies of thymic iNKT cell subsets which found 
that the NKT2 subset is enriched in both SLAMf6 and cell cycle gene transcripts (Engel 
et al., 2016; Georgiev et al., 2016). In addition, recent reports demonstrate that thymic 
NKT2 and NKT17 cells are significantly more proliferative than their NKT1 counterparts 
(Cameron and Godfrey, 2018) and that all iNKT cell subsets pass through an IL-13-
expressing (i.e., NKT2-like) intermediate during thymic development (O'Brien et al., 
2016). These studies suggest that the NKT2 and NKT17 subsets may represent a cycling 
population that is a precursor to the NKT1 subset (Engel et al., 2016; Lee et al., 2015). 
Together with these findings, our data suggests that SLAMf6 may function at an early 
stage of thymic development to foster cycling and expansion of the NKT2 and NKT17 




subsets are precursors to NKT1 cells since the absence of SLAMf6 did not have 
significant impact on the NKT1 subset.  
Consistent with its proliferative phenotype, we observed an increase in an 
“NKT2-like” population of iNKT cells 3 days after αGalCer administration. These cells 
expressed high levels of PLZF and SLAMf6, but also expressed high levels of T-bet, 
making an unambiguous NKT subset identification difficult. The expanded iNKT cells 
could be NKT1 cells exhibiting increased PLZF expression after activation, but most 
reports suggest that PLZF is only induced after TCR signaling in the thymus and is not 
inducible on mature T cells (Savage et al., 2011; Zhang et al., 2015). While T-bet is 
widely used as a marker of NKT1 cells, a population of PLZFhighTbethigh NKT2 
precursors has been described (Engel et al., 2016; Pellicci et al., 2002), which could 
represent the SLAMf6high NKT subset that we observe in the spleen 3 days after 
activation.  
 Whether highly proliferative SLAMf6high NKT2 cells preferentially expand in 
the periphery or whether they represent recent thymic emigrants is unclear. NRP-1 which 
is highly expressed on the SLAMf6high NKT2 and NKT17 subsets has been suggested to 
mark recent thymic emigrants (Milpied et al., 2011), and it was demonstrated that NKT2 
cells express more homing markers than do NKT1 cells, and that NKT2 and NKT17 
emigrate from the thymus at higher rates than NKT1 (Georgiev et al., 2016). After 
activation with αGalCer, iNKT cells either downregulate their TCR or undergo activation 
induced cell death (Subleski et al., 2011; Wilson et al., 2003). Liver iNKT cells, which 




death within 24 h of αGalCer treatment, which is followed by repopulation of the liver 
with iNKT cells that are ICOShighTCRβhighNK1.1neg, a phenotype consistent with what we 
now know are NKT2 cells (Subleski et al., 2011). We report here that these repopulating 
cells also expressed high levels of SLAMf6, another marker of NKT2 cells. Additional 
experiments will be needed to determine the relative contributions of the proliferation of 
peripheral iNKT cells and contributions from the recent thymic emigrant pool in the 
SLAMf6-dependent proliferation of iNKT cells.  
Regulation provided by SLAMf6 is thought to occur at the immunological 
synapse upon TCR engagement (Tuttle et al., 2018; Zhao et al., 2012). A recent report 
observed that SLAMf6 crosslinking is required for the upregulation of Egr2, a protein 
activated downstream of TCR engagement (Tuttle et al., 2018). Once Egr2 expression 
reached a sustained, high level, PLZF expression was induced, allowing for the 
differentiation of iNKT cell subsets (Dutta et al., 2013; Tuttle et al., 2018). These data are 
consistent with previous reports revealing SLAMf6 as an inducer of PLZF on double 
positive thymocytes (Dutta et al., 2013). Interestingly, we did not see any significant 
differences in PLZF expression between C57BL/6 and SLAMf6-/- iNKT cell subsets in 
either the thymus or the spleen (Supplementary Figure 4), suggesting the possibility that 
other SLAM receptors may be compensating in the absence of SLAMf6.  
Although it has been known for some time that both SLAMf1 and SLAMf6 
contribute to iNKT cell development (Griewank et al., 2007), the relative contributions of 
these SLAM receptors has been difficult to define. In this manuscript, we demonstrate a 




increased proliferative capacity. Our finding that SLAMf6 primarily regulate NKT2 and 
NKT17 proliferation suggests the possibility that the requirement for both SLAMf1 and 
SLAMf6 may not simply be due to their additive effects. Rather, each SLAM receptor 
may play a distinct role in iNKT cell development. These observations may aid in our 
understanding of how NKT cell subsets develop and proliferate in tissues,b which may 





3.5. Materials and Methods 
 
3.5.1 Mice and reagents 
 C57BL/6 and BALB/cJ mice were obtained from The Jackson Laboratory (Bar 
Harbor, ME). B6.Slamf6-/- mice have been described previously (Dutta et al., 2013). 
Mice were bred in the specific pathogen free barrier facility at the University of Vermont. 
All procedures involving animals were approved by the University of Vermont 
Institutional Animal Care and Use Committee. αGalCer (Avanti Lipids) was resuspended 
in PBS + 0.05% Tween20, and administered to mice intraperitoneally (i.p.). 
 
3.5.2 Flow cytometry 
Splenocytes and thymocytes were obtained by gently pressing through a 70 m 
nylon mesh. Splenic red blood cells were lysed using Gey’s solution. Cells were stained 
at 4°C in PBS + 2% FBS containing 0.2% sodium azide for 30 min., after which they 
were washed and resuspended in PBS + 1% PFA when appropriate. Surface antibodies 
used in these studies were anti-CD16/32 (Fc block), CD4, CD45, TCRβ, NK1.1, Nkp46, 
CD8, SLAMf1, SLAMf3, SLAMf6, ICOS, and NRP-1 (Biolegend, San Diego, CA). 
CD11b and CD19 antibodies were obtained from BD Biosciences. UV Live Dead 
staining reagent was included in surface and transcription factor stains (Life 
Technologies, ThermoFisher, Waltham, MA), with the exception of stains for cell sorting 
in which efluor780 Live/Dead stain was used. CD1d tetramer loaded with PBS-57 was 
provided by the National Institutes of Health (NIH) tetramer facility (Emory University 




For nuclear transcription factor staining, cells were surface stained as above, after 
which they were fixed overnight using the Foxp3 transcription factor staining buffer set 
(EBiosciences, ThermoFisher, Waltham, MA). The next day, cells were washed, blocked 
with rat IgG, and stained with anti-PLZF (9E12) (Biolegend) and RORγt (Q31-378) (BD 
Biosciences), and Ki67 (Biolegend). After staining, cells were washed, resuspended, and 
data were immediately collected on a LSRII flow cytometer (BD Biosciences, Franklin 
Lake, NJ) and analyzed with FlowJo software (FlowJo LLC). 
  
 
3.5.3 In vitro proliferation of sorted NKT cells 
Splenocytes were enriched for NKT cells using the STEMCELL EasySep CD4+ 
negative selection kit according to the manufacturer’s instructions. After which, cells 
were stained with Live/Dead efluor780 (EBiosiences), anti-TCRβ, CD11b, CD8, Nkp46, 
ICOS and NRP-1, and the addition of CD1d/PBS-57 loaded-tetramer. NKT cells were 
sort-purified using fluorescent activated cell sorting (FACS Aria III). Cell purity for all 
sorts was between 80% and 95%. After sorting, cells were stained with Viotracker blue 
for 30min. Subsequently, 40,000 cells/well were placed in modified Click’s culture 
medium (5% FBS, 2mM glutamine, Pen/Strep, 50µM 2-mercaptoethanol, 20µg/mL 
gentamycin) and incubated on anti-CD3 (5 g/ml) coated plates in the presence of 
soluble CD28 (1 g/ml) at 37 oC and 5% CO2. 72 h later, supernatants were harvested 
and analyzed via ELISA (Biolegend and R&D systems).  
After culture, supernatants were harvested and media replaced with cold PBS + 




quantification of live/dead. Harvested cells were immediately analyzed on a MACSQuant 
Vyb flow cytometer.  All data was analyzed using FlowJo Software (FlowJo LLC).  
 
 
3.5.4 BrdU incorporation  
 Bromodeoxyuridine was resuspended in PBS at 10mg/mL. Mice were injected 
with 1mg 24 hrs prior to the scheduled end-point. A second injection was administered 
i.p. 4hrs prior to harvest. Cells were surface stained as above, then fixed in 1% PFA 
overnight. The next day, the BD Biosciences BrdU staining and fixation kit was used 
according to manufacturer’s instructions to prepare the cells for the transcription factor 





All animal experiments were conducted in a non-randomized and non-blinded 
fashion.  Statistical analyses were performed using an unpaired T test, multiple T tests, or 
2-way ANOVA where appropriate. In all cases, tests were considered significant when p 
≤ 0.05. All groups were shown to have similar variance in distribution.   Sample size 
estimates were based on previous experience. When data were combined from multiple 
different experiments, data were first normalized to the C57BL/6 reference strain in each 
experiment. Normalization was accomplished by dividing each data point in an 
experiment by the average of the C57BL/6 response in that experiment. All statistical 
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FIGURE 3-1: SLAMf6 expression marks proliferating thymic NKT2 and NKT17 
subsets.  
C57BL/6 thymocytes were harvested and iNKT cells identified using CD1d-
tetramer/PBS57 and TCRβ. iNKT cell subsets were identified using transcription factors 
PLZF and RORγt as indicated in the colored boxes A). Thymus NKT2 and NKT17 
subsets are highly proliferative in comparison to their NKT1 counterparts. Upper: 
Representative contour plot demonstrating gating strategy to identify NKT cell subsets 
and median fluorescence intensity of Ki67 on iNKT cell subsets. Lower: Quantification 
of the frequency of Ki67 expression in distinct iNKT subsets. Statistical analysis was 
performed using multiple t tests followed by the Holm-Sidak multiple comparisons test. 
****p ≤ 0.0001 B). Increased SLAMf6 expression on Ki67+ iNKT cells. Upper: 




Quantification of the frequency of Ki67+ cells expressing SLAMf6. Data are 
representative of 2 separate experiments. Statistical analysis was performed using an 







FIGURE 3-2:  SLAMf6high iNKT cells are more proliferative than SLAMf6low 
iNKT cells.  
 
C57BL/6 splenic SLAMf6high and SLAMf6low iNKT cells were sorted, plated at equal 
numbers, and stimulated with anti-CD3 and CD28 for 72hrs. A). Representative flow 
cytometry gating for sorting iNKT cell subsets. SLAMf6high cells encompass NKT2 and 
NKT17 cells while SLAMf6low populations are NKT1 and NKT17 cells. B). 
Representative flow cytometry of live iNKT cells recovered after sorting SLAMf6low and 
SLAMf6high iNKT cells. Middle: Quantification of live cell counts recovered. Right: 
Representative flow cytometry histograms of iNKT cells stained with Viotracker and 




SLAMf6low iNKT cells. Data is representative of 3 separate experiments. Statistical 
analysis was performed using one-way ANOVA followed by Tukey’s multiple 






























FIGURE 3-3: SLAMf6highPLZFhigh iNKT cells preferentially expand after in vivo 
activation.  
 
C57BL/6 mice were treated with either vehicle or αGalCer for 72h. A). All iNKT cells in 
the spleen after in vivo αGalCer stimulation express high levels of SLAMf6. 
Representative flow cytometry of SLAMf6, SLAMf1, and SLAMf3 expression of iNKT 
cells in vehicle treated (heavy dark line), and αGalCer treated (shaded histogram) 
C57BL/6 mice. Middle: SLAM receptor staining on conventional T cells treated with or 
without αGalCer. Data is representative of 3 separate experiments. Right: Median 
fluorescence intensity of SLAMf1, SLAMf3, and SLAMf6 on splenic iNKT cells in 
naïve (day 0), and αGalCer treated (day 3 and 5) mice. All data is representative of 2 
separate experiments at each time point. Statistical analysis was performed using two-
way ANOVA followed by Tukey’s multiple comparison test. **** p ≤ 0.0001 B). 
Expansion of iNKT2-like cells in the spleen after administration of αGalCer. 
Representative flow cytometry of iNKT cell subsets after gating on SLAMf6high and 
SLAMf6low populations before (left) and after αGalCer challenge (right). C). 
Incorporation of BrdU in iNKT cell subset 72h after αGalCer administration. Upper: 
Representative flow cytometry of BrdU+ iNKT cells stained with either isotype control 
(black) or anti-BrdU (red). Conventional T cell BrdU incorporation is shown for 
comparison (right). Lower: Representative flow cytometry of PLZFhigh iNKT cells 






FIGURE 3-4: SLAMf6 deficiency abrogates NKT2 and NKT17 cell proliferation.  
 
C57BL/6 naïve splenocytes were harvested, and NKT cells identified using CD1d-
tetramer/PBS57 and TCRβ. ICOShighNRP-1high and ICOSlowNRP-1low iNKT cells were 
sorted and plated in equal numbers on anti-CD3 with CD28 for 72hrs. SLAMf6 deficient 
ICOShighNRP-1high iNKT cells have a defect in cell growth after stimulation. Left: 
Representative flow cytometry of live C57BL/6 (top) and B6.SLAMf6-/- (bottom) iNKT 
cells 72hrs after stimulation. Right: Live cell number of C57BL/6 versus B6.SLAMf6-/- 
iNKT cells recovered. Data is representative of 2 separate sorts. Live cell numbers are the 




analysis was performed using a 2-way ANOVA followed by Sidak multiple comparison 








SUPPLEMENTAL FIGURE 3-1: Sorting iNKT cells using SLAMf6 or ICOS and 
NRP-1 surrogate markers yielded iNKT cells with 78.4-96.6% purity.  
 
A). Representative post-sort analysis sorting iNKT cells using CD1d-tetramer/PBS57 and 
SLAMf6high and SLAMf6low. B). Representative post-sort analysis sorting iNKT cells 




C57BL/6 mice (top) and B6.SLAM6-/- mice. Data is representative of 2 experiments for 






SUPPLEMENTAL FIGURE 3-2: BALBc SLAMf6high splenic iNKT cells are more 
proliferative than SLAMf6low iNKT cells.  
 
BALBc splenocytes were harvested, sorted after first gating on iNKT cells using CD1d-
tetramer/PBS57 and TCRβ, then on levels of SLAMf6. Cells were plated in equal 
numbers on anti-CD3 with CD28 for 72hrs Left: Representative flow cytometry of live 
iNKT cells after 72hrs. Right: Proliferation of BALBc iNKT cell SLAMf6high and 
SLAMf6low iNKT cells as indicated by Viotracker blue proliferation dye. MFI is reported 
for the anti-CD3 and CD28 stimulated and the isotype control. Data is representative of 









SUPPLEMENTAL FIGURE 3-3: Kinetics of iNKT cell expansion.  
 
C57BL/6 mice were challenged with αGalCer. At each time-point the number of liver 
iNKT cells were identified using CD1d-tetramer/PBS57 and TCRβ. Data is the 











SUPPLEMENTAL FIGURE 3-4: C57BL/6 and B6.SLAMf6-/- iNKT cells express 
similar levels of PLZF.  
 
Naïve thymic (left) and spleen (right) iNKT cells were identified using CD1d-
tetramer/PBS57 and TCRβ. The mean fluorescence intensity of PLZF was determined on 
total iNKT cells and each iNKT cell subset. Data is representative from 1 experiment. 
Statistical analysis was performed using multiple t test and Holm-Sidak multiple 








CHAPTER 4: REGULATION OF INVARIANT NKT CELL DEVELOPMENT 
AND FUNCTION BY A 0.14 MBP LOCUS ON CHROMOSOME 1: A 
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 Invariant NKT (iNKT) cells are tissue-resident innate-like T cells critical to the 
host immune response. We previously identified a 6.6 Mbp region on chromosome 1 as a 
major regulator of iNKT cell number and function in C57BL/6 and 129X1/SvJ mice.  
Here, we fine-mapped this locus by assessing the iNKT cell response to alpha-
galactosylceramide (αGalCer) in a series of B6.129 congenic lines. This analysis revealed 
the presence of at least two genetic elements that regulate iNKT cell cytokine production 
in response to αGalCer. While one of these genetic elements mapped to the B6.129c6 
interval containing Slam genes, the dominant regulator in this region mapped to the 0.14 
Mbp B6.129c3 interval. In addition, we found that numbers of thymic iNKT cells and DP 
thymocytes were significantly lower in B6.129c3 mice, indicating that this interval also 
regulates iNKT cell development. Candidate gene analysis revealed a 5-fold increase in 
Fcgr3 expression in B6.129c3 iNKT cells, and we observed increased expression of 
FcγR3 protein on B6.129c3 iNKT cells, NK cells, and neutrophils. These data identify 
the B6.129c3 interval as a novel locus regulating the response of iNKT cells to 
glycosphingolipid, revealing a link between this phenotype and a polymorphism that 





  Semi-invariant iNKT cells comprise an unusual innate-like T cell subset that 
plays significant roles in the host immune response to bacterial and viral pathogens 
(Behar and Porcelli, 2007; Godfrey and Rossjohn, 2011; Gumperz and Brenner, 2001). 
iNKT cells recognize glycolipids and glycosphingolipids presented by the MHC class I-
like molecule CD1d (Kawano et al., 1997; Pellicci et al., 2009; Spada et al., 1998). The 
prototypical glycosphingolipid agonist alpha-galactosylceramide (αGalCer) is structurally 
similar to glycosphingolipids from Bacteroides fragilis (Wieland Brown et al., 2013) and 
is a potent activator of iNKT cells (Borg et al., 2007; Kawano et al., 1997; Kawano et al., 
1998; Koch et al., 2005; Takahashi et al., 2000). Upon activation by αGalCer presented 
by CD1d, iNKT cells rapidly produce large amounts of chemokines and cytokines 
(Coquet et al., 2008; Gumperz et al., 2002; Yoshimoto and Paul, 1994) and contribute to 
an orchestrated activation of both innate and adaptive immune cells including dendritic 
cells, macrophages, and natural killer (NK) cells (Carnaud et al., 1999; Eberl and 
MacDonald, 2000; Hermans et al., 2003; Kitamura et al., 1999; Sada-Ovalle et al., 2008). 
The iNKT cell subset, therefore, is uniquely poised to shape the quality and magnitude of 
the developing host immune response.   
 Invariant NKT cell number and function varies dramatically among mice of 
different genetic backgrounds. Wild-derived inbred strains (e.g., PWD/PhJ, Cast/EiJ) 
have barely detectable numbers of iNKT cells (Borg et al., 2014; Chen et al., 2012), and 
there is significant strain-dependent variability even among common laboratory inbred 




Rymarchyk et al., 2008). Accumulating evidence suggests that the genetic background 
has a significant influence on the role of iNKT cells in the host immune response. For 
example, iNKT cells are critical in the clearance of the opportunistic pathogen 
Pseudomonas aeruginosa from the lung in BALB/cJ mice, but are dispensable in 
C57BL/6J mice (Benoit et al., 2015). Similarly, pathology in iNKT cell-deficient mice 
infected with Borrelia burgdorferi manifests as joint inflammation in BALB/c mice 
(Tupin et al., 2008) and as myocarditis in C57BL/6J mice (Olson et al., 2009). Therefore, 
a thorough understanding of the genetic determinants that regulate iNKT cell 
development and function is necessary to understand the role of iNKT cells in the host 
immune response.  
 Numerous reports have described polymorphic genetic loci that regulate iNKT 
cell number and function (Aktan et al., 2010; Araujo et al., 2000; Borg et al., 2014; 
Esteban LM, 2003; Fletcher et al., 2008; Jordan et al., 2007b; Wesley et al., 2007; Zhang 
et al., 2003). We and others have identified a region on chromosome 1 that regulates 
iNKT cell development and the response to αGalCer (Aktan et al., 2010; Gombert JM, 
1996; Jordan et al., 2007b; Rocha-Campos et al., 2006). We previously demonstrated that 
iNKT cells in 129X1/SvJ mice produced significantly lower amounts of cytokine after 
αGalCer challenge than did iNKT cells in C57BL/6J mice. Using B6.129 congenic mice, 
we identified the genetic interval spanning from rs222297065 to D1MIT115 (Chr1: 
171.03 - 177.68 Mbp) as a regulator of the response of iNKT cells to in vivo αGalCer 
challenge (Aktan et al., 2010). This ~6.6 Mbp locus is densely populated with numerous 




(SLAMs) that modulate iNKT cell development and function (Griewank et al., 2007). 
Interestingly, this locus overlaps extensively with several autoimmune susceptibility loci 
(Edberg et al., 2002; Morel et al., 2001; Wandstrat et al., 2004) and there are numerous 
reports of an association between iNKT cell numbers and autoimmunity (Baxter et al., 
1997; Cardell, 2006; Esteban et al., 2003; Gombert JM, 1996). 
 To refine this interval and identify candidate genes that regulated the 
responsiveness of iNKT cells to αGalCer, we generated additional B6.129 subcongenic 
lines with overlapping intervals. Here, we report the mapping of the iNKT cell response 
to αGalCer to a minimal 0.14 Mbp interval (Chr1: 171.032-171.170) containing 4 genes 
and 2 microRNAs. In addition, we found that this interval regulates total thymocyte 
numbers and total iNKT cell number. Finally, we identify Fcgr3 as a possible candidate 
iNKT cell regulatory gene due to the association of increased iNKT cell FcγR3 
expression and impaired response of iNKT cells to αGalCer stimulation observed in 





4.3.1 Refinement of the 129X1/SvJ interval on chromosome 1 
    We previously reported that a 6.6 Mbp genetic region on chromosome 1 
containing the Slam genes regulated iNKT cell function (Aktan et al., 2010). Given 
previous reports that SLAMf1 and SLAMf6 are required for iNKT cell development and 
the Slam genes have been reported to regulate thymic iNKT cell numbers (Aktan et al., 
2010; Jordan et al., 2011), we hypothesized that polymorphisms in one or more of the 
Slam genes are responsible for the differences in the iNKT cell response to αGalCer 
between C57BL/6 and 129X1/SvJ mice. To test this hypothesis, we generated 4 
subcongenic strains: B6.129c2, B6.129c3, B6.129c4, and B6.129c6 with overlapping 
129X1/SvJ intervals ranging from 0.14 Mbp to 1.1 Mbp that spanned the centromeric 
region of the B6.129c1 interval containing Slam family genes (Figure 1a). Mapping of 
the 129 derived-interval boundaries (Figure 1b) revealed that B6.129c2 and B6.129c6 
strains possess Slam family genes derived from 129X1/SvJ, while B6.129c3 and 
B6.129c4 strains possess Slam family genes derived from C57BL/6J.  
 
4.3.2 Invariant NKT cell cytokine production in response to αGalCer maps to a 
0.14Mbp region on chromosome 1 
 To determine which 129X1/SvJ intervals regulate the iNKT cell response to 
glycolipid, we assessed serum IFNγ and IL-4 cytokine levels after administration of 
αGalCer to C57BL/6 and B6.129 congenic strains. This analysis revealed that each of the 




in comparison to the B6 control (Figure 2a). To determine whether this decrease in 
αGalCer-induced cytokine was due to reduced production by iNKT cells, we evaluated 
IFNγ and IL-4 production by CD1dtetramer/PBS57-gated cells in response to αGalCer 
using intracellular staining and flow cytometry (Figure 2b). Consistent with the reduced 
serum cytokine production in the B6.129 congenic strains in response to αGalCer 
administration, we observed significantly lower levels of iNKT IFN- and IL-4 
production in B6.129c2, B6.129c3, and B6.129c4 strains as compared to the B6 parental 
strain (Figure 2b). These data indicated that the dominant regulator of iNKT cell cytokine 
production in response to GalCer mapped to the minimal 0.14 Mbp B6.129c3 interval.  
 Interestingly, examination of the cytokine production in B6.129c6 mice revealed 
an intermediate phenotype.  iNKT IFN-γ and IL-4 production in B6.129c6 mice were 
significantly higher in comparison to B6.129c3 mice, while B6.129c6 IFN-was 
significantly lower in comparison to B6 parental mice (Fig. 2b). B6.129c6 IL-4 was also 
lower than B6 mice, although this reduction did not reach statistical significance 
(p=0.0880) (Figure 2b). Together, these data indicated the presence of at least two genetic 
elements in the B6.129c2 region that regulate iNKT cell cytokine production in response 
to αGalCer: a dominant regulator mapping to the 0.14 Mbp B6.129c3 interval that did not 
contain Slam genes, and a second subdominant regulator mapping to the B6.129c6 
interval containing Slam genes.  
 Differences in in vivo iNKT cell cytokine production could be the result of an 
iNKT cell-intrinsic phenomenon, or from differences in antigen processing and 




an iNKT-intrinsic phenomenon, we directly compared cytokine production from purified 
B6 and B6.129c3 iNKT cells after stimulation. Equal numbers of sorted splenic iNKT 
cells from B6 WT and B6.129c3 mice were stimulated with anti-CD3 and anti-CD28, 
after which supernatants were analyzed for cytokine and chemokine production. We 
observed a significant reduction in cytokines and chemokine secretion from B6.129c3 
iNKT cells compared to their B6 counterparts (Figure 3). Taken together, these data 
indicate that one or more of the genes contained within the B6.129c3 interval regulates 
iNKT cell cytokine production through an iNKT-intrinsic process.  
 
4.3.3 Reduced numbers of thymic iNKT cells in B6.129c3 mice 
 Since it has been previously reported that the Nkt1 locus that encompasses the 
B6.129c3 congenic interval regulates thymic iNKT cell number (Jordan et al., 2007b), we 
asked whether this phenotype could be mapped to the B6.129c3 interval. A comparison of 
thymic iNKT cell numbers revealed a significant reduction in B6.129c3 thymic iNKT 
cells compared to their B6 counterparts (Figure 4a). Further analysis revealed that there 
was no significant difference in the overall frequency of thymic iNKT cells (data not 
shown), and that the decrease in thymic iNKT cell number in B6.129c3 mice was 
associated with a decrease in total thymocyte number (Figure 4a). Specifically, we 
observed a specific decrease in the number of DP, but not DN, CD4 or CD8 SP, B6.129c3 
thymocytes. These data suggest that the B6.129c3 interval indirectly regulates iNKT cell 




 Accumulating data suggest that there is significant strain-dependent variation in 
the distribution of iNKT cell subsets (Lee et al., 2013; Lee et al., 2015). Therefore, we 
considered the possibility that the iNKT cell-intrinsic differences in cytokine production 
was due to regulation of the distribution of iNKT cell subsets by the B6.129c3 congenic 
interval. iNKT1, iNKT2, and iNKT17 subsets were identified according to their 
expression of PLZF and RORγt (Lee et al., 2013) (Figure 4b, left). Examination of the 
frequency and number of thymic iNKT cell subsets in C57BL/6 and B6.129c3 mice 
revealed a decrease in the numbers of iNKT1 and iNKT2 cells, consistent with the 
decrease in total iNKT cell numbers (Figure 4b). The iNKT17 subset also showed a trend 
toward lower numbers in the B6.129c3 mouse, albeit not significantly lower. Taken 
together, these results suggest that the B6.129c3 interval regulates the number of thymic 
iNKT cells but does not significantly affect the distribution of iNKT cell subsets.  
  
4.3.4 Increased expression of FcγR3 on B6.129c3 iNKT cells 
 The B6.129c3 congenic interval contains 4 genes and two micro-RNAs (Table 1). 
Examination of gene expression data using the Immgen database (Heng et al., 2008) 
suggested that one of the genes, Mpz (myelin protein zero) is not expressed in leukocytes, 
and we confirmed this data using PCR and gene-specific primers (data not shown).   
 We next investigated whether one or more of the remaining three genes, Fcgr3 
(Fc receptor, IgG, low affinity III), Cfap126 (cilia and flagella associated protein), or 
Sdhc (succinate dehydrogenase complex c), were differentially expressed in B6.129c3 




and B6.129c3 mice and used quantitative PCR to assess gene expression. Interestingly, 
we found that Fcgr3 gene expression was significantly higher (5.5-fold change) on 
B6.129c3 iNKT cells compared to their B6 counterparts (Figure 5a). In contrast, no 
significant differences in Cfap126 or Sdhc expression were observed between the two 
strains.  
We next determined whether the increase in Fcgr3 gene expression correlated 
with an increase in protein expression on the surface of B6.129c3 iNKT cells. Similar to a 
previous report (Kim et al., 2006), we observed a very low, but detectable level of FcγR3 
expression on naïve iNKT cells from B6.129c3 mice as well as from parental strain 
129X1/SvJ mice (Figure 5b). To confirm the increased expression of FcγR3 in B6.129c3 
mice, we also assessed expression on neutrophils that express significant levels of this 
protein. This analysis similarly revealed increased FcγR3 expression on neutrophils from 
both B6.129c3 and 129X1/SvJ parental mice (Fig. 5b). We then compared iNKT FcγR3 
expression between αGalCer-treated B6 and B6.129c3 mice to determine if activation 
altered the relative expression. While this analysis revealed significantly greater FcγR3 
on iNKT cells and NK cells, the relative expression difference was similar to that seen in 
naïve mice (Fig. 5c). Together, these data suggest that one or more polymorphisms in the 
B6.129c3 interval regulates Fcgr3 gene and cell surface expression, and identifies Fcgr3 







The ability of iNKT cells to rapidly produce large amounts of cytokines and 
chemokines in response to pathogens puts them in a unique position to shape the 
developing host immune response. In this context, natural genetic variants that modulate 
iNKT cell function could have significant downstream effects on the host immune 
response to pathogens. We recently demonstrated that two seemingly conflicting reports 
regarding the role of iNKT cells in the clearance of Pseudomonas aeruginosa from the 
lung (Nieuwenhuis et al., 2002; Stevenson et al., 1995) could be reconciled when genetic 
background was taken into consideration (Benoit et al., 2015). For reasons that are still 
unclear, BALB/c iNKT cells make a significant contribution to the host immune response 
after P. aeruginosa infection, but B6 iNKT cells do not. The strain-dependent role of 
iNKT cells in bacterial clearance was associated with strain-dependent differences in the 
response of lung iNKT cells to αGalCer. Elucidation of genetic variants that regulate 
iNKT cell function is necessary to understand their role in the host immune response.  
Invariant NKT cell number, function, and tissue-specific homing varies widely 
among inbred strains of mice (Aktan et al., 2010; Lee et al., 2013; Lee et al., 2015; 
Rymarchyk et al., 2008) and several polymorphic loci that regulate iNKT cell number 
have been identified (Aktan et al., 2010; Borg et al., 2014; Esteban et al., 2003; Fletcher 
et al., 2008; Gombert JM, 1996; Jordan et al., 2004; Jordan et al., 2007b; Rocha-Campos 
et al., 2006). In an investigation into the role of iNKT cells in type 1 diabetes, it was 
reported that autoimmune-prone non-obese diabetic (NOD) mice possessed very low 




genetic locus, Nkt1, regulating the number of thymic iNKT cells was identified and 
mapped to a distal region on chromosome 1 (D1MIT15 - D1MIT155). The Nkt1 locus 
contained several immunologically relevant genes, including CD247, FcγR2b, FcγR3, 
and the Slam family of receptors including Slamf1 and Slamf6 (Esteban LM, 2003; 
Rocha-Campos et al., 2006), which are required for iNKT cell development in the thymus 
(Griewank et al., 2007). A subsequent report implicated Slamf1 in the regulation of 
thymic iNKT cell numbers as well as iNKT IL-4, but not IFN, production (Jordan et al., 
2007b). Here, we have refined this locus further and have found evidence suggesting the 
presence of at least two regulators of NKT cell number and function. Our data suggest 
that Slam genes may not be the major regulators of the iNKT cell response to αGalCer in 
this region. Although B6.129c6 mice that possess the Slam129 and FcgrB6 alleles exhibited 
reduced IFN- and IL-4 production in comparison to B6 mice, the dominant effect was 
observed in B6.129c3 and B6.129c4 mice that possess SlamB6 and Fcgr129 alleles. 
Conversely, the observation that B6.129c6 iNKT cell cytokine production was 
significantly greater than their B6.129c3 counterparts in both cytokines measured is 
consistent with the presence of an additional gene or genetic modifier regulating this 
phenotype. Together, these data suggest the possibility that there are multiple genetic 
elements in the larger B6.129c2 interval that regulate the function of iNKT cells: a novel 
genetic element that we identified in the B6.129c3 interval, and one or more genes (most 
likely Slam genes) or genetic modifiers in the B6.129c6 interval.  
We identified Fcgr3 as a candidate gene in regulating the iNKT cell response. 




tyrosine activation domain (ITAM) and is highly expressed on monocytes, macrophages, 
neutrophils, and NK cells (Kim et al., 2006; Nimmerjahn and Ravetch, 2007). We found 
that FcγR3 gene and protein expression was significantly increased on iNKT cells, NK 
cells, and neutrophils from B6.129c3 and 129X1/SvJ parental mice compared to 
C57BL/6 controls. The underlying basis for this differential expression is still unclear. A 
comparison of Fcgr3 promoter sequence (as defined by the Eukaryotic promoter 
database, (Dreos et al., 2017) between C57BL/6 and 129S1/SvImJ strains revealed no 
nucleotide differences. However, over 100 upstream variants were identified, suggesting 
the possibility that a substitution in an enhancer element could affect expression (data not 
shown).  
 Here, we confirm previous reports that iNKT cells express low, but detectable 
levels of FcR3 (Araujo et al., 2011; Kim et al., 2006; Park-Min et al., 2007). These 
previous reports demonstrate that engagement of Fc receptors can significantly modulate 
iNKT cell function. In one study, intravenous Ig (IVIG) treatment was found to exert 
some of its effect through its action on iNKT cells (Park-Min et al., 2007), and IVIG 
administration to C57BL/6 mice resulted in diminished iNKT cell activation. Co-
administration of αGalCer and IVIG resulted in severely reduced IL-4 and IFNγ 
production compared to mice treated with αGalCer alone, and this inhibition was 
dependent on FcγR3 (Araujo et al., 2011). Our finding that increased expression of 
FcγR3 on B6.129c3 iNKT cells is associated with decreased cytokine production is 
consistent with these data, although it remains unclear whether there is increased FcγR3 




Given the association of increased Fcgr3 in B6.129c3 mice and alterations in 
thymocyte number, it is possible that the NKT cell-intrinsic changes in function stem 
from differences in development. FcγR3 is expressed on developing thymocytes 
(Rodewald et al., 1992; Sandor et al., 1994) and Fcɛr1γ, which encodes the signaling 
chain of FcγR3 contributes to TCR signaling (Flamand et al., 1996; Shores et al., 1997). 
Interestingly, Fcɛr1γ was recently demonstrated to be over-expressed in NKT1 cells, and 
deletion of Fcɛr1γresulted in altered frequencies of NKT1 and NKT2 subsets (Georgiev 
et al., 2016). Whether the impaired iNKT cell function observed in B6.129c3 mice is 
associated altered FcγR3 and/or Fcɛr1γ signaling will require further study.  
Although our results suggest a role for Fcgr3 in the regulation of iNKT cells, we 
cannot rule out the other genetic elements that lie within the B6.129c3 region. We did not 
observe differences in gene expression of Sdhc or Cfap126 genes on sorted splenic iNKT 
cells. Mutations in the Sdha, b, and c genes have been linked to susceptibility to 
mitochondrial disorders (Renkema et al., 2015). Cfap126 has been shown to have a 
function on pancreatic β cells (Bader et al., 2016), but studies of this gene on iNKT cells 
have not been performed. Several microRNAs have had reported roles in regulating 
iNKT cell development, including the Let-7 family of microRNAs (Burocchi et al., 2015; 
Fedeli et al., 2016; Frias et al., 2017). The microRNA Mir6546 present in the B6.129c3 
interval appears to be rare (Castellano and Stebbing, 2013; Meunier et al., 2013) and its 
function has not been studied in immune cells. Therefore, although this interval contains 
multiple genes and genetic elements, the most likely iNKT cell regulator within our 




In summary, we have fine-mapped a locus that regulates the iNKT cell response 
to the agonist glycolipid αGalCer. Our findings suggest that the previously described 
Nkt1 locus contains at least two genetic elements that regulate NKT cell number and 
function, and that the dominant regulator in the region maps to a congenic interval 
containing Fcgr3, identifying it as a probable candidate gene for these phenotypes. 
Further characterization of this genetic locus and of the Fc receptor signaling pathway 





4.5. Materials and Methods 
4.5.1 Mice and Reagents 
C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, ME). 
B6.129c1 mice were described previously (Wandstrat et al., 2004), and B6.129c2, 
B6.129c3, B6.129c4 and B6.129c6 strains were generated by backcrossing B6.129c1 
mice to C57BL/6J mice, and intercrossing the heterozygous progeny.  Offspring in which 
recombinants were identified were backcrossed B6 to allow for the generation of 
homozygous congenic lines. The congenic interval boundaries were determined using 
primer sets designed to amplify across informative insertions/deletions and SNPs (Table 
2).  PCR products were sequenced to confirm boundaries. All mice were age and sex 
matched as indicated in the figure legends. All mice were housed and bred in the specific 
pathogen-free barrier facility at the University of Vermont. The alpha-galactosylceramide 
(Avanti Polar Lipids, Alabaster, Alabama) was prepared as described previously (Aktan 
et al., 2010) and administered i.p. at indicated doses in a 100µL volume. All procedures 
involving animals were approved by the University of Vermont Institutional Animal Care 
and Use Committee.  
 
4.5.2 Serum cytokine analysis 
Mice were bled via cardiac puncture, after which serum was collected and frozen 
at -20°C until analysis by ELISA according to the manufacturer’s instructions 





4.5.3 Flow cytometry 
Splenocytes and thymocytes were obtained by gently pressing through a 70 m 
nylon mesh. RBCs were lysed using Gey’s solution. Cells were stained at 4°C in PBS + 
2% FBS containing 0.2% sodium azide for 30 min., after which they were washed and 
resuspended in PBS + 1% PFA. Abs used in these experiments were anti-CD4 (RM4-5), 
CD45 (30-F11), TCRβ (H57-597), NK1.1 (PK136), CD8 (53-6.7) (Biolegend), and 
CD11b (M1/70), CD16/32 (2.4G2) and CD19 (6D5) (BD Biosciences). UV Live Dead 
staining reagent was included in all experiments (Life technologies, ThermoFisher, Grand 
Island, NY). CD1d tetramer loaded with PBS-57 was provided by the National Institutes 
of Health (NIH) tetramer facility (Emory University Vaccine Center, Atlanta, GA).  
For intracellular cytokine staining (ICS), cells were isolated from the spleen as 
described above and stained with Ab to surface markers. In every ICS experiment, cells 
were analyzed directly ex vivo without further treatment. After washing in staining buffer, 
cells were fixed with 4% PFA for 30 min at 4oC. After washing in permeabilization 
buffer (0.1% saponin, 1% FCS, 0.1% sodium azide in PBS), cells were stained with anti-
IL-4 (11B11) and anti-IFNγ (XMG1.2) or isotype-matched control antibodies. All 
intracellular antibodies were from Biolegend. Data was collected on an LSRII (BD 
Biosciences) and analyzed using FlowJo software (FlowJo LLC, Ashland, OR).  
Purified CD16/32 (Clone 93) (Biolegend) was used in all samples prior to the 
addition of Abs to block nonspecific Ab binding, except for samples in which FcγR3 
expression was being assessed. In those cases, Fc block was not performed, and 




surface stain master mix. As controls for FcγR3 staining and to control for the addition of 
conjugated 2.4G2 on all Fc receptors, cells were stained with unconjugated 2.4G2 Ab in 
order to block receptors and subsequently stained with conjugated 2.4G2. As a separate 
control, cells were stained with unconjugated 2.4G2 Ab and subsequently stained with an 
isotype matched control (IgG2a, Biolegend).  
For nuclear transcription factor staining, cells were surface stained as above, after 
which they were fixed overnight using the Foxp3 transcription factor staining buffer set 
(eBiosciences/ThermoFisher, San Diego, CA). The next day cells were washed, blocked 
with rat IgG, and stained with anti-PLZF (9E12) and RORγt (Q31-378) (BD). After 
staining, cells were washed, resuspended, and data were immediately collected on a 
LSRII flow cytometer (BD Bioscience) and analyzed with FlowJo software (FlowJo 
LLC).  
 
4.5.4 Cell isolation and culture for ex vivo cytokine analysis 
Splenocytes were enriched for CD4 T cells by depletion of CD8 (53-6.7), CD11b 
(M1/70), MHCII (M5-114) (BioXcell, West Lebanon, NH) with anti-rat and anti-mouse 
IgG magnetic beads (Qiagen, Hilden, Germany). After enrichment, cells were stained 
with anti-TCRβ, CD1dtetramer/PBS57, and DAPI, and iNKT cells were purified by 
fluorescence activated cell sorting (FACS Aria III). Cell purity for all sorts was between 
83% and 97%. After sorting, cells were placed in modified Click’s culture medium (5% 
FBS, 2mM glutamine, Pen/Strep, 50µM 2-mercaptoethanol, 20µg/mL gentamycin) and 




CO2.  72 h later, supernatants were harvested and analyzed via Milliplex assay, according 
to the manufacturer’s instructions (EMD Millipore, Darmstadt, Germany).  The milliplex 
kits used were the Mouse cytokine/chemokine magnetic bead panel followed by a custom 
kit containing GM-CSF, IFNγ, IL-2, IL-4, IL-5, IL-10, IL-13, and IL-17.  
 
Quantitative real-time PCR 
Sorted iNKT cells were washed in cold PBS, after which cell pellets were snap 
frozen and kept at -80oC until RNA was isolated. RNA isolation was performed using the 
RNeasy Micro kit according to the manufacturer’s instructions (Qiagen, Hilden, 
Germany). cDNA was synthesized using Superscript III (ThermoFisher, San Diego, CA).  
Mpz and Pcp4l-1 expression was evaluated by PCR using the gene specific primers: Mpz 
forward 5’-CGGACAGGGAAATCTATGGTGC-3’, reverse 5’-
TGGTAGCGCCAGGTAAAAGAG-3’. Pcp4l-1 forward 5’-
ATGAGCGAGCTTAACACCAAA-3’, reverse 5’- CTGCCAGGCTTCCCTTTTTC-3’ 
using cDNA derived from central nervous system tissue (a gift from D. Krementsov, 
University of Vermont). Expression of Fcgr3, Sdhc, and Cfap126 was evaluated using 
Assay on Demand (AOD) Taqman probes (Life Technologies, Carlsbad, CA) according 
to the manufacturer’s instructions. qPCR assay on demand (AOD) was run using the 
Perfecta qPCR SuperMix (Quanta Biosciences, Beverly MA). Samples were incubated 
with UNG SuperMIX at 45°C for 5m, then denatured initially at 95°C for 3m, followed 
by: 95°C denaturation for 15 s, and a combined 60°C annealing and extension step for 




as the endogenous control. Data was collected on an ABI Prism 7900HT Sequence 
Detection System.  
 
4.5.5 Statistics  
All animal experiments were conducted in a non-randomized and non-blinded 
fashion. One way-ANOVA, two-way ANOVA, or unpaired T tests were used where 
appropriate. ANOVA post-hoc analysis comparisons were made using Dunnett’s test, 
Sidak’s multiple comparisons test, Tukey’s multiple comparisons test, or Holm-Sidak’s 
multiple comparisons test where appropriate. In all cases, tests were considered 
significant when p ≤ 0.05. All groups were shown to have similar variance in distribution. 
 Sample size estimates were based on previous experience. In Figure 2B, 3 mice were 
excluded from the analysis due to poor αGalCer injections. When data were combined 
from multiple different experiments, data were first normalized to the C57BL/6 reference 
strain in each experiment. Normalization was accomplished by dividing each data point 
in an experiment by the average of the C57BL/6 response in that experiment. All 
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FIGURE 4-1: Fine-mapping of the B6.129c1 congenic interval 
A). (Left) Schematic of the chromosome 1 congenic intervals used in this study. Black 
regions denote C57BL/6 derived regions, white denotes 129X1/SvJ derived regions, and 
the cross-hatched region is either C57BL/6 or 129X1/SvJ derived (undefined). For 
reference, the Slam family genes are denoted in red and the Fc receptor gene family is 
denoted in green. B). Number of protein-coding genes predicted in each subcongenic 
interval. Lower: Reference SNPs that define boundaries for each congenic line on the 








FIGURE 4-2: Regulation of αGalCer-induced iNKT cell cytokine production 
maps to a 0.14 Mbp region on chromosome 1 
A). Decreased serum cytokine in B6.129 congenic mice in response to αGalCer. Blood 
was collected from B6 or B6.129 congenic mice 2 h after αGalCer administration. Serum 
cytokine levels were assessed using ELISA. Statistical analysis was performed using 2-
way ANOVA followed by Tukey’s multiple comparisons test, *p ≤ 0.05, **p ≤ 0.01, 
***p ≤ 0.001, ****p ≤ 0.0001 B). Top: Representative intracellular staining of cytokine-
producing iNKT cells in response to GalCer. Splenocytes were isolated 2 h after 
αGalCer administration. iNKT cells were identified using CD1d-tetramer/PBS57 and 
TCRβ. The percentages of iNKT cells expressing cytokines were determined using an 
isotype control for each mouse. Lower: Decreased iNKT cell cytokine production in 
B6.129 congenic mice in response to αGalCer. The data represent the relative level of 
iNKT cell cytokine production.  Data are the combined data from 5 separate experiments 
using female mice 8 -14wks of age and are presented as the mean ± s.d. All mice were 
age-matched to controls in each experiment. Statistical analysis was performed using 2-
way ANOVA followed by Tukey’s multiple comparison test. * = comparison of B6 to 
B6.129 congenics. # = comparison of B6.129c3 to B6.129 congenics. *,# p ≤ 0.05, **, ## p 






FIGURE 4-3: Reduced cytokine production in B6.129c3 is iNKT cell-intrinsic. 
iNKT cells were sorted from C57BL/6 or B6.129c3 splenocytes. 
Cells were stimulated using anti-CD3 and anti-CD28 for 72 h, after which supernatants 
were analyzed using Milliplex. Data represent the cumulative results from 3 separate 
experiments using 8 - 11week old female mice. Mice were age-matched in each 
experiment. Statistical analysis was performed using a 2-way ANOVA followed by the 
Holm-Sidak multiple comparison test and is reported as the mean normalized 





FIGURE 4-4: iNKT cell numbers in the thymus are regulated by the B6.129c3 
interval. 
 
A). iNKT cell (left), total thymocyte (middle), thymocyte subset (right) numbers were 
compared between C57BL/6 and B6.129c3 mice. B). No significant difference in the 
distribution of thymic iNKT subsets between B6 and B6.129c3 mice. iNKT cell subsets 
were identified based on PLZF and RORt expression as indicated by colored boxes 
(left). Cumulative numbers of iNKT cell subsets are shown (right). Data represent the 
cumulative results of 4 separate experiments using 9 – 13 week old female mice. Mice 
were age matched in each experiment. Statistical analysis was performed using an 







FIGURE 4-5: Increased Fcgr3 gene and protein expression on B6.129c3 iNKT 
cells. 
Increased Fcgr3 gene and protein expression on B6.129c3 iNKT cells. A) Increased 
Fcgr3 gene expression in B6.129c3 splenic iNKT cells. Spleen iNKT cells were sorted 
using CD1d tetramer/PBS-57 for RNA isolation. Gene expression was determined using 
quantitative PCR. Data is reported as the fold change relative to B6.  B) Increased cell 
surface protein expression of FcγR3 on naive B6.129c3 iNKT and neutrophils. 
Representative flow cytometry histograms show expression levels of FcγR3 on B6.129c3 




blocked with unconjugated 2.4G2 Ab and subsequently stained with conjugated isotype 
control. Heavy lined histograms are cells stained with conjugated 2.4G2 Ab. The 
numbers represent the median fluorescence intensity (MFI). Graphs depict the 
normalized MFI of 2.4G2 relative to the B6 control. Data represents the mean ± s.d. and 
is the cumulative data from 2 separate experiments of female mice aged 6-8wks. C) 
Increased cell surface protein expression of FcγR3 on αGalCer treated B6.129c3 iNKT 
and NK cells. Shaded dark histograms represent cells blocked with unconjugated 2.4G2 
Ab and subsequently stained with conjugated isotype control. Heavy lined histograms are 
cells stained with conjugated 2.4G2 Ab. The numbers represent the median fluorescence 
intensity (MFI). Graphs depict normalized MFI of 2.4G2 relative to the B6 control. Data 
represents the mean ± s.d. and is representative data from 2 independent experiments 
using 10 or 14 week old female mice. Statistics were performed using a 1-way ANOVA 
and followed by a post-hoc comparison to B6 controls using Dunnett’s test. **p ≤ .01, 










































Gene Name Position Non-
synonymous 
SNPs 
Fcgr3 Fc receptor, IgG 
low affinity III 
171.051-171.064 
12 





















Gene positions were determined according to Ensembl release 90. Structural 
variants, missense variants, and splice variants were determined using the 
Mouse Phenome Database, Sanger 4 and NCBI dbSNP databases. SNP values 
are those that result in amino acid changes between C57BL/6 and 
129S1/SvImJ. The B6.129c3 interval boundaries are on chromosome 1 





CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS 
 
Initial identification of an unusual T cell expressing the Vβ8 invariant TCR was 
performed in 1987 (Budd et al., 1987; Fowlkes et al., 1987). It was not until 8 years later 
that these cells were defined as a new αβ T cell subset called natural killer T cells 
(Macdonald, 2007). In the 8 years that it took for iNKT cells to be agreed upon, reports 
were generated showing how these cells did not fit the definition of a traditional T cell. 
Immunologists describe new cells by defined functional or phenotypic markers that fit 
into a defined “box”. Natural killer T cells, so named due to both function and the 
markers they express, do not fit into a classic box for immune cells, and have been 
challenging to define. In some instances, they are protective, in others, pathogenic 
(Crosby and Kronenberg, 2018). After activation they make numerous Th1, Th2, Th17, 
or Treg cytokines, displaying a diverse repertoire of function. Some iNKT cells are 
cytotoxic, some undergo activation induced cell death, and others are long lived. It can be 
safely said that iNKT cells do not fit into any one box, but many, bridging both innate 
and adaptive immunity and showcasing incredibly versatility to contribute to host 
immunity (Godfrey et al., 2004) (Figure 5-1).  
Diversity within the iNKT cell lineage and among the iNKT cell subsets may be 
important for the ways in which iNKT cells contribute to host immune responses.   Since 
the SLAM receptors are heterogeneously expressed on iNKT cells (Aktan et al., 2010), 
we can envision a scenario in which interactions with a SLAM family receptor 




It has already been shown that SLAMf6 crosslinking on an APC and iNKT cell are 
required for proper IFNγ and IL-4 production (Baglaenko et al., 2017). There is evidence 
to suggest that a certain subset of dendritic cells can present antigen that results in a Th1 
Th2 bias, but the mechanisms for how this presentation could be specific to a certain 
iNKT cell subset is currently unknown (Arora et al., 2014). Does SLAM family receptor 
crosslinking induce the production of cytokines from the APC, which then changes how 
the iNKT cell responds? Does one subset lead to increased kinetics of immune cell 
activation or vice versa? Is the repertoire of SLAM family receptors on the APC just as 
important for effector function as the SLAM family receptor repertoire on the iNKT cell?  
These questions, given our added knowledge of iNKT cell subsets, and our contribution 
of how SLAM family receptors modulate iNKT cell subset responses, can now be 
addressed.  
 An interesting point of further investigation is whether organ specific iNKT 
cells can be stimulated with different agonists at the same time. While this is likely a 
normal occurrence within different tissues with self-glycolipids, it would be interesting to 
“polarize” iNKT cell subsets into distinct cytokine or cytotoxic inducing cells for 
different disease treatments. We already know that there are distinct ligands that can 
induce IFNγ versus IL-4, such as αGalCer and OCH respectively (Sullivan et al., 2010; 
Velmourougane et al., 2009), but how these agonists induce specific iNKT cell TCRβ 
chains and subsets leading to cytokine production has only recently been investigated 
(Cameron, Godfrey 2015). Several of these agonists are being used as adjuvants to induce 




ability to increase iNKT cell responses in humans (Giaccone et al., 2002; Ishikawa et al., 
2005). One interesting line of study would be to deliver specific iNKT cell agonists that 
would activate distinct iNKT cell subsets.   
Our data shows that the SLAM family expression patterns on iNKT cell subsets 
are determined during thymic development. This suggests additional programming and 
lineages where iNKT cells are “destined” to become NKT1, NKT2, or NKT17. Before 
the work shared in this dissertation, the role of SLAM receptors in this process had not 
been studied in detail.  
Recent reports identifying determinants of iNKT cell development give us some 
clues into how iNKT subset cell development could be regulated.  Programming of the 
NKT cell lineage is said to require signaling through Id (inhibitor of DNA binding and 
differentiation) and E proteins (helix-loop-helix proteins), which serve as transcriptional 
regulators, often functioning to antagonize the function of the other (Roy and Zhuang, 
2018). Downstream of Id proteins is a protein responsible for the induction of the master 
transcription factor PLZF termed Egr2 (early growth response protein). Surprisingly, 
SLAMf6 has been shown to induce expression of PLZF via the regulation of Egr2 after 
ligation of the TCR on iNKT cells (Tuttle et al., 2018). E proteins, which function 
downstream from the TCR and SLAM family receptor crosslinking, can bind to the PLZF 
promoter, while Id proteins inhibit this interaction, indicating that these proteins can aid 
in the regulation of iNKT cell PLZF expression. Intriguingly, Id proteins are required for 
the development of iNKT cells, but appear to inhibit production of the SAP dependent 




al., 2010), indicating that Id proteins are intimately involved in the developmental 
programs of these subsets.  
Additional data suggest that upon deletion of SAP in a Vα14 transgenic model, 
development of NKT2 cells is decreased while NKT17 cells are increased and NKT1 
cells are not affected, indicating separate, but overlapping signaling mechanisms in iNKT 
cell development (Michel et al., 2016). Taken together, we speculate that these reports 
suggest that TCR ligation in concert with SLAM family receptor crosslinking potentiates 
separate signaling cascades involving E and Id protein regulation of iNKT cell subset 
development. Our findings that SLAMf6 specifically regulates NKT2 and NKT17, but 
not NKT1, subsets suggests that signaling from distinct SLAM family receptors 
augments TCR signals in developing iNKT cells that ultimately shape their 
differentiation fate. The molecular nature of these signaling mechanisms during iNKT 
cell development currently needs more investigation.    
  In Chapter 3, we found that NKT2 and NKT17 cells were more proliferative 
than their NKT1 counterparts. We show that after αGalCer-mediated expansion of iNKT 
cells, there appears to be an influx of NKT2-like iNKT cells. There are several 
possibilities for this observation. First, this phenotype could result from the upregulation 
of PLZF and Tbet after activation in the predominant spleen NKT1 cell population, 
resulting in their acquisition of an NKT2 phenotype. Alternatively, proliferative NKT2 
cells could be preferentially expanding and repopulating the peripheral organs, thereby 
outnumbering NKT1 cells 3 days after activation. The first model would suggest that the 




useful only in resting iNKT cell populations, and suggests a degree of plasticity in the 
iNKT cell population. Although plasticity among conventional T helper cells is now 
recognized (Gagliani et al., 2015), the degree of plasticity exhibited by the different NKT 
cell subsets remains unknown. The second model suggests that the ratio of iNKT cell 
subsets changes after activation due to the repopulation of the periphery with NKT2 cells, 
possibly from cells repopulating the thymus. We know that repeated administration of 
GalCer over a period of weeks reveals the presence of IL-10-producing NKT cells 
(NKT10) (Sag et al., 2014). Whether this results from the differentiation of NKT cells or 
the preferential expansion of a small pre-existing NKT10 subset remains to be 
determined. Interestingly in Chapter 3, supplemental figure 1, we show that the number 
of iNKT cells in the spleen returns toward baseline levels 5 days after activation with 
GalCer. An analysis of the iNKT cell subsets at this time-point could reveal whether a 
different subset is present or whether immature NKT2 precursors then convert into NKT1 
and NKT2 cells once in the tissue. In the future, adoptive transfers of different iNKT cell 
subsets marked with congenic markers will be necessary to address these questions in the 
future. In summary, while NKT1, NKT2, and NKT17 subsets are apparent during 
development (Lee et al., 2013), these definitions are less apparent after peripheral 
activation, indicating a degree of plasticity that has yet to be determined.       
We show in Chapter 4 that Slam haplotypes play a role in regulating iNKT cell 
subset development and function (Aktan et al., 2010; DeVault et al., 2018). However, we 
found the altered iNKT cell function in B6.129 congenic mice was not primarily due to 




candidate in this regulation.  Investigation into the exact mechanisms that control Fcgr3 
regulation of iNKT cells are currently ongoing in the lab. Our data in Chapter 4 suggested 
both Fcgr3 and SLAM family receptors as regulating the iNKT cell responses. While 
these genes do not necessarily have to work together and epistatic mechanisms may be at 
play, there is some speculation that these receptors do work in concert. Interestingly, 
FcγR3 appears to signal synergistically with the CD2 receptor in activation of NK cells 
(Liu et al., 2016). SLAM family receptors are said to be a part of the CD2 family of 
receptors and SLAMf2 can bind hetero-typically to CD2 (van der Merwe et al., 1995). 
We therefore speculate that SLAM family receptors, such as CD2, could act as co-
receptors for activation and signaling through FcγR3. Additionally, this data could 
suggest that other SLAM family receptors, such as SLAMf4 (which binds to SLAMf2), 
may have the ability to bind to CD2, allowing for crosslinking and co-receptor functions 
of CD2 to FcγR3.  
The work provided within this dissertation could have broader implications for 
human innate T cell biology. The data we show here raise questions as to whether similar 
SLAM family receptor modulation is present on human innate-like T cells and iNKT 
cells. Data has suggested evidence for human iNKT cell subsets, although they are less 
defined than those in the mouse (Zeng et al., 2013). To date, a complete analysis of 
SLAM family receptor expression on human iNKT, γδT, or MAIT cells has not been 
completed. We have already discussed that there are SAP dependent γδ T cells and iNKT 
cells (Nichols et al., 2005a; Verykokakis et al., 2010). MAIT cells do not appear to be 




number of MAIT cells that are dependent on B cells and the gut microbiome for 
development (Chandra and Kronenberg, 2015). While subsets of MAIT cells have not 
been determined, SLAM family receptors could play a role in MAIT cell effector 
functions, especially upon engagement with an APC. Similar SLAM family receptor 
analyses on γδ T cells and ILC populations are currently being performed in the lab, 
suggesting that differing SLAM receptor expression mediating function are not unique to 
iNKT cell subsets. Instead, these patterns lend diversity to many different innate-like 
cells in the mouse, and potentially, the human.   
With the renewed interest in human cancer immunotherapies, iNKT cell subsets 
are being thought of as important cells in modulating the immune response toward solid 
tumors such as melanoma and neuroblastoma (Wolf et al., 2018). We show in Chapter 3 
that NKT2 and NKT17 cells are more proliferative than their NKT1 counterparts, 
indicating that some iNKT cell subsets may be better for expansion for immunotherapy. 
In addition, the repertoire of cytotoxic iNKT cells to kill tumors, as well as cytokine 
producing iNKT cells (if they are not the same), should be taken into consideration. In a 
search of clinical trials at the US National Library of Medicine website, there were over 
30 NKT cell related clinical trials (as of 09/20/2018). In most of these studies, iNKT cells 
were isolated from the patient, expanded in vitro, and then given back to the same patient 
to stimulate the immune system, especially NK cells and cytotoxic T cells. Some of the 
data from completed trials show that expanded iNKT cells produced only IFNγ and no 
IL-4 or IL-10 (Exley et al., 2017), suggesting that only one type of iNKT cell may have 




specific expansion protocol (Exley et al., 2014), it would be beneficial to trials in the 
future to determine whether subsets of iNKT cells can be expanded independently for 
differential cytokine production, and to potentially, aid in stimulating different parts of 
the immune system for treating different types of cancers.  
 In conclusion, this dissertation reveals specificity of distinct regulatory 
mechanisms on iNKT cell subsets provided by the SLAM family of signaling receptors 
as well as a novel candidate gene, Fcgr3 (Figure 5-1). This work provides context for the 






FIGURE 5-1: Diversity SLAM family receptor expression patterns controls the 
development and function of iNKT cell subsets 
 
A). The regulatory mechanisms behind how iNKT cells produce a myriad of cytokines, home to 
particular tissues, and how particular SLAM family receptors specifically function on iNKT cells 
have not been elucidated B). Upon the identification of iNKT cell subsets, information about the 
tissue localization and specific cytokine production of these cells began to emerge. In this 
dissertation, we reveal specific SLAM family receptor expression profiles on distinct iNKT cell 
subsets. C). SLAMf6, highly expressed on NKT2 and NKT17 cells, specifically affects the 
cytokine production and cell growth of NKT2 and NKT17 cells, but not that of NKT1 cells. This 






Adachi, Y., Koseki, H., Zijlstra, M., and Taniguchi, M. (1995). Positive selection of 
invariant V alpha 14+ T cells by non-major histocompatibility complex-encoded class I-
like molecules expressed on bone marrow-derived cells. Proc Natl Acad Sci U S A 92, 
1200-1204. 
Akbari O, S.P., Meyer E, Kronenberg M, Sidobre S, Nakayama T, Taniguchi M, Grusby 
MJ, DeKruyff RH, Umetsu DT. (2003). Essential role of NKT cells producing IL-4 and 
IL-13 in the development of allergen-induced airway hyperreactivity. Nature Medicine 9, 
582-588. 
Aktan, I., Chant, A., Borg, Z.D., Damby, D.E., Leenstra, P.C., Lilley, G.W., Petty, J., 
Suratt, B.T., Teuscher, C., Wakeland, E.K., et al. (2010). Slam haplotypes modulate the 
response to lipopolysaccharide in vivo through control of NKT cell number and function. 
J Immunol 185, 144-156. 
Araujo, L.M., Chauvineau, A., Zhu, R., Diem, S., Bourgeois, E.A., Levescot, A., Huerre, 
M., Gombert, J.M., Bayry, J., Daeron, M., et al. (2011). Cutting edge: intravenous Ig 
inhibits invariant NKT cell-mediated allergic airway inflammation through 
FcgammaRIIIA-dependent mechanisms. J Immunol 186, 3289-3293. 
Araujo, L.M., Puel, A., Gouarin, C., Hameg, A., Mevel, J.C., Koezuka, Y., Bach, J.F., 
Mouton, D., and Herbelin, A. (2000). NKT lymphocyte ontogeny and function are 
impaired in low antibody- producer Biozzi mice: gene mapping in the interval-specific 
congenic strains raised for immunomodulatory genes. Int Immunol 12, 1613-1622. 
Arora, P., Baena, A., Yu, K.O., Saini, N.K., Kharkwal, S.S., Goldberg, M.F., Kunnath-
Velayudhan, S., Carreno, L.J., Venkataswamy, M.M., Kim, J., et al. (2014). A single 
subset of dendritic cells controls the cytokine bias of natural killer T cell responses to 
diverse glycolipid antigens. Immunity 40, 105-116. 
Aversa, G., Chang, C.C., Carballido, J.M., Cocks, B.G., and de Vries, J.E. (1997). 
Engagement of the signaling lymphocytic activation molecule (SLAM) on activated T 
cells results in IL-2-independent, cyclosporin A-sensitive T cell proliferation and IFN-
gamma production. J Immunol 158, 4036-4044. 
Bader, E., Migliorini, A., Gegg, M., Moruzzi, N., Gerdes, J., Roscioni, S.S., Bakhti, M., 
Brandl, E., Irmler, M., Beckers, J., et al. (2016). Identification of proliferative and mature 
beta-cells in the islets of Langerhans. Nature 535, 430-434. 
Baglaenko, Y., Cruz Tleugabulova, M., Gracey, E., Talaei, N., Manion, K.P., Chang, 
N.H., Ferri, D.M., Mallevaey, T., and Wither, J.E. (2017). Invariant NKT Cell Activation 




Baker, J., Verneris, M.R., Ito, M., Shizuru, J.A., and Negrin, R.S. (2001). Expansion of 
cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease 
induction due to interferon gamma production. Blood 97, 2923-2931. 
Bank, I., DePinho, R.A., Brenner, M.B., Cassimeris, J., Alt, F.W., and Chess, L. (1986). 
A functional T3 molecule associated with a novel heterodimer on the surface of immature 
human thymocytes. Nature 322, 179-181. 
Baxter, A.G., Kinder, S.J., Hammond, K.J., Scollay, R., and Godfrey, D.I. (1997). 
Association between alphabetaTCR+CD4-CD8- T-cell deficiency and IDDM in NOD/Lt 
mice. Diabetes 46, 572-582. 
Behar, S.M., Dascher, C.C., Grusby, M.J., Wang, C.R., and Brenner, M.B. (1999). 
Susceptibility of mice deficient in CD1D or TAP1 to infection with Mycobacterium 
tuberculosis. J Exp Med 189, 1973-1980. 
Behar, S.M., and Porcelli, S.A. (2007). CD1-restricted T cells in host defense to 
infectious diseases. Current topics in microbiology and immunology 314, 215-250. 
Bendelac, A. (1995). Positive selection of mouse NK1+ T cells by CD1-expressing 
cortical thymocytes. J Exp Med 182, 2091-2096. 
Bendelac, A., Hunziker, R.D., and Lantz, O. (1996). Increased interleukin 4 and 
immunoglobulin E production in transgenic mice overexpressing NK1 T cells. J Exp Med 
184, 1285-1293. 
Bendelac, A., and Schwartz, R.H. (1991). CD4+ and CD8+ T cells acquire specific 
lymphokine secretion potentials during thymic maturation. Nature 353, 68-71. 
Benlagha, K., Kyin, T., Beavis, A., Teyton, L., and Bendelac, A. (2002). A Thymic 
Precursor to the NKT Cell Lineage. Science 14, 14. 
Benlagha, K., Wei, D.G., Veiga, J., Teyton, L., and Bendelac, A. (2005). Characterization 
of the early stages of thymic NKT cell development. J Exp Med 202, 485-492. 
Benoit, P., Sigounas, V.Y., Thompson, J.L., van Rooijen, N., Poynter, M.E., Wargo, 
M.J., and Boyson, J.E. (2015). The role of CD1d-restricted NKT cells in the clearance of 
Pseudomonas aeruginosa from the lung is dependent on the host genetic background. 
Infect Immun 83, 2557-2565. 
Beristain-Covarrubias, N., Canche-Pool, E., Gomez-Diaz, R., Sanchez-Torres, L.E., and 
Ortiz-Navarrete, V. (2015). Reduced iNKT cells numbers in type 1 diabetes patients and 




Berzins, S.P., McNab, F.W., Jones, C.M., Smyth, M.J., and Godfrey, D.I. (2006). Long-
term retention of mature NK1.1+ NKT cells in the thymus. Journal of Immunology 176, 
4059-4065. 
Bienemann, K., Iouannidou, K., Schoenberg, K., Krux, F., Reuther, S., Feyen, O., 
Bienemann, K., Schuster, F., Uhrberg, M., Laws, H.J., and Borkhardt, A. (2011). iNKT 
cell frequency in peripheral blood of Caucasian children and adolescent: the absolute 
iNKT cell count is stable from birth to adulthood. Scand J Immunol 74, 406-411. 
Birkholz, A., Nemcovic, M., Yu, E.D., Girardi, E., Wang, J., Khurana, A., Pauwels, N., 
Farber, E., Chitale, S., Franck, R.W., et al. (2015). Lipid and Carbohydrate Modifications 
of alpha-Galactosylceramide Differently Influence Mouse and Human Type I Natural 
Killer T Cell Activation. The Journal of biological chemistry 290, 17206-17217. 
Borg, N.A., Wun, K.S., Kjer-Nielsen, L., Wilce, M.C., Pellicci, D.G., Koh, R., Besra, 
G.S., Bharadwaj, M., Godfrey, D.I., McCluskey, J., and Rossjohn, J. (2007). CD1d-lipid-
antigen recognition by the semi-invariant NKT T-cell receptor. Nature 448, 44-49. 
Borg, Z.D., Benoit, P.J., Lilley, G.W., Aktan, I., Chant, A., DeVault, V.L., Rincon, M., 
and Boyson, J.E. (2014). Polymorphisms in the CD1d promoter that regulate CD1d gene 
expression are associated with impaired NKT cell development. J Immunol 192, 189-199. 
Brenner, M.B., McLean, J., Scheft, H., Riberdy, J., Ang, S.L., Seidman, J.G., Devlin, P., 
and Krangel, M.S. (1987). Two forms of the T-cell receptor gamma protein found on 
peripheral blood cytotoxic T lymphocytes. Nature 325, 689-694. 
Brigl, M., Bry, L., Kent, S.C., Gumperz, J.E., and Brenner, M.B. (2003). Mechanism of 
CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol. 
Brossay, L., Chioda, M., Burdin, N., Koezuka, Y., Casorati, G., Dellabona, P., and 
Kronenberg, M. (1998). CD1d-mediated recognition of an alpha-galactosylceramide by 
natural killer T cells is highly conserved through mammalian evolution. J Exp Med 188, 
1521-1528. 
Brutkiewicz, R.R. (2006). CD1d ligands: the good, the bad, and the ugly. J Immunol 177, 
769-775. 
Budd, R.C., Miescher, G.C., Howe, R.C., Lees, R.K., Bron, C., and MacDonald, H.R. 
(1987). Developmentally regulated expression of T cell receptor beta chain variable 
domains in immature thymocytes. J Exp Med 166, 577-582. 
Burocchi, A., Pittoni, P., Tili, E., Rigoni, A., Costinean, S., Croce, C.M., and Colombo, 
M.P. (2015). Regulated Expression of miR-155 is Required for iNKT Cell Development. 




Cameron, G., and Godfrey, D.I. (2018). Differential surface phenotype and context-
dependent reactivity of functionally diverse NKT cells. Immunol Cell Biol. 
Cannons, J.L., Tangye, S.G., and Schwartzberg, P.L. (2011). SLAM family receptors and 
SAP adaptors in immunity. Annual review of immunology 29, 665-705. 
Cannons, J.L., Yu, L.J., Jankovic, D., Crotty, S., Horai, R., Kirby, M., Anderson, S., 
Cheever, A.W., Sher, A., and Schwartzberg, P.L. (2006). SAP regulates T cell-mediated 
help for humoral immunity by a mechanism distinct from cytokine regulation. J Exp Med 
203, 1551-1565. 
Capone, M., Troesch, M., Eberl, G., Hausmann, B., Palmer, E., and MacDonald, H.R. 
(2001). A critical role for the T cell receptor alpha-chain connecting peptide domain in 
positive selection of CD1-independent NKT cells. Eur J Immunol 31, 1867-1875. 
Cardell, S.L. (2006). The natural killer T lymphocyte: a player in the complex regulation 
of autoimmune diabetes in non-obese diabetic mice. Clinical and Experimental 
Immunology 143, 194-202. 
Carnaud, C., Lee, D., Donnars, O., Park, S.H., Beavis, A., Koezuka, Y., and Bendelac, A. 
(1999). Cutting edge: Cross-talk between cells of the innate immune system: NKT cells 
rapidly activate NK cells. J Immunol 163, 4647-4650. 
Castellano, L., and Stebbing, J. (2013). Deep sequencing of small RNAs identifies 
canonical and non-canonical miRNA and endogenous siRNAs in mammalian somatic 
tissues. Nucleic Acids Res 41, 3339-3351. 
Cella, M., Fuchs, A., Vermi, W., Facchetti, F., Otero, K., Lennerz, J.K., Doherty, J.M., 
Mills, J.C., and Colonna, M. (2009). A human natural killer cell subset provides an innate 
source of IL-22 for mucosal immunity. Nature 457, 722-725. 
Chandra, S., and Kronenberg, M. (2015). Activation and Function of iNKT and MAIT 
Cells. Adv Immunol 127, 145-201. 
Chang, P.P., Barral, P., Fitch, J., Pratama, A., Ma, C.S., Kallies, A., Hogan, J.J., 
Cerundolo, V., Tangye, S.G., Bittman, R., et al. (2011). Identification of Bcl-6-dependent 
follicular helper NKT cells that provide cognate help for B cell responses. Nat Immunol 
13, 35-43. 
Chatterjee, M., Kis-Toth, K., Thai, T.H., Terhorst, C., and Tsokos, G.C. (2011). 
SLAMF6-driven co-stimulation of human peripheral T cells is defective in SLE T cells. 
Autoimmunity 44, 211-218. 
Chatterjee, M., Rauen, T., Kis-Toth, K., Kyttaris, V.C., Hedrich, C.M., Terhorst, C., and 




systemic lupus erythematosus T lymphocytes promotes Th17 differentiation. Journal of 
Immunology 188, 1206-1212. 
Chen, S., Cai, C., Li, Z., Liu, G., Wang, Y., Blonska, M., Li, D., Du, J., Lin, X., Yang, 
M., and Dong, Z. (2017). Dissection of SAP-dependent and SAP-independent SLAM 
family signaling in NKT cell development and humoral immunity. J Exp Med 214, 475-
489. 
Chen, Y.G., Tsaih, S.W., and Serreze, D.V. (2012). Genetic control of murine invariant 
natural killer T-cell development dynamically differs dependent on the examined tissue 
type. Genes Immun 13, 164-174. 
Chennamadhavuni, D., Saavedra-Avila, N.A., Carreno, L.J., Guberman-Pfeffer, M.J., 
Arora, P., Yongqing, T., Pryce, R., Koay, H.F., Godfrey, D.I., Keshipeddy, S., et al. 
(2018). Dual Modifications of alpha-Galactosylceramide Synergize to Promote 
Activation of Human Invariant Natural Killer T Cells and Stimulate Anti-tumor 
Immunity. Cell Chem Biol 25, 571-584 e578. 
Chien, Y.H., Meyer, C., and Bonneville, M. (2014). gammadelta T cells: first line of 
defense and beyond. Annual review of immunology 32, 121-155. 
Chlewicki, L.K., Velikovsky, C.A., Balakrishnan, V., Mariuzza, R.A., and Kumar, V. 
(2008). Molecular basis of the dual functions of 2B4 (CD244). J Immunol 180, 8159-
8167. 
Cho, Y.N., Kee, S.J., Lee, S.J., Seo, S.R., Kim, T.J., Lee, S.S., Kim, M.S., Lee, W.W., 
Yoo, D.H., Kim, N., and Park, Y.W. (2011). Numerical and functional deficiencies of 
natural killer T cells in systemic lupus erythematosus: their deficiency related to disease 
activity. Rheumatology (Oxford) 50, 1054-1063. 
Christmas, S.E., Meager, A., and Moore, M. (1987). Production of interferon and tumour 
necrosis factor by cloned human natural cytotoxic lymphocytes and T cells. Clin Exp 
Immunol 69, 441-450. 
Chuang, Y.T., Leung, K., Chang, Y.J., DeKruyff, R.H., Savage, P.B., Cruse, R., Benoit, 
C., Elewaut, D., Baumgarth, N., and Umetsu, D.T. (2018). A natural killer T-cell subset 
that protects against airway hyperreactivity. J Allergy Clin Immunol. 
Chung, B., Aoukaty, A., Dutz, J., Terhorst, C., and Tan, R. (2005). Signaling 
lymphocytic activation molecule-associated protein controls NKT cell functions. J 
Immunol 174, 3153-3157. 
Coffey, A.J., Brooksbank, R.A., Brandau, O., Oohashi, T., Howell, G.R., Bye, J.M., 
Cahn, A.P., Durham, J., Heath, P., Wray, P., et al. (1998). Host response to EBV 
infection in X-linked lymphoproliferative disease results from mutations in an SH2-




Coles, M.C., and Raulet, D.H. (2000). NK1.1+ T cells in the liver arise in the thymus and 
are selected by interactions with class I molecules on CD4+CD8+ cells. J Immunol 164, 
2412-2418. 
Colonna, M. (2018). Innate Lymphoid Cells: Diversity, Plasticity, and Unique Functions 
in Immunity. Immunity 48, 1104-1117. 
Coquet, J.M., Chakravarti, S., Kyparissoudis, K., McNab, F.W., Pitt, L.A., McKenzie, 
B.S., Berzins, S.P., Smyth, M.J., and Godfrey, D.I. (2008). Diverse cytokine production 
by NKT cell subsets and identification of an IL-17-producing CD4-NK1.1- NKT cell 
population. Proc Natl Acad Sci U S A 105, 11287-11292. 
Coquet, J.M., Kyparissoudis, K., Pellicci, D.G., Besra, G., Berzins, S.P., Smyth, M.J., 
and Godfrey, D.I. (2007). IL-21 is produced by NKT cells and modulates NKT cell 
activation and cytokine production. J Immunol 178, 2827-2834. 
Coquet, J.M., Skak, K., Davis, I.D., Smyth, M.J., and Godfrey, D.I. (2013). IL-21 
Modulates Activation of NKT Cells in Patients with Stage IV Malignant Melanoma. Clin 
Transl Immunology 2, e6. 
Crosby, C.M., and Kronenberg, M. (2018). Tissue-specific functions of invariant natural 
killer T cells. Nat Rev Immunol 18, 559-574. 
Crowe, N.Y., Uldrich, A.P., Kyparissoudis, K., Hammond, K.J., Hayakawa, Y., Sidobre, 
S., Keating, R., Kronenberg, M., Smyth, M.J., and Godfrey, D.I. (2003). Glycolipid 
antigen drives rapid expansion and sustained cytokine production by NK T cells. Journal 
of Immunology 171, 4020-4027. 
Cunninghame Graham, D.S., Vyse, T.J., Fortin, P.R., Montpetit, A., Cai, Y.C., Lim, S., 
McKenzie, T., Farwell, L., Rhodes, B., Chad, L., et al. (2008). Association of LY9 in UK 
and Canadian SLE families. Genes Immun 9, 93-102. 
D'Cruz, L.M., Stradner, M.H., Yang, C.Y., and Goldrath, A.W. (2014). E and Id proteins 
influence invariant NKT cell sublineage differentiation and proliferation. J Immunol 192, 
2227-2236. 
Das, R., Bassiri, H., Guan, P., Wiener, S., Banerjee, P.P., Zhong, M.C., Veillette, A., 
Orange, J.S., and Nichols, K.E. (2013). The adaptor molecule SAP plays essential roles 
during invariant NKT cell cytotoxicity and lytic synapse formation. Blood 121, 3386-
3395. 
De Calisto, J., Wang, N., Wang, G., Yigit, B., Engel, P., and Terhorst, C. (2014). SAP-
Dependent and -Independent Regulation of Innate T Cell Development Involving 




DeVault, V.L., Malagic, M., Mei, L., Dienz, O., Lilley, G.W.J., Benoit, P., Mistri, S.K., 
Musial, S.C., Ather, J.L., Poynter, M.E., and Boyson, J.E. (2018). Regulation of invariant 
NKT cell development and function by a 0.14 Mbp locus on chromosome 1: a possible 
role for Fcgr3. Genes Immun. 
Dong, Z., Cruz-Munoz, M.E., Zhong, M.C., Chen, R., Latour, S., and Veillette, A. 
(2009). Essential function for SAP family adaptors in the surveillance of hematopoietic 
cells by natural killer cells. Nat Immunol 10, 973-980. 
Dong, Z., Davidson, D., Perez-Quintero, L.A., Kurosaki, T., Swat, W., and Veillette, A. 
(2012). The adaptor SAP controls NK cell activation by regulating the enzymes Vav-1 
and SHIP-1 and by enhancing conjugates with target cells. Immunity 36, 974-985. 
Dreos, R., Ambrosini, G., Groux, R., Cavin Perier, R., and Bucher, P. (2017). The 
eukaryotic promoter database in its 30th year: focus on non-vertebrate organisms. 
Nucleic Acids Res 45, D51-D55. 
Dusseaux, M., Martin, E., Serriari, N., Peguillet, I., Premel, V., Louis, D., Milder, M., Le 
Bourhis, L., Soudais, C., Treiner, E., and Lantz, O. (2011). Human MAIT cells are 
xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood 117, 1250-
1259. 
Dutta, M., Kraus, Z.J., Gomez-Rodriguez, J., Hwang, S.H., Cannons, J.L., Cheng, J., Lee, 
S.Y., Wiest, D.L., Wakeland, E.K., and Schwartzberg, P.L. (2013). A role for Ly108 in 
the induction of promyelocytic zinc finger transcription factor in developing thymocytes. 
J Immunol 190, 2121-2128. 
Dutta, M., and Schwartzberg, P.L. (2012). Characterization of Ly108 in the thymus: 
evidence for distinct properties of a novel form of Ly108. J Immunol 188, 3031-3041. 
Eberl, G., Colonna, M., Di Santo, J.P., and McKenzie, A.N. (2015). Innate lymphoid 
cells. Innate lymphoid cells: a new paradigm in immunology. Science 348, aaa6566. 
Eberl, G., and MacDonald, H.R. (1998). Rapid death and regeneration of NKT cells in 
anti-CD3epsilon- or IL-12- treated mice: a major role for bone marrow in NKT cell 
homeostasis. Immunity 9, 345-353. 
Eberl, G., and MacDonald, H.R. (2000). Selective induction of NK cell proliferation and 
cytotoxicity by activated NKT cells. Eur J Immunol 30, 985-992. 
Edberg, J.C., Langefeld, C.D., Wu, J., Moser, K.L., Kaufman, K.M., Kelly, J., Bansal, V., 
Brown, W.M., Salmon, J.E., Rich, S.S., et al. (2002). Genetic linkage and association of 
Fcgamma receptor IIIA (CD16A) on chromosome 1q23 with human systemic lupus 




Egawa, T., Eberl, G., Taniuchi, I., Benlagha, K., Geissmann, F., Hennighausen, L., 
Bendelac, A., and Littman, D.R. (2005). Genetic evidence supporting selection of the 
Valpha14i NKT cell lineage from double-positive thymocyte precursors. Immunity 22, 
705-716. 
Eisenberg, G., Engelstein, R., Geiger-Maor, A., Hajaj, E., Merims, S., Frankenburg, S., 
Uzana, R., Rutenberg, A., Machlenkin, A., Frei, G., et al. (2018). Soluble SLAMF6 
Receptor Induces Strong CD8(+) T-cell Effector Function and Improves Anti-Melanoma 
Activity In Vivo. Cancer Immunol Res 6, 127-138. 
Engel, I., Seumois, G., Chavez, L., Samaniego-Castruita, D., White, B., Chawla, A., 
Mock, D., Vijayanand, P., and Kronenberg, M. (2016). Innate-like functions of natural 
killer T cell subsets result from highly divergent gene programs. Nat Immunol 17, 728-
739. 
Engel, P., Eck, M.J., and Terhorst, C. (2003). The SAP and SLAM families in immune 
responses and X-linked lymphoproliferative disease. Nat Rev Immunol 3, 813-821. 
Esteban, L.M., Tsoutsman, T., Jordan, M.A., Roach, D., Poulton, L.D., Brooks, A., 
Naidenko, O.V., Sidobre, S., Godfrey, D.I., and Baxter, A.G. (2003). Genetic control of 
NKT cell numbers maps to major diabetes and lupus loci. J Immunol 171, 2873-2878. 
Esteban LM, T.T., Jordan MA, Roach D, Poulton LD, Brooks A, Naidenko OV, Sidobre 
S, Godfrey DI, Baxter AG (2003). Genetic control of NKT cell numbers maps to major 
diabetes and lupus loci. Journal of Immunology 171, 2873-2878. 
Exley, M.A., Friedlander, P., Alatrakchi, N., Vriend, L., Yue, S., Sasada, T., Zeng, W., 
Mizukami, Y., Clark, J., Nemer, D., et al. (2017). Adoptive Transfer of Invariant NKT 
Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial. Clin Cancer 
Res 23, 3510-3519. 
Exley, M.A., Hand, L., O'Shea, D., and Lynch, L. (2014). Interplay between the immune 
system and adipose tissue in obesity. J Endocrinol 223, R41-48. 
Fedeli, M., Riba, M., Garcia Manteiga, J.M., Tian, L., Vigano, V., Rossetti, G., Pagani, 
M., Xiao, C., Liston, A., Stupka, E., et al. (2016). miR-17 approximately 92 family 
clusters control iNKT cell ontogenesis via modulation of TGF-beta signaling. Proc Natl 
Acad Sci U S A 113, E8286-E8295. 
Flamand, V., Shores, E.W., Tran, T., Huang, K., Lee, E., Grinberg, A., Kinet, J.P., and 
Love, P.E. (1996). Delayed maturation of CD4- CD8- Fc gamma RII/III+ T and natural 
killer cell precursors in Fc epsilon RI gamma transgenic mice. J. Exp. Med. 184, 1725-
1735. 
Fletcher, J.M., Jordan, M.A., Snelgrove, S.L., Slattery, R.M., Dufour, F.D., 




analysis of the NKT cell control gene Nkt2 implicates the peroxisomal protein Pxmp4. 
Journal of Immunology 181, 3400-3412. 
Fowlkes, B.J., Kruisbeek, A.M., Ton-That, H., Weston, M.A., Coligan, J.E., Schwartz, 
R.H., and Pardoll, D.M. (1987). A novel population of T-cell receptor alpha beta-bearing 
thymocytes which predominantly expresses a single V beta gene family. Nature 329, 251-
254. 
Fox, L.M., Cox, D.G., Lockridge, J.L., Wang, X., Chen, X., Scharf, L., Trott, D.L., 
Ndonye, R.M., Veerapen, N., Besra, G.S., et al. (2009). Recognition of lyso-
phospholipids by human natural killer T lymphocytes. PLoS Biol 7, e1000228. 
Frias, A.B., Jr., Buechel, H.M., Neupane, A., and D'Cruz, L.M. (2017). Invariant natural 
killer T-cell development and function with loss of microRNA-155. Immunology.153(2): 
238-245 
Fuchs, A., Vermi, W., Lee, J.S., Lonardi, S., Gilfillan, S., Newberry, R.D., Cella, M., and 
Colonna, M. (2013). Intraepithelial type 1 innate lymphoid cells are a unique subset of 
IL-12- and IL-15-responsive IFN-gamma-producing cells. Immunity 38, 769-781. 
Fujii, S., Liu, K., Smith, C., Bonito, A.J., and Steinman, R.M. (2004). The linkage of 
innate to adaptive immunity via maturing dendritic cells in vivo requires CD40 ligation in 
addition to antigen presentation and CD80/86 costimulation. J Exp Med 199, 1607-1618. 
Gadue, P., and Stein, P.L. (2002). NK T cell precursors exhibit differential cytokine 
regulation and require Itk for efficient maturation. J Immunol 169, 2397-2406. 
Gagliani, N., Vesely, M.C., Iseppon, A., Brockmann, L., Xu, H., Palm, N.W., de Zoete, 
M.R., Licona-Limon, P., Paiva, R.S., Ching, T., et al. (2015). Th17 cells 
transdifferentiate into regulatory T cells during resolution of inflammation. Nature 523, 
221-225. 
Gao, Y., and Williams, A.P. (2015). Role of Innate T Cells in Anti-Bacterial Immunity. 
Front Immunol 6, 302. 
Gapin, L., Matsuda, J.L., Surh, C.D., and Kronenberg, M. (2001). NKT cells derive from 
double-positive thymocytes that are positively selected by CD1d. Nat Immunol 2, 971-
978. 
Garner, L.C., Klenerman, P., and Provine, N.M. (2018). Insights Into Mucosal-
Associated Invariant T Cell Biology From Studies of Invariant Natural Killer T Cells. 
Front Immunol 9, 1478. 
Garni-Wagner, B.A., Purohit, A., Mathew, P.A., Bennett, M., and Kumar, V. (1993). A 
novel function-associated molecule related to non-MHC-restricted cytotoxicity mediated 




Gasteiger, G., Fan, X., Dikiy, S., Lee, S.Y., and Rudensky, A.Y. (2015). Tissue residency 
of innate lymphoid cells in lymphoid and nonlymphoid organs. Science 350, 981-985. 
Georgiev, H., Ravens, I., Benarafa, C., Forster, R., and Bernhardt, G. (2016). Distinct 
gene expression patterns correlate with developmental and functional traits of iNKT 
subsets. Nat Commun 7, 13116. 
Giaccone, G., Punt, C.J., Ando, Y., Ruijter, R., Nishi, N., Peters, M., von Blomberg, 
B.M., Scheper, R.J., van der Vliet, H.J., van den Eertwegh, A.J., et al. (2002). A phase I 
study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients 
with solid tumors. Clin Cancer Res 8, 3702-3709. 
Girardi, E., and Zajonc, D.M. (2012). Molecular basis of lipid antigen presentation by 
CD1d and recognition by natural killer T cells. Immunol Rev 250, 167-179. 
Godfrey, D.I., Kinder, S.J., Silvera, P., and Baxter, A.G. (1997). Flow cytometric study 
of T cell development in NOD mice reveals a deficiency in alphabetaTCR+CDR-CD8- 
thymocytes. J Autoimmun 10, 279-285. 
Godfrey, D.I., MacDonald, H.R., Kronenberg, M., Smyth, M.J., and Van Kaer, L. (2004). 
NKT cells: what's in a name? Nat Rev Immunol 4, 231-237. 
Godfrey, D.I., and Rossjohn, J. (2011). New ways to turn on NKT cells. The Journal of 
experimental medicine 208, 1121-1125. 
Gombert JM, H.A., Tancrede-Bohin E, Dy M, Carnaud C, Bach JF. (1996). Early 
quantitative and functional deficiency of NK1+-like thymocytes in the NOD mouse. 
European journal of immunology 26, 2989-2998. 
Gonzalez-Aseguinolaza, G., Van Kaer, L., Bergmann, C.C., Wilson, J.M., Schmieg, J., 
Kronenberg, M., Nakayama, T., Taniguchi, M., Koezuka, Y., and Tsuji, M. (2002). 
Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity 
induced by malaria vaccines. J Exp Med 195, 617-624. 
Graham, D.B., Bell, M.P., McCausland, M.M., Huntoon, C.J., van Deursen, J., Faubion, 
W.A., Crotty, S., and McKean, D.J. (2006). Ly9 (CD229)-deficient mice exhibit T cell 
defects yet do not share several phenotypic characteristics associated with SLAM- and 
SAP-deficient mice. Journal of Immunology 176, 291-300. 
Griewank, K., Borowski, C., Rietdijk, S., Wang, N., Julien, A., Wei, D.G., Mamchak, 
A.A., Terhorst, C., and Bendelac, A. (2007). Homotypic interactions mediated by Slamf1 
and Slamf6 receptors control NKT cell lineage development. Immunity 27, 751-762. 
Gumperz, J.E., and Brenner, M.B. (2001). CD1-specific T cells in microbial immunity. 




Gumperz, J.E., Miyake, S., Yamamura, T., and Brenner, M.B. (2002). Functionally 
Distinct Subsets of CD1d-restricted Natural Killer T Cells Revealed by CD1d Tetramer 
Staining. J Exp Med 195, 625-636. 
Hameg, A., Apostolou, I., Leite-De-Moraes, M., Gombert, J.M., Garcia, C., Koezuka, Y., 
Bach, J.F., and Herbelin, A. (2000). A subset of NKT cells that lacks the NK1.1 marker, 
expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen. J 
Immunol 165, 4917-4926. 
Hammond, K.J., Pellicci, D.G., Poulton, L.D., Naidenko, O.V., Scalzo, A.A., Baxter, 
A.G., and Godfrey, D.I. (2001). CD1d-restricted NKT cells: an interstrain comparison. J 
Immunol 167, 1164-1173. 
Hayakawa, Y., Takeda, K., Yagita, H., Smyth, M.J., Van Kaer, L., Okumura, K., and 
Saiki, I. (2002). IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer 
T-cell ligand, alpha-galactosylceramide. Blood 100, 1728-1733. 
Hayday, A., and Tigelaar, R. (2003). Immunoregulation in the tissues by gammadelta T 
cells. Nat Rev Immunol 3, 233-242. 
Heng, T.S., Painter, M.W., and Immunological Genome Project, C. (2008). The 
Immunological Genome Project: networks of gene expression in immune cells. Nat 
Immunol 9, 1091-1094. 
Hermans, I.F., Silk, J.D., Gileadi, U., Salio, M., Mathew, B., Ritter, G., Schmidt, R., 
Harris, A.L., Old, L., and Cerundolo, V. (2003). NKT cells enhance CD4+ and CD8+ T 
cell responses to soluble antigen in vivo through direct interaction with dendritic cells. 
Journal of Immunology 171, 5140-5147. 
Hongo, D., Tang, X., Baker, J., Engleman, E.G., and Strober, S. (2014). Requirement for 
interactions of natural killer T cells and myeloid-derived suppressor cells for 
transplantation tolerance. Am J Transplant 14, 2467-2477. 
Hongo, D., Tang, X., Dutt, S., Nador, R.G., and Strober, S. (2012). Interactions between 
NKT cells and Tregs are required for tolerance to combined bone marrow and organ 
transplants. Blood 119, 1581-1589. 
Howie, D., Laroux, F.S., Morra, M., Satoskar, A.R., Rosas, L.E., Faubion, W.A., Julien, 
A., Rietdijk, S., Coyle, A.J., Fraser, C., and Terhorst, C. (2005). Cutting edge: the SLAM 
family receptor Ly108 controls T cell and neutrophil functions. J Immunol 174, 5931-
5935. 
Howie, D., Simarro, M., Sayos, J., Guirado, M., Sancho, J., and Terhorst, C. (2002). 
Molecular dissection of the signaling and costimulatory functions of CD150 (SLAM): 




Hu, J.K., Crampton, J.C., Locci, M., and Crotty, S. (2016). CRISPR-Mediated 
Slamf1Delta/Delta Slamf5Delta/Delta Slamf6Delta/Delta Triple Gene Disruption Reveals 
NKT Cell Defects but Not T Follicular Helper Cell Defects. PLoS One 11, e0156074. 
Huang, B., Gomez-Rodriguez, J., Preite, S., Garrett, L.J., Harper, U.L., and 
Schwartzberg, P.L. (2016). CRISPR-Mediated Triple Knockout of SLAMF1, SLAMF5 
and SLAMF6 Supports Positive Signaling Roles in NKT Cell Development. PLoS One 
11, e0156072. 
Huber, S.A., Roberts, B., Moussawi, M., and Boyson, J.E. (2013). Slam haplotype 2 
promotes NKT but suppresses Vgamma4+ T-cell activation in coxsackievirus B3 
infection leading to increased liver damage but reduced myocarditis. Am J Pathol 182, 
401-409. 
Hung, J.T., Huang, J.R., and Yu, A.L. (2017). Tailored design of NKT-stimulatory 
glycolipids for polarization of immune responses. J Biomed Sci 24, 22. 
Ishikawa, A., Motohashi, S., Ishikawa, E., Fuchida, H., Higashino, K., Otsuji, M., Iizasa, 
T., Nakayama, T., Taniguchi, M., and Fujisawa, T. (2005). A phase I study of alpha-
galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and 
recurrent non-small cell lung cancer. Clin Cancer Res 11, 1910-1917. 
Ivanov, S., Fontaine, J., Paget, C., Macho Fernandez, E., Van Maele, L., Renneson, J., 
Maillet, I., Wolf, N.M., Rial, A., Leger, H., et al. (2012). Key role for respiratory 
CD103(+) dendritic cells, IFN-gamma, and IL-17 in protection against Streptococcus 
pneumoniae infection in response to alpha-galactosylceramide. J Infect Dis 206, 723-734. 
Jordan, M.A., Fletcher, J., and Baxter, A.G. (2004). Genetic control of NKT cell 
numbers. Immunol Cell Biol 82, 276-284. 
Jordan, M.A., Fletcher, J.M., Jose, R., Chowdhury, S., Gerlach, N., Allison, J., and 
Baxter, A.G. (2011). Role of SLAM in NKT cell development revealed by transgenic 
complementation in NOD mice. Journal of Immunology 186, 3953-3965. 
Jordan, M.A., Fletcher, J.M., Pellicci, D., and Baxter, A.G. (2007a). Slamf1, the NKT 
cell control gene Nkt1. J Immunol 178, 1618-1627. 
Jordan, M.A., Fletcher, J.M., Pellicci, D., and Baxter, A.G. (2007b). Slamf1, the NKT 
cell control gene Nkt1. Journal of Immunology 178, 1618-1627. 
Kageyama, R., Cannons, J.L., Zhao, F., Yusuf, I., Lao, C., Locci, M., Schwartzberg, P.L., 
and Crotty, S. (2012). The receptor Ly108 functions as a SAP adaptor-dependent on-off 




Kain, L., Costanzo, A., Webb, B., Holt, M., Bendelac, A., Savage, P.B., and Teyton, L. 
(2015). Endogenous ligands of natural killer T cells are alpha-linked glycosylceramides. 
Molecular immunology 68, 94-97. 
Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Motoki, K., Ueno, H., 
Nakagawa, R., Sato, H., Kondo, E., et al. (1997). CD1d-restricted and TCR-mediated 
activation of valpha14 NKT cells by glycosylceramides. Science 278, 1626-1629. 
Kawano, T., Cui, J., Koezuka, Y., Toura, I., Kaneko, Y., Sato, H., Kondo, E., Harada, M., 
Koseki, H., Nakayama, T., et al. (1998). Natural killer-like nonspecific tumor cell lysis 
mediated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci U S A 95, 
5690-5693. 
Keszei, M., Detre, C., Rietdijk, S.T., Munoz, P., Romero, X., Berger, S.B., Calpe, S., 
Liao, G., Castro, W., Julien, A., et al. (2011). A novel isoform of the Ly108 gene 
ameliorates murine lupus. J Exp Med 208, 811-822. 
Kiessling, R., Petranyi, G., Karre, K., Jondal, M., Tracey, D., and Wigzell, H. (1976). 
Killer cells: a functional comparison between natural, immune T-cell and antibody-
dependent in vitro systems. J Exp Med 143, 772-780. 
Kim, H.Y., Kim, S., and Chung, D.H. (2006). FcgammaRIII engagement provides 
activating signals to NKT cells in antibody-induced joint inflammation. J Clin Invest 116, 
2484-2492. 
Kinjo, Y., Illarionov, P., Vela, J.L., Pei, B., Girardi, E., Li, X., Li, Y., Imamura, M., 
Kaneko, Y., Okawara, A., et al. (2011). Invariant natural killer T cells recognize 
glycolipids from pathogenic Gram-positive bacteria. Nat Immunol 12, 966-974. 
Kitamura, H., Iwakabe, K., Yahata, T., Nishimura, S., Ohta, A., Ohmi, Y., Sato, M., 
Takeda, K., Okumura, K., Van Kaer, L., et al. (1999). The natural killer T (NKT) cell 
ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing 
interleukin (IL)- 12 production by dendritic cells and IL-12 receptor expression on NKT 
cells. J Exp Med 189, 1121-1128. 
Kitamura, H., Ohta, A., Sekimoto, M., Sato, M., Iwakabe, K., Nakui, M., Yahata, T., 
Meng, H., Koda, T., Nishimura, S., et al. (2000). alpha-galactosylceramide induces early 
B-cell activation through IL-4 production by NKT cells. Cellular immunology 199, 37-
42. 
Koch, M., Stronge, V.S., Shepherd, D., Gadola, S.D., Mathew, B., Ritter, G., Fersht, 
A.R., Besra, G.S., Schmidt, R.R., Jones, E.Y., and Cerundolo, V. (2005). The crystal 





Korver, W., Singh, S., Liu, S., Zhao, X., Yonkovich, S., Sweeney, A., Anton, K., Lomas, 
W.E., 3rd, Greenwood, R., Smith, A., et al. (2007). The lymphoid cell surface receptor 
NTB-A: a novel monoclonal antibody target for leukaemia and lymphoma therapeutics. 
Br J Haematol 137, 307-318. 
Koseki, H., Imai, K., Ichikawa, T., Hayata, I., and Taniguchi, M. (1989). Predominant 
use of a particular alpha-chain in suppressor T cell hybridomas specific for keyhole 
limpet hemocyanin. Int Immunol 1, 557-564. 
Koseki, H., Imai, K., Nakayama, F., Sado, T., Moriwaki, K., and Taniguchi, M. (1990). 
Homogenous junctional sequence of the V14+ T-cell antigen receptor alpha chain 
expanded in unprimed mice. Proc Natl Acad Sci U S A 87, 5248-5252. 
Kreslavsky, T., Savage, A.K., Hobbs, R., Gounari, F., Bronson, R., Pereira, P., Pandolfi, 
P.P., Bendelac, A., and von Boehmer, H. (2009). TCR-inducible PLZF transcription 
factor required for innate phenotype of a subset of gammadelta T cells with restricted 
TCR diversity. Proc Natl Acad Sci U S A 106, 12453-12458. 
Kumar, A., Suryadevara, N., Hill, T.M., Bezbradica, J.S., Van Kaer, L., and Joyce, S. 
(2017). Natural Killer T Cells: An Ecological Evolutionary Developmental Biology 
Perspective. Front Immunol 8, 1858. 
Kurioka, A., Walker, L.J., Klenerman, P., and Willberg, C.B. (2016). MAIT cells: new 
guardians of the liver. Clin Transl Immunology 5, e98. 
Kuylenstierna, C., Bjorkstrom, N.K., Andersson, S.K., Sahlstrom, P., Bosnjak, L., 
Paquin-Proulx, D., Malmberg, K.J., Ljunggren, H.G., Moll, M., and Sandberg, J.K. 
(2011). NKG2D performs two functions in invariant NKT cells: direct TCR-independent 
activation of NK-like cytolysis and co-stimulation of activation by CD1d. Eur J Immunol 
41, 1913-1923. 
Lee, W.Y., Moriarty, T.J., Wong, C.H., Zhou, H., Strieter, R.M., van Rooijen, N., 
Chaconas, G., and Kubes, P. (2010). An intravascular immune response to Borrelia 
burgdorferi involves Kupffer cells and iNKT cells. Nat Immunol 11, 295-302. 
Lee, Y.J., Holzapfel, K.L., Zhu, J., Jameson, S.C., and Hogquist, K.A. (2013). Steady-
state production of IL-4 modulates immunity in mouse strains and is determined by 
lineage diversity of iNKT cells. Nat Immunol 14, 1146-1154. 
Lee, Y.J., Starrett, G.J., Lee, S.T., Yang, R., Henzler, C.M., Jameson, S.C., and Hogquist, 
K.A. (2016). Lineage-Specific Effector Signatures of Invariant NKT Cells Are Shared 
amongst gammadelta T, Innate Lymphoid, and Th Cells. J Immunol 197, 1460-1470. 
Lee, Y.J., Wang, H., Starrett, G.J., Phuong, V., Jameson, S.C., and Hogquist, K.A. 
(2015). Tissue-Specific Distribution of iNKT Cells Impacts Their Cytokine Response. 




Leite-de-Moraes, M.C., Herbelin, A., Gouarin, C., Koezuka, Y., Schneider, E., and Dy, 
M. (2000). Fas/Fas ligand interactions promote activation-induced cell death of NK T 
lymphocytes. J Immunol 165, 4367-4371. 
Li, L., Huang, L., Sung, S.S., Lobo, P.I., Brown, M.G., Gregg, R.K., Engelhard, V.H., 
and Okusa, M.D. (2007). NKT cell activation mediates neutrophil IFN-gamma 
production and renal ischemia-reperfusion injury. Journal of Immunology 178, 5899-
5911. 
Limaye, N., Belobrajdic, K.A., Wandstrat, A.E., Bonhomme, F., Edwards, S.V., and 
Wakeland, E.K. (2008). Prevalence and evolutionary origins of autoimmune 
susceptibility alleles in natural mouse populations. Genes Immun 9, 61-68. 
Liu, L.L., Landskron, J., Ask, E.H., Enqvist, M., Sohlberg, E., Traherne, J.A., Hammer, 
Q., Goodridge, J.P., Larsson, S., Jayaraman, J., et al. (2016). Critical Role of CD2 Co-
stimulation in Adaptive Natural Killer Cell Responses Revealed in NKG2C-Deficient 
Humans. Cell Rep 15, 1088-1099. 
Luci, C., Reynders, A., Ivanov, II, Cognet, C., Chiche, L., Chasson, L., Hardwigsen, J., 
Anguiano, E., Banchereau, J., Chaussabel, D., et al. (2009). Influence of the transcription 
factor RORgammat on the development of NKp46+ cell populations in gut and skin. Nat 
Immunol 10, 75-82. 
Lynch, L., Michelet, X., Zhang, S., Brennan, P.J., Moseman, A., Lester, C., Besra, G., 
Vomhof-Dekrey, E.E., Tighe, M., Koay, H.F., et al. (2015). Regulatory iNKT cells lack 
expression of the transcription factor PLZF and control the homeostasis of T(reg) cells 
and macrophages in adipose tissue. Nat Immunol 16, 85-95. 
Lynch, L., Nowak, M., Varghese, B., Clark, J., Hogan, A.E., Toxavidis, V., Balk, S.P., 
O'Shea, D., O'Farrelly, C., and Exley, M.A. (2012). Adipose tissue invariant NKT cells 
protect against diet-induced obesity and metabolic disorder through regulatory cytokine 
production. Immunity 37, 574-587. 
Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., Agdashian, D., Terabe, 
M., Berzofsky, J.A., Fako, V., et al. (2018). Gut microbiome-mediated bile acid 
metabolism regulates liver cancer via NKT cells. Science 360. 
Macdonald, H.R. (2007). NKT cells: In the beginning. Eur J Immunol 37 Suppl 1, S111-
115. 
Makino, Y., Kanno, R., Ito, T., Higashino, K., and Taniguchi, M. (1995). Predominant 
expression of invariant V alpha 14+ TCR alpha chain in NK1.1+ T cell populations. Int 




Matsuda, J.L., Gapin, L., Baron, J.L., Sidobre, S., Stetson, D.B., Mohrs, M., Locksley, 
R.M., and Kronenberg, M. (2003). Mouse V alpha 14i natural killer T cells are resistant 
to cytokine polarization in vivo. Proc Natl Acad Sci U S A 100, 8395-8400. 
Mattner, J., Debord, K.L., Ismail, N., Goff, R.D., Cantu, C., 3rd, Zhou, D., Saint-Mezard, 
P., Wang, V., Gao, Y., Yin, N., et al. (2005). Exogenous and endogenous glycolipid 
antigens activate NKT cells during microbial infections. Nature 434, 525-529. 
McNab, F.W., Berzins, S.P., Pellicci, D.G., Kyparissoudis, K., Field, K., Smyth, M.J., 
and Godfrey, D.I. (2005). The influence of CD1d in postselection NKT cell maturation 
and homeostasis. Journal of Immunology 175, 3762-3768. 
Meinke, S., and Watzl, C. (2013). NK cell cytotoxicity mediated by 2B4 and NTB-A is 
dependent on SAP acting downstream of receptor phosphorylation. Front Immunol 4, 3. 
Meunier, J., Lemoine, F., Soumillon, M., Liechti, A., Weier, M., Guschanski, K., Hu, H., 
Khaitovich, P., and Kaessmann, H. (2013). Birth and expression evolution of mammalian 
microRNA genes. Genome Res 23, 34-45. 
Meyer EH, G.S., Akbari O, Berry GJ, Savage PB, Kronenberg M, Nakayama T, 
DeKruyff RH, Umetsu DT. (2006). Glycolipid activation of invariant T cell receptor+ 
NK T cells is sufficient to induce airway hyperreactivity independent of conventional 
CD4+ T cells. PNAS 103, 2782-2787. 
Michel, M.L., Lenoir, C., Massot, B., Diem, S., Pasquier, B., Sawa, S., Rignault-Bricard, 
R., Lehuen, A., Eberl, G., Veillette, A., et al. (2016). SLAM-associated protein favors the 
development of iNKT2 over iNKT17 cells. Eur J Immunol 46, 2162-2174. 
Milpied, P., Massot, B., Renand, A., Diem, S., Herbelin, A., Leite-de-Moraes, M., Rubio, 
M.T., and Hermine, O. (2011). IL-17-producing invariant NKT cells in lymphoid organs 
are recent thymic emigrants identified by neuropilin-1 expression. Blood 118, 2993-3002. 
Miyamoto, K., Miyake, S., and Yamamura, T. (2001). A synthetic glycolipid prevents 
autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 
413, 531-534. 
Mjosberg, J., and Spits, H. (2012). Type 2 innate lymphoid cells-new members of the 
"type 2 franchise" that mediate allergic airway inflammation. European journal of 
immunology 42, 1093-1096. 
Monticelli, L.A., Sonnenberg, G.F., Abt, M.C., Alenghat, T., Ziegler, C.G., Doering, 
T.A., Angelosanto, J.M., Laidlaw, B.J., Yang, C.Y., Sathaliyawala, T., et al. (2011). 
Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza 




Montoya, C.J., Pollard, D., Martinson, J., Kumari, K., Wasserfall, C., Mulder, C.B., 
Rugeles, M.T., Atkinson, M.A., Landay, A.L., and Wilson, S.B. (2007). Characterization 
of human invariant natural killer T subsets in health and disease using a novel invariant 
natural killer T cell-clonotypic monoclonal antibody, 6B11. Immunology 122, 1-14. 
Morel, L., Blenman, K.R., Croker, B.P., and Wakeland, E.K. (2001). The major murine 
systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally 
related genes. Proc Natl Acad Sci U S A 98, 1787-1792. 
Morita, M., Motoki, K., Akimoto, K., Natori, T., Sakai, T., Sawa, E., Yamaji, K., 
Koezuka, Y., Kobayashi, E., and Fukushima, H. (1995). Structure-activity relationship of 
alpha-galactosylceramides against B16-bearing mice. J Med Chem 38, 2176-2187. 
Morshed, S.R., Takahashi, T., Savage, P.B., Kambham, N., and Strober, S. (2009). Beta-
galactosylceramide alters invariant natural killer T cell function and is effective treatment 
for lupus. Clin Immunol 132, 321-333. 
Motomura, Y., Kitamura, H., Hijikata, A., Matsunaga, Y., Matsumoto, K., Inoue, H., 
Atarashi, K., Hori, S., Watarai, H., Zhu, J., et al. (2011). The transcription factor E4BP4 
regulates the production of IL-10 and IL-13 in CD4+ T cells. Nat Immunol 12, 450-459. 
Murphy, K., Travers, P., Walport, M., and Janeway, C. (2012). Janeway's 
immunobiology, 8th edn (New York: Garland Science). 
Nakamatsu, M., Yamamoto, N., Hatta, M., Nakasone, C., Kinjo, T., Miyagi, K., Uezu, 
K., Nakamura, K., Nakayama, T., Taniguchi, M., et al. (2007). Role of interferon-gamma 
in Valpha14+ natural killer T cell-mediated host defense against Streptococcus 
pneumoniae infection in murine lungs. Microbes and infection / Institut Pasteur 9, 364-
374. 
Natori, T., Akimoto, K., Motoki, K., Koezuka, Y., and Higa, T. (1997). [Development of 
KRN7000, derived from agelasphin produced by Okinawan sponge]. Nihon Yakurigaku 
Zasshi 110 Suppl 1, 63P-68P. 
Neill, D.R., Wong, S.H., Bellosi, A., Flynn, R.J., Daly, M., Langford, T.K., Bucks, C., 
Kane, C.M., Fallon, P.G., Pannell, R., et al. (2010). Nuocytes represent a new innate 
effector leukocyte that mediates type-2 immunity. Nature 464, 1367-1370. 
Nguyen, K.D., Vanichsarn, C., and Nadeau, K.C. (2008). Increased cytotoxicity of CD4+ 
invariant NKT cells against CD4+CD25hiCD127lo/- regulatory T cells in allergic 
asthma. Eur J Immunol 38, 2034-2045. 
Nichols, K.E., Harkin, D.P., Levitz, S., Krainer, M., Kolquist, K.A., Genovese, C., 
Bernard, A., Ferguson, M., Zuo, L., Snyder, E., et al. (1998). Inactivating mutations in an 
SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proceedings of 




Nichols, K.E., Hom, J., Gong, S.Y., Ganguly, A., Ma, C.S., Cannons, J.L., Tangye, S.G., 
Schwartzberg, P.L., Koretzky, G.A., and Stein, P.L. (2005a). Regulation of NKT cell 
development by SAP, the protein defective in XLP. Nat Med 11, 340-345. 
Nichols, K.E., Ma, C.S., Cannons, J.L., Schwartzberg, P.L., and Tangye, S.G. (2005b). 
Molecular and cellular pathogenesis of X-linked lymphoproliferative disease. 
Immunological Reviews 203, 180-199. 
Nicol, A., Nieda, M., Koezuka, Y., Porcelli, S., Suzuki, K., Tadokoro, K., Durrant, S., 
and Juji, T. (2000). Human invariant valpha24+ natural killer T cells activated by alpha- 
galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms 
distinct from T cells and natural killer cells. Immunology 99, 229-234. 
Nieuwenhuis, E.E., Matsumoto, T., Exley, M., Schleipman, R.A., Glickman, J., Bailey, 
D.T., Corazza, N., Colgan, S.P., Onderdonk, A.B., and Blumberg, R.S. (2002). CD1d-
dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lung. Nat 
Med 8, 588-593. 
Nimmerjahn, F., and Ravetch, J.V. (2007). Fc-receptors as regulators of immunity. Adv 
Immunol 96, 179-204. 
Nishimura, T., Santa, K., Yahata, T., Sato, N., Ohta, A., Ohmi, Y., Sato, T., Hozumi, K., 
and Habu, S. (1997). Involvement of IL-4-producing Vbeta8.2+ CD4+ CD62L- 
CD45RB- T cells in non-MHC gene-controlled predisposition toward skewing into T 
helper type-2 immunity in BALB/c mice. J Immunol 158, 5698-5706. 
O'Brien, T.F., Bao, K., Dell'Aringa, M., Ang, W.X., Abraham, S., and Reinhardt, R.L. 
(2016). Cytokine expression by invariant natural killer T cells is tightly regulated 
throughout development and settings of type-2 inflammation. Mucosal Immunol 9, 597-
609. 
O'Reilly, V., Zeng, S.G., Bricard, G., Atzberger, A., Hogan, A.E., Jackson, J., Feighery, 
C., Porcelli, S.A., and Doherty, D.G. (2011). Distinct and overlapping effector functions 
of expanded human CD4+, CD8alpha+ and CD4-CD8alpha- invariant natural killer T 
cells. PLoS One 6, e28648. 
Oguro, H., Ding, L., and Morrison, S.J. (2013). SLAM family markers resolve 
functionally distinct subpopulations of hematopoietic stem cells and multipotent 
progenitors. Cell Stem Cell 13, 102-116. 
Oki, S., Chiba, A., Yamamura, T., and Miyake, S. (2004). The clinical implication and 
molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated 




Olson, C.M., Jr., Bates, T.C., Izadi, H., Radolf, J.D., Huber, S.A., Boyson, J.E., and 
Anguita, J. (2009). Local production of IFN-gamma by invariant NKT cells modulates 
acute Lyme carditis. J Immunol 182, 3728-3734. 
Paidipally, P., Tripathi, D., Van, A., Radhakrishnan, R.K., Dhiman, R., 
Venkatasubramanian, S., Devalraju, K.P., Tvinnereim, A.R., Valluri, V.L., and 
Vankayalapati, R. (2018). Interleukin-21 Regulates Natural Killer Cell Responses During 
Mycobacterium tuberculosis Infection. J Infect Dis 217, 1323-1333. 
Parekh, V.V., Singh, A.K., Wilson, M.T., Olivares-Villagomez, D., Bezbradica, J.S., 
Inazawa, H., Ehara, H., Sakai, T., Serizawa, I., Wu, L., et al. (2004). Quantitative and 
qualitative differences in the in vivo response of NKT cells to distinct alpha- and beta-
anomeric glycolipids. J Immunol 173, 3693-3706. 
Park-Min, K.H., Serbina, N.V., Yang, W., Ma, X., Krystal, G., Neel, B.G., Nutt, S.L., 
Hu, X., and Ivashkiv, L.B. (2007). FcgammaRIII-dependent inhibition of interferon-
gamma responses mediates suppressive effects of intravenous immune globulin. 
Immunity 26, 67-78. 
Pasquier, B., Yin, L., Fondaneche, M.C., Relouzat, F., Bloch-Queyrat, C., Lambert, N., 
Fischer, A., de Saint-Basile, G., and Latour, S. (2005). Defective NKT cell development 
in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome 
gene product. J Exp Med 201, 695-701. 
Pellicci, D.G., Clarke, A.J., Patel, O., Mallevaey, T., Beddoe, T., Le Nours, J., Uldrich, 
A.P., McCluskey, J., Besra, G.S., Porcelli, S.A., et al. (2011). Recognition of beta-linked 
self glycolipids mediated by natural killer T cell antigen receptors. Nat Immunol 12, 827-
833. 
Pellicci, D.G., Hammond, K.J., Uldrich, A.P., Baxter, A.G., Smyth, M.J., and Godfrey, 
D.I. (2002). A natural killer T (NKT) cell developmental pathway iInvolving a thymus-
dependent NK1.1(-)CD4(+) CD1d-dependent precursor stage. The Journal of 
experimental medicine 195, 835-844. 
Pellicci, D.G., Patel, O., Kjer-Nielsen, L., Pang, S.S., Sullivan, L.C., Kyparissoudis, K., 
Brooks, A.G., Reid, H.H., Gras, S., Lucet, I.S., et al. (2009). Differential recognition of 
CD1d-alpha-galactosyl ceramide by the V beta 8.2 and V beta 7 semi-invariant NKT T 
cell receptors. Immunity 31, 47-59. 
Porcelli, S., Yockey, C.E., Brenner, M.B., and Balk, S.P. (1993). Analysis of T cell 
antigen receptor (TCR) expression by human peripheral blood CD4-8- alpha/beta T cells 
demonstrates preferential use of several V beta genes and an invariant TCR alpha chain. J 
Exp Med 178, 1-16. 
Purtilo, D.T., Cassel, C.K., Yang, J.P., and Harper, R. (1975). X-linked recessive 




Rachitskaya, A.V., Hansen, A.M., Horai, R., Li, Z., Villasmil, R., Luger, D., Nussenblatt, 
R.B., and Caspi, R.R. (2008). Cutting edge: NKT cells constitutively express IL-23 
receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-
independent fashion. J Immunol 180, 5167-5171. 
Radomir, L., Cohen, S., Kramer, M.P., Bakos, E., Lewinsky, H., Barak, A., Porat, Z., 
Bucala, R., Stepensky, P., Becker-Herman, S., and Shachar, I. (2017). T Cells Regulate 
Peripheral Naive Mature B Cell Survival by Cell-Cell Contact Mediated through 
SLAMF6 and SAP. J Immunol 199, 2745-2757. 
Renkema, G.H., Wortmann, S.B., Smeets, R.J., Venselaar, H., Antoine, M., Visser, G., 
Ben-Omran, T., van den Heuvel, L.P., Timmers, H.J., Smeitink, J.A., and Rodenburg, 
R.J. (2015). SDHA mutations causing a multisystem mitochondrial disease: novel 
mutations and genetic overlap with hereditary tumors. Eur J Hum Genet 23, 202-209. 
Rhost, S., Sedimbi, S., Kadri, N., and Cardell, S.L. (2012). Immunomodulatory type II 
natural killer T lymphocytes in health and disease. Scand J Immunol 76, 246-255. 
Rivat, C., Booth, C., Alonso-Ferrero, M., Blundell, M., Sebire, N.J., Thrasher, A.J., and 
Gaspar, H.B. (2013). SAP gene transfer restores cellular and humoral immune function in 
a murine model of X-linked lymphoproliferative disease. Blood 121, 1073-1076. 
Rocha-Campos, A.C., Melki, R., Zhu, R., Deruytter, N., Damotte, D., Dy, M., Herbelin, 
A., and Garchon, H.J. (2006). Genetic and functional analysis of the Nkt1 locus using 
congenic NOD mice: improved Valpha14-NKT cell performance but failure to protect 
against type 1 diabetes. Diabetes 55, 1163-1170. 
Rodewald, H.R., Moingeon, P., Lucich, J.L., Dosiou, C., Lopez, P., and Reinherz, E.L. 
(1992). A population of early fetal thymocytes expressing Fc gamma RII/III contains 
precursors of T lymphocytes and natural killer cells. Cell 69, 139-150. 
Roy, S., and Zhuang, Y. (2018). Paradoxical role of Id proteins in regulating tumorigenic 
potential of lymphoid cells. Front Med 12, 374-386. 
Rymarchyk, S.L., Lowenstein, H., Mayette, J., Foster, S.R., Damby, D.E., Howe, I.W., 
Aktan, I., Meyer, R.E., Poynter, M.E., and Boyson, J.E. (2008). Widespread natural 
variation in murine natural killer T-cell number and function. Immunology 125, 331-343. 
Sada-Ovalle, I., Chiba, A., Gonzales, A., Brenner, M.B., and Behar, S.M. (2008). Innate 
invariant NKT cells recognize Mycobacterium tuberculosis-infected macrophages, 
produce interferon-gamma, and kill intracellular bacteria. PLoS pathogens 4, e1000239. 
Sag, D., Krause, P., Hedrick, C.C., Kronenberg, M., and Wingender, G. (2014). IL-10-





Saito, H., Kranz, D.M., Takagaki, Y., Hayday, A.C., Eisen, H.N., and Tonegawa, S. 
(1984). Complete primary structure of a heterodimeric T-cell receptor deduced from 
cDNA sequences. Nature 309, 757-762. 
Sanderson, J.P., Brennan, P.J., Mansour, S., Matulis, G., Patel, O., Lissin, N., Godfrey, 
D.I., Kawahara, K., Zahringer, U., Rossjohn, J., et al. (2013). CD1d protein structure 
determines species-selective antigenicity of isoglobotrihexosylceramide (iGb3) to 
invariant NKT cells. Eur J Immunol 43, 815-825. 
Sandor, M., Galon, J., Takacs, L., Tatsumi, Y., Mueller, A.L., Sautes, C., and Lynch, 
R.G. (1994). An alternative Fc gamma-receptor ligand: potential role in T-cell 
development. Proc. Natl. Acad. Sci. U. S. A. 91, 12857-12861. 
Savage, A.K., Constantinides, M.G., and Bendelac, A. (2011). Promyelocytic leukemia 
zinc finger turns on the effector T cell program without requirement for agonist TCR 
signaling. J Immunol 186, 5801-5806. 
Savage, A.K., Constantinides, M.G., Han, J., Picard, D., Martin, E., Li, B., Lantz, O., and 
Bendelac, A. (2008). The transcription factor PLZF directs the effector program of the 
NKT cell lineage. Immunity 29, 391-403. 
Sayos, J., Wu, C., Morra, M., Wang, N., Zhang, X., Allen, D., van Schaik, S., 
Notarangelo, L., Geha, R., Roncarolo, M.G., et al. (1998). The X-linked 
lymphoproliferative-disease gene product SAP regulates signals induced through the co-
receptor SLAM. Nature 395, 462-469. 
Scanlon, S.T., Thomas, S.Y., Ferreira, C.M., Bai, L., Krausz, T., Savage, P.B., and 
Bendelac, A. (2011). Airborne lipid antigens mobilize resident intravascular NKT cells to 
induce allergic airway inflammation. J Exp Med 208, 2113-2124. 
Shlapatska, L.M., Mikhalap, S.V., Berdova, A.G., Zelensky, O.M., Yun, T.J., Nichols, 
K.E., Clark, E.A., and Sidorenko, S.P. (2001). CD150 association with either the SH2-
containing inositol phosphatase or the SH2-containing protein tyrosine phosphatase is 
regulated by the adaptor protein SH2D1A. J Immunol 166, 5480-5487. 
Shores, E., Flamand, V., Tran, T., Grinberg, A., Kinet, J.P., and Love, P.E. (1997). Fc 
epsilonRI gamma can support T cell development and function in mice lacking 
endogenous TCR zeta-chain. J. Immunol. 159, 222-230. 
Sintes, J., Cuenca, M., Romero, X., Bastos, R., Terhorst, C., Angulo, A., and Engel, P. 
(2013). Cutting edge: Ly9 (CD229), a SLAM family receptor, negatively regulates the 
development of thymic innate memory-like CD8+ T and invariant NKT cells. J Immunol 
190, 21-26. 
Skak, K., Kragh, M., Hausman, D., Smyth, M.J., and Sivakumar, P.V. (2008). Interleukin 




Smyth, M.J., Crowe, N.Y., Pellicci, D.G., Kyparissoudis, K., Kelly, J.M., Takeda, K., 
Yagita, H., and Godfrey, D.I. (2002). Sequential production of interferon-gamma by 
NK1.1(+) T cells and natural killer cells is essential for the antimetastatic effect of alpha-
galactosylceramide. Blood 99, 1259-1266. 
Snow, A.L., Marsh, R.A., Krummey, S.M., Roehrs, P., Young, L.R., Zhang, K., van 
Hoff, J., Dhar, D., Nichols, K.E., Filipovich, A.H., et al. (2009). Restimulation-induced 
apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease 
caused by SAP deficiency. J Clin Invest 119, 2976-2989. 
Sobel, E.S., Satoh, M., Chen, Y., Wakeland, E.K., and Morel, L. (2002). The major 
murine systemic lupus erythematosus susceptibility locus Sle1 results in abnormal 
functions of both B and T cells. J Immunol 169, 2694-2700. 
Song, T., Dong, C., and Xiong, S. (2015). Signaling lymphocyte-activation molecule 
SLAMF1 augments mycobacteria BCG-induced inflammatory response and facilitates 
bacterial clearance. Int J Med Microbiol 305, 572-580. 
Spada, F.M., Koezuka, Y., and Porcelli, S.A. (1998). CD1d-restricted recognition of 
synthetic glycolipid antigens by human natural killer T cells. J Exp Med 188, 1529-1534. 
Sriram, V., Du, W., Gervay-Hague, J., and Brutkiewicz, R.R. (2005). Cell wall 
glycosphingolipids of Sphingomonas paucimobilis are CD1d-specific ligands for NKT 
cells. Eur J Immunol 35, 1692-1701. 
St Leger, A.J., Hansen, A.M., Karauzum, H., Horai, R., Yu, C.R., Laurence, A., Mayer-
Barber, K.D., Silver, P., Villasmil, R., Egwuagu, C., et al. (2018). STAT-3-independent 
production of IL-17 by mouse innate-like alphabeta T cells controls ocular infection. J 
Exp Med 215, 1079-1090. 
Stetson, D.B., Mohrs, M., Reinhardt, R.L., Baron, J.L., Wang, Z.E., Gapin, L., 
Kronenberg, M., and Locksley, R.M. (2003). Constitutive cytokine mRNAs mark natural 
killer (NK) and NK T cells poised for rapid effector function. J Exp Med 198, 1069-1076. 
Stevenson, M.M., Kondratieva, T.K., Apt, A.S., Tam, M.F., and Skamene, E. (1995). In 
vitro and in vivo T cell responses in mice during bronchopulmonary infection with 
mucoid Pseudomonas aeruginosa. Clin Exp Immunol 99, 98-105. 
Subleski, J.J., Hall, V.L., Wolfe, T.B., Scarzello, A.J., Weiss, J.M., Chan, T., Hodge, 
D.L., Back, T.C., Ortaldo, J.R., and Wiltrout, R.H. (2011). TCR-dependent and -
independent activation underlie liver-specific regulation of NKT cells. J Immunol 186, 
838-847. 
Sullivan, B.A., Nagarajan, N.A., Wingender, G., Wang, J., Scott, I., Tsuji, M., Franck, 




glycolipid antigen-driven cytokine polarization by Valpha14i NKT cells. J Immunol 184, 
141-153. 
Tagawa, T., Wu, L., Anraku, M., Yun, Z., Rey-McIntyre, K., and de Perrot, M. (2013). 
Antitumor impact of interferon-gamma producing CD1d-restricted NKT cells in murine 
malignant mesothelioma. J Immunother 36, 391-399. 
Takahashi, T., Nieda, M., Koezuka, Y., Nicol, A., Porcelli, S.A., Ishikawa, Y., Tadokoro, 
K., Hirai, H., and Juji, T. (2000). Analysis of human V alpha 24+ CD4+ NKT cells 
activated by alpha- glycosylceramide-pulsed monocyte-derived dendritic cells. J 
Immunol 164, 4458-4464. 
Tang, X., Zhang, B., Jarrell, J.A., Price, J.V., Dai, H., Utz, P.J., and Strober, S. (2014). 
Ly108 expression distinguishes subsets of invariant NKT cells that help autoantibody 
production and secrete IL-21 from those that secrete IL-17 in lupus prone NZB/W mice. J 
Autoimmun 50, 87-98. 
Tangye, S.G., Phillips, J.H., Lanier, L.L., and Nichols, K.E. (2000). Functional 
requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed 
by the X-linked lymphoproliferative syndrome. Journal of Immunology 165, 2932-2936. 
Thanabalasuriar, A., Neupane, A.S., Wang, J., Krummel, M.F., and Kubes, P. (2016). 
iNKT Cell Emigration out of the Lung Vasculature Requires Neutrophils and Monocyte-
Derived Dendritic Cells in Inflammation. Cell Rep 16, 3260-3272. 
Treiner, E., Duban, L., Bahram, S., Radosavljevic, M., Wanner, V., Tilloy, F., Affaticati, 
P., Gilfillan, S., and Lantz, O. (2003). Selection of evolutionarily conserved mucosal-
associated invariant T cells by MR1. Nature 422, 164-169. 
Tsuji, M. (2006). Glycolipids and phospholipids as natural CD1d-binding NKT cell 
ligands. Cell Mol Life Sci 63, 1889-1898. 
Tupin, E., Benhnia, M.R., Kinjo, Y., Patsey, R., Lena, C.J., Haller, M.C., Caimano, M.J., 
Imamura, M., Wong, C.H., Crotty, S., et al. (2008). NKT cells prevent chronic joint 
inflammation after infection with Borrelia burgdorferi. Proc Natl Acad Sci U S A 105, 
19863-19868. 
Tupin, E., and Kronenberg, M. (2006). Activation of natural killer T cells by glycolipids. 
Methods Enzymol 417, 185-201. 
Tuttle, K.D., Krovi, S.H., Zhang, J., Bedel, R., Harmacek, L., Peterson, L.K., Dragone, 
L.L., Lefferts, A., Halluszczak, C., Riemondy, K., et al. (2018). TCR signal strength 




Tyznik, A.J., Verma, S., Wang, Q., Kronenberg, M., and Benedict, C.A. (2014). Distinct 
requirements for activation of NKT and NK cells during viral infection. J Immunol 192, 
3676-3685. 
van der Merwe, P.A., McNamee, P.N., Davies, E.A., Barclay, A.N., and Davis, S.J. 
(1995). Topology of the CD2-CD48 cell-adhesion molecule complex: implications for 
antigen recognition by T cells. Curr Biol 5, 74-84. 
van Driel, B., Wang, G., Liao, G., Halibozek, P.J., Keszei, M., O'Keeffe, M.S., Bhan, 
A.K., Wang, N., and Terhorst, C. (2015). The cell surface receptor Slamf6 modulates 
innate immune responses during Citrobacter rodentium-induced colitis. Int Immunol 27, 
447-457. 
Van Kaer, L., and Joyce, S. (2005). Innate immunity: NKT cells in the spotlight. Curr 
Biol 15, R429-431. 
Velmourougane, G., Raju, R., Bricard, G., Im, J.S., Besra, G.S., Porcelli, S.A., and 
Howell, A.R. (2009). Synthesis and evaluation of an acyl-chain unsaturated analog of the 
Th2 biasing, immunostimulatory glycolipid, OCH. Bioorg Med Chem Lett 19, 3386-
3388. 
Verykokakis, M., Boos, M.D., Bendelac, A., Adams, E.J., Pereira, P., and Kee, B.L. 
(2010). Inhibitor of DNA binding 3 limits development of murine slam-associated 
adaptor protein-dependent "innate" gammadelta T cells. PLoS One 5, e9303. 
Wandstrat, A.E., Nguyen, C., Limaye, N., Chan, A.Y., Subramanian, S., Tian, X.H., Yim, 
Y.S., Pertsemlidis, A., Garner, H.R., Jr., Morel, L., and Wakeland, E.K. (2004). 
Association of extensive polymorphisms in the SLAM/CD2 gene cluster with murine 
lupus. Immunity 21, 769-780. 
Wang, H.X., Li, W.J., Hou, C.L., Lai, S., Zhang, Y.L., Tian, C., Yang, H., Du, J., and Li, 
H.H. (2018). CD1d-dependent natural killer T cells attenuate angiotensin II-induced 
cardiac remodeling via IL-10 signaling in mice. Cardiovascular research. 
Wang, N., Halibozek, P.J., Yigit, B., Zhao, H., O'Keeffe, M.S., Sage, P., Sharpe, A., and 
Terhorst, C. (2015). Negative Regulation of Humoral Immunity Due to Interplay between 
the SLAMF1, SLAMF5, and SLAMF6 Receptors. Front Immunol 6, 158. 
Wesley, J.D., Tessmer, M.S., Chaukos, D., and Brossay, L. (2008). NK cell-like behavior 
of Valpha14i NK T cells during MCMV infection. PLoS pathogens 4, e1000106. 
Wesley, J.D., Tessmer, M.S., Paget, C., Trottein, F., and Brossay, L. (2007). A Y 
chromosome-linked factor impairs NK T development. J Immunol 179, 3480-3487. 
Wieland Brown, L.C., Penaranda, C., Kashyap, P.C., Williams, B.B., Clardy, J., 




(2013). Production of alpha-galactosylceramide by a prominent member of the human gut 
microbiota. PLoS Biol 11, e1001610. 
Wilson, M.T., Johansson, C., Olivares-Villagomez, D., Singh, A.K., Stanic, A.K., Wang, 
C.R., Joyce, S., Wick, M.J., and Van Kaer, L. (2003). The response of natural killer T 
cells to glycolipid antigens is characterized by surface receptor down-modulation and 
expansion. Proc Natl Acad Sci U S A 100, 10913-10918. 
Wilson, T.J., Garner, L.I., Metcalfe, C., King, E., Margraf, S., and Brown, M.H. (2014). 
Fine specificity and molecular competition in SLAM family receptor signalling. PLoS 
One 9, e92184. 
Wolf, B.J., Choi, J.E., and Exley, M.A. (2018). Novel Approaches to Exploiting Invariant 
NKT Cells in Cancer Immunotherapy. Front Immunol 9, 384. 
Wong, E.B., Soni, C., Chan, A.Y., Domeier, P.P., Shwetank, Abraham, T., Limaye, N., 
Khan, T.N., Elias, M.J., Chodisetti, S.B., et al. (2015). B cell-intrinsic CD84 and Ly108 
maintain germinal center B cell tolerance. J Immunol 194, 4130-4143. 
Wu, C., Li, Z., Fu, X., Yu, S., Lao, S., and Yang, B. (2015). Antigen-specific human 
NKT cells from tuberculosis patients produce IL-21 to help B cells for the production of 
immunoglobulins. Oncotarget 6, 28633-28645. 
Wu, D., Xing, G.W., Poles, M.A., Horowitz, A., Kinjo, Y., Sullivan, B., Bodmer-
Narkevitch, V., Plettenburg, O., Kronenberg, M., Tsuji, M., et al. (2005). Bacterial 
glycolipids and analogs as antigens for CD1d-restricted NKT cells. Proceedings of the 
National Academy of Sciences of the United States of America 102, 1351-1356. 
Wu, N., and Veillette, A. (2016). SLAM family receptors in normal immunity and 
immune pathologies. Curr Opin Immunol 38, 45-51. 
Yankelevich, B., Knobloch, C., Nowicki, M., and Dennert, G. (1989). A novel cell type 
responsible for marrow graft rejection in mice. T cells with NK phenotype cause acute 
rejection of marrow grafts. J Immunol 142, 3423-3430. 
Yoshimoto, T., and Paul, W.E. (1994). CD4pos, NK1.1pos T cells promptly produce 
interleukin 4 in response to in vivo challenge with anti-CD3. J Exp Med 179, 1285-1295. 
Zeng, S.G., Ghnewa, Y.G., O'Reilly, V.P., Lyons, V.G., Atzberger, A., Hogan, A.E., 
Exley, M.A., and Doherty, D.G. (2013). Human invariant NKT cell subsets differentially 
promote differentiation, antibody production, and T cell stimulation by B cells in vitro. J 
Immunol 191, 1666-1676. 
Zhang, F., Liang, Z., Matsuki, N., Van Kaer, L., Joyce, S., Wakeland, E.K., and Aune, 
T.M. (2003). A murine locus on chromosome 18 controls NKT cell homeostasis and th 




Zhang, S., Laouar, A., Denzin, L.K., and Sant'Angelo, D.B. (2015). Zbtb16 (PLZF) is 
stably suppressed and not inducible in non-innate T cells via T cell receptor-mediated 
signaling. Sci Rep 5, 12113. 
Zhao, F., Cannons, J.L., Dutta, M., Griffiths, G.M., and Schwartzberg, P.L. (2012). 
Positive and negative signaling through SLAM receptors regulate synapse organization 
and thresholds of cytolysis. Immunity 36, 1003-1016. 
Zhou, D., Mattner, J., Cantu, C., 3rd, Schrantz, N., Yin, N., Gao, Y., Sagiv, Y., Hudspeth, 
K., Wu, Y.P., Yamashita, T., et al. (2004). Lysosomal glycosphingolipid recognition by 
NKT cells. Science 306, 1786-1789. 
 
